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A B S T R A C T
Infectious diseases are a major threat to the wellbeing of humans, livestock, and wildlife.
However, there is often a paucity of information for responding to these threats, and
thus a need to make efficient use of existing data. This thesis shows how to use Bayesian
analysis to maximise the information gained from already collected diagnostic test data.
First, the commonly used latent class analysis of multiple binary diagnostic tests is ex-
tended to account for vaccinated individuals, and used to estimate the effect of study size
on sensitivity and specificity estimates of DIVA (”Distinguishing Infected and Vaccinated
Animals”) tests for bovine Tuberculosis.
It is then shown how quantitative test responses can be used as clocks indicating the
time since infection to “hindcast” historic trends of disease incidence using cross-sectional
data. This is used to determine whether an endemic disease is increasing or decreasing
up to the time of sampling, enabling the tracking of trends in populations where routine
surveillance data is not available.
It is further demonstrated how to hindcast the rise and fall of disease outbreaks. Using
the 2007 UK Bluetongue virus outbreak and a whooping cough outbreak as examples, it
is shown that hindcasting can be used to determine whether an outbreak is increasing or
past its peak at the time of sampling, thus informing potential outbreak responses.
In the light of these methods for analysing quantitative test data, the challenges of
generating data on test kinetics are discussed. Suggestions are given for how to improve
on current methods by modelling the development of paired diagnostic tests as a dynamic
host-pathogen system.
This thesis demonstrates that multiple quantitative tests can be used to recover disease
trends in a population. These methods have far-reaching consequences for the design and
practice of disease surveillance in all contexts.
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1C H A P T E R 1 : I N T R O D U C T I O N A N D O V E RV I E W
On the 17th of April 2009 the Mexican Institute for Social Security
sounded an epidemiological alert regarding an unusual pattern of
reported influenza cases (Echevarría-Zuno et al., 2009). Later stud-
ies suggested this outbreak started in February of 2009 (Echevarría-
Zuno et al., 2009) or possibly earlier (Smith et al., 2009). On April
23rd, the cause was identified as a novel influenza virus with serotype
H1N1 (Girard et al., 2010) and by the end of April, cases infected
with the identical strain had been reported in several different
countries (Fineberg, 2014). The presented symptoms in this flu out-
break were severe: of 899 patients hospitalised in Mexico, 6.5%
suffered critical illness; 41% of these critically ill patients died.
In the following months and for most of 2009, this novel strain,
spread from country to country under the moniker “swine flu”.
On the 11th of June 2009, WHO officially classified H1N1 as a pan-
demic flu (Chan, 2009), thereby triggering emergency responses by
governments across the world.
Despite the severity of initial cases, the pandemic H1N1 flu was
soon found to have similar morbidity to regular seasonal flu (Tu-
ite et al., 2010). In light of this, the responses by WHO and others
has been criticised (Durodié, 2011; Flynn, 2010), but most official
reports have subsequently concluded that the response was appro-
priate given the data available at the time (Fineberg, 2014; Leung
and Nicoll, 2010).
The case of the H1N1 outbreak highlights the difficulty of making
decisions in the face of an infectious disease outbreak, and the im-
portance of having enough information available so that action can
1
2 chapter 1 : introduction and overview
be taken proportionately to the true rather than perceived threat.
Disease surveillance can tell us what pathogens occur at what time
and in which hosts and environments. It is thus a critical link in the
chain between awareness and action. However, surveillance data is
often patchy and incomplete. Statistical techniques can contribute
substantially to the interpretation of these data, and in-depth statis-
tical analyses make it possible to maximise the information gained.
The statistical frameworks developed in this thesis have implications
for and relevance to multiple aspects of the interactions between di-
agnosing disease, developing new diagnostics and designing surveil-
lance systems and appropriate control policies.
The specific types of information required differ depending on the
epidemiology of the disease. Section 1.1 discusses different types
of disease epidemiology, and how the goals of surveillance differ
depending on the pattern of spread. Section 1.2 provides a brief dis-
ease description of how surveillance systems function, and typical
gaps and limitations in performance. Section 1.3 focusses on diag-
nostic tests and how more comprehensive analyses of collected test
results could help mitigate key gaps in the performance of exist-
ing surveillance systems. Section 1.4 highlights major current and
historical uses of statistical analysis in disease surveillance. Section
1.5 introduces key notations and the foundations necessary for con-
ducting the statistical analyses used in this thesis. Finally, section
1.6 describes the focus of the thesis, and lays out the structure of the
following chapters.
1.1 characterising patterns of infectious disease
The epidemiology of infectious diseases vary greatly in the particu-
lar. In general, however, there are a few categories of epidemiolog-
ical patterns that are often used for describing diseases. These are
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not distinct classes, but describe different aspects of observed pat-
terns of spread.
1.1.1 The basic reproduction number R0
A natural starting point is to consider the infectiousness of a pathogen.
This can be quantified by defining the seemingly theoretical concept
of the “basic reproduction number”, or R0 as the average number
of new cases infected by a single original case in a large host pop-
ulation in which every individual is susceptible to infection. Intu-
itively, it is clear that if R0 is less than 1, i.e. if each case infects on
average less than a single new host before recovering (i.e. ceasing
to be infectious, dying or leaving the population under study), the
pathogen will die out. If R0 > 1, the pathogen will instead spread
exponentially. As the pathogen spreads through the population the
number of susceptible individuals declines and the number of cases
infected by each new infective (the R number) is lower than R0. The
development of the R number over time determines the type of epi-
demiological pattern the pathogen follows.Observed values of R0
vary tremendously across infectious pathogens; studies have indi-
cated that in a totally susceptible population, a single measles case
can infect (i.e. have an R0 of) between 12 and 18 (Fine, 1993), while
for scrapie, R0 has been estimated to be 3.9 (Heffernan et al., 2005).
1.1.2 Endemic and epidemic disease
The terms endemic and epidemic are frequently used to characterize
disease. However, the terms are not exclusive and depend on the
spatial and temporal scale being considered.
An endemic pathogen is a pathogen that is continually present in a
population. This implies that the pathogen has reached a (possi-
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bly dynamic) steady state, where an individual infected with the
pathogen will on average spread the pathogen to one other indi-
vidual before recovering or dying (i.e. R ≈ 1). Note that this says
nothing about the absolute prevalence (i.e. proportion of the pop-
ulation infected) or incidence (number of individuals infected per
time unit) of the pathogen. The incidence of new infections could
exhibit a relatively stable trend in the population if the pathogen
spreads slowly and/or is chronic. Alternatively, it could show a reg-
ular or irregular pattern of fluctuations over a period of time, as the
infectiousness and/or the number of susceptible individuals change
or simply due to stochastic variation in disease contact. One exam-
ple of such a disease is Nephropatia epidemica, caused by the Pu-
umala virus (PUUV) (Family Bunyaviridae, genus hantavirus). It is a
zoonotic pathogen that has voles as its main host, but has an annual
season of a few months in winter when the voles are forced inside
buildings, and the pathogen can infect humans, causing seasonal
epidemics (Zeimes et al., 2012). That the pathogen is endemic does
not mean that the average incidence is stable; if the point of equilib-
rium increase or decrease, so does the incidence or prevalence. In
this context a major concern is the impact of climate change on in-
fectious pathogens, where it is feared that increasing temperatures
will lead to higher rates of transmission (e.g by increasing the num-
bers of disease vectors such as ticks or mosquitos (McMichael et al.,
2006) ), as well as a shift in the endemic regions for a wide range of
pathogens, leading to changes in the incidence for many pathogens
in both in humans and animals (Fox et al., 2011).
An epidemic pathogen is characterised by the change in incidence be-
ing dominated by the dynamics of the pathogen spread, rather than
changes in the equilibrium point. This could mean a classic outbreak
scenario, such as the rapid spread of Norovirus (winter vomiting
disease) in a naive population aboard cruise ships after food contam-
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ination (Isakbaeva et al., 2005). But it could also refer to a pathogen
such as HIV, where the number of cases are still increasing, only
lately showing some signs of having reached equilibrium (Nagelk-
erke et al., 2014); in this case, the increase is slow and steady, but
undeniably positive, and only rarely exhibits fluctuations.
As noted above the terms “epidemic” and “endemic” are comple-
mentary, not in contradiction. A pathogen could be endemic and
epidemic at the same time. Such pathogens tend to circulate in a
population (or in a nearby reservoir host) at a low level, causing oc-
casional outbreaks once some epidemic threshold is reached. Within
the wider population the pathogen would be technically endemic
but may remain undetected at low levels, only being detected dur-
ing ‘epidemic’ outbreaks. Alternatively, if the pathogen remains in
a reservoir population (where it is endemic) it may cause true epi-
demic outbreaks in connected and completely susceptible popula-
tions. A classic example of this is the epidemiology of measles in the
UK pre-vaccination. At some scale, it would always be present, caus-
ing occasional cases in the population. On a regular basis, however,
the number of children who had not been exposed would increase
to a critical level, and a measles epidemic would occur. Interestingly,
these epidemics nearly always started in London before spreading
to the rest of the country, probably because high population density
meant that a critical mass was reached earlier than in other cities
(Grenfell et al., 2001).
The terms emerging disease or reemerging disease have been increas-
ingly used, in particular in connection with climate change and
some of the high-profile outbreaks seen in the last decades. The
term is usually used to refer to diseases caused by pathogens that
have a high risk of being introduced or have recently been intro-
duced in a population, but where there is no (recent) history of oc-
currence in that particular population. Many examples of emerging
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diseases are arthropod-borne pathogens; Bluetongue (Wilson and
Mellor, 2009), Chikungunya (Thiboutot et al., 2010), and West Nile
Virus (Bernard et al., 2001) are all spread via arthropod bites. Since
the range and population densities of insects are highly affected by
micro- and macro- climate, a changing climate can be expected to
have a substantial effect on the locations and populations where
arthropod vectors are to be found (Daszak et al., 2000). An emerg-
ing (re-emerging) disease can also refer to diseases that have been
present in the past but were either not discovered or did not cause
problems until some recent change in circumstances increased the
incidence or the consequences of infection. The foot-and-mouth
disease outbreak in 2001 in the UK (Scudamore and Harris, 2002)
can be considered as a classic example of both an epidemic and an
emerging disease of concern for northern Europe, while in many
parts of the world, such as sub-saharan Africa, foot-and-mouth dis-
ease is endemic (Bronsvoort et al., 2004).
1.2 the implementation of surveillance systems
Disease surveillance can be defined as the systematic collection,
analysis and dissemination of disease information with the aim of
informing action towards the management of the disease (CDC,
2001). It can thus refer to any kind of data collection; covering an
entire population or just a representative sample, aggregated or
individual-based information, the registration of laboratory-confirmed
cases or monitoring high concentrations of pathogens that are likely
to cause disease. Given the above definition, it is crucial that col-
lected data are used to inform a suitable course of action with re-
gards to a particular disease or group of diseases.
The purpose of disease surveillance may differ depending on the
epidemiological pattern of the pathogen of interest. For endemic
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pathogens, the role of disease surveillance is to keep track of the
trend (for example changing incidence due to climate change), to
understand the burden of disease (Kosek et al., 2003; Parashar et
al., 2003), the epidemiology of the pathogen (Ali et al., 2002), and
to evaluate the effectiveness of any implemented control measures.
Infections might be underreported, which does not affect trend es-
timates as long as the proportion of cases being reported remains
stable, but can cause problems for comparisons over time, between
regions or between different surveillance systems. For epidemic dis-
eases, the role of disease surveillance is to catch an outbreak as early
as possible (Chan et al., 2010), provide information from which to
act to to limit its spread (Zhang et al., 2013), and help in the process
of understanding the likely cause of the outbreak (Communications,
2006) . It is usually (at least in the western world) the case that there
are existing surveillance systems and routines for reporting cases
and tracking the incidence curves. However, those surveillance sys-
tems might well have substantial reporting delay, which can limit
their usefulness for rapid response. Depending on the disease, it
is more or less likely that surveillance systems will fail to detect
cases; some, like measles, have clear and relatively severe symptoms,
while others such as chickenpox will probably not go unnoticed but
might go unreported as they usually have mild symptoms. For truly
emerging diseases i.e. those that have not been experienced previ-
ously anywhere, we know know almost nothing initially; there has
been no opportunity for extensive study, and while it is possible to
use disease models to predict behaviour uncertainty in any predic-
tions is large. In this scenario, the role of disease surveillance is first
to detect the initial incursion, and second to track development as
the disease spreads (or not) in the community (Chan et al., 2010).
Both of these are crucial in informing decisions as to what measures
are appropriate, enabling an effective response to be mounted.
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Figure 1.1: Generic structure of a disease surveillance system, showing the var-
ious tasks, stakeholder, and flows of information that needs to come
together in a functioning surveillance system, whether based on diag-
nosed cases or registration of syndromic indicators. Figure reproduced
from Triple S Consortium (2013) .
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However, no matter the objective, all surveillance systems are com-
posed of several different tasks linked together. Figure 1.1 highlights
the task flow that needs to be successfully implemented to form a
functioning surveillance system, using the surveillance of wildlife
disease as an example. This starts with the occurrence of a case, fol-
lows through to the case being recorded, and then being (correctly!)
communicated to statisticians and epidemiologists. Thus, the num-
ber of different people and organizations that are involved in pro-
ducing disease information is large and susceptible to miscommuni-
cations and errors. While the idea of taking note of infected individ-
uals can be traced back to the 1300s, the resources for coordinating
systematic population-level registration of deaths and cases of ill-
ness only became available in the 19th century; in the UK, the first
disease registry was introduced in 1838 by William Farr (Langmuir,
1976). The concept of surveillance as it is known today, in which the
informing of action is a critical aspect, was only set out in 1968 by
the WHO technical assembly (Declich and Carter, 1994). Computeri-
zation and automation has made the implementation of surveillance
systems easier and faster, but setting up large-scale surveillance pro-
grams is still a challenge requiring substantial expertise and capital
(CDC, 2001).
While it is easy to assume that data collection is a simple and pain-
less process, in reality it is one of the major hurdles within surveil-
lance, and worth describing in more detail. Starting from the occur-
rence of infection, a chain of events need to occur before a diagno-
sis is recorded in the database. First, the individual needs to either
show symptoms that are severe enough to be noticed, or be sampled
at random as part of a screening program. For many pathogens,
a substantial number of infected hosts exhibit mild or subclinical
symptoms, and are therefore not captured by passive surveillance.
Subclinical infections, while of limited consequence for the individ-
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Figure 1.2: Flowchart of the process from infection of a wild animal to the regis-
tration of a case in a database. After personal communication with
D. Gavier-Widen, Head of Pathology, Swedish National Veterinary
Institute.
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ual, can be crucial for understanding the pattern of spread and the
epidemiology of disease. Figure 1.2 show a schematic of the vari-
ous phases that a wildlife infection goes through from occurrence
up until the infection is registered in a database (D. Xavier-Widen,
personal communication).
After a case has been recorded, the doctor or veterinarian needs to
go through the effort of establishing a diagnosis, often by taking
samples that are sent for testing at a regional biomedical veterinary
or health care laboratory. Depending on available resources, includ-
ing time and interest of the veterinarian or doctor, this might only
happen for particularly unusual or severe cases. Once a sample is
analysed, the diagnostic laboratory procedures used need to be sen-
sitive enough to correctly establish the diagnosis. Depending on the
pathogen, this can be more or less difficult, and choosing the opti-
mal test would usually require that the referring doctor or veterinar-
ian has a suspicion of which pathogen to look for. Some pathogens
are predominantly present in a particular part of the body; as an
example, Bovine TB in cattle is only present in localized encapsu-
lated lesion, and the bacterium is unlikely to be found in other tis-
sue samples (OIE, 2009). Such pathogens would thus require sam-
ples to be taken from the correct tissues in order for the presence
of the pathogen to be detected. For wildlife diseases in particular,
where animals are received without knowledge of their clinical his-
tory, it is often a substantial detective effort to identify the correct
causative agent(s), and there is little doubt that a lot of infections go
undetected (Mörner et al., 2002).
The net effect of this chain of events is to create a pyramid of cases
(see figure 1.3, reproduced from Gibbons et al. (2014)). This can
lead to the “iceberg” phenomenon of disease (Last, 1963). For many
pathogens, only the very tip of the iceberg is detected and reported,
the cases that are most severe and/or noticeable. For some pathogens,
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Figure 1.3: The set of all cases of a particular disease, and the various levels of
registration of those cases. UE stands for the overall extent of Under
Estimation of cases which arise from Under Reporting of cases UR,
and Under Ascertained cases UA. Ignoring the non-reported cases
will lead to an underestimation of the disease incidence, if the disease
suffer non-neglible levels of UR and UA cases. Reproduced from Gib-
bons et al. (2014) .
seroepidemiology has indicated that the majority of cases go unde-
tected; two examples are Salmonella (Simonsen et al., 2011) and Per-
tussis (Boven et al., 2004). These are pathogens for which infection is
often asymptomatic or causing subclinical disease, leading to large
number of undetected cases. In fact, for a number of pathogens, it
was not possible to detect most infections before the advent of sen-
sitive PCR-based diagnostics (Watzinger et al., 2006) and advanced
antibody arrays (Uttamchandani et al., 2009).
In order to track cases from the lower levels of the pyramid, one can
broaden the inclusion criteria, at the risk of including false positive
cases. Another option is to target the lower levels via wider (longitu-
dinal or cross-sectional) screening programs that target either some
of the lower levels of the pyramid or the entire population (Gib-
bons et al., 2014). One of the hurdles to ongoing population level
screening is that it can be expensive, and thus particularly difficult
to implement, in particular in settings with limited resources, such
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as pathogen surveillance in developing countries. Occasional cross-
sectional studies are cheaper to implement than continuous surveil-
lance, but reliance on these limits the ability to track disease trends.
Infectious diseases were seen as a solved problem during the lat-
ter part of the 20th century (Fauci, 2001), with the result that dis-
ease surveillance started lagging behind. The AIDS epidemic that
began in the 1980s caused an increased awareness of the continu-
ing risk posed by infectious diseases, but as late as 1994, Berkelman
et al. (1994) referred to infectious disease surveillance as a “crum-
bling foundation”. The capacity for infectious disease surveillance
in general has improved greatly since then. With the advent of mod-
ern diagnostic measures such as those made possible by the PCR
revolution (Yang and Rothman, 2004) the ability to rapidly identify
pathogens has increased, and the effort of organizations such as the
European Centre for Disease Control (ECDC) and the World Organ-
isation for Animal Health (OIE) to standardize, unify and improve
disease surveillance databases has improved our ability to compare
pathogen occurrence and prevalence between different locations and
countries. The development of the internet has also been a great
help, with surveillance networks such as the ProMed mailing list
(Madoff, 2004) and HealthMap (Freifeld et al., 2008) making even
early warning signals of disease events available globally. However,
the quality of disease surveillance is uneven across different nations,
and in different contexts (The Institute of Medicine, 2007). Jones
et al. (2008) analysed which areas of the world new pathogens are
likely to emerge in, and compared that with how much research has
been focused on the same areas. They concluded that the research
and surveillance to a large extent are biased towards “the richer, de-
veloped countries of Europe, North America, Australia and some
parts of Asia, than in developing regions”. On the other hand, their
analysis indicated that lower-latitude developing countries have the
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highest risk for emerging infectious disease events (EID). One im-
plication of their study is that improving surveillance systems in
highly resource-constrained countries would have a high pay-off
for improving the ability of the global community to detect and re-
spond to EID.
Wildlife disease surveillance is another area that has often been ne-
glected, despite the growing awareness of the interdependence of
diseases in livestock, humans, and wildlife, and thus the mutual
importance of surveillance in all three types of hosts (Zinsstag et
al., 2011). However, since wildlife disease research is constrained in
funding (as few strong economical interests are directly affected),
and is technically challenging (Mörner et al., 2002), improving the
current state of surveillance systems has been difficult. Kuiken and
Gortázar (2011) describes the state of wildlife surveillance across
Europe, and concludes that a majority of countries have no gen-
eral surveillance established beyond targeted efforts for a few key
pathogens. In developing countries, surveillance systems for human
diseases are often severely lacking, and animal disease surveillance
has been referred to as “nonexistent” (Butler, 2006).
1.3 the use of diagnostics in disease surveillance
A veterinarian or medical doctor can use symptoms to diagnose dis-
ease in a patient. However, in order to confidently establish that the
disease is caused by a particular pathogen, rigorous and tested di-
agnostics procedures based on chemical or other assays are almost
always necessary. The suggestion that infectious diseases might be
caused by unseen organisms dates back to the 16th century, but only
gained widespread acceptance in the 19th. A particularly important
development was made by the german physician Robert Koch in
1890. Koch’s postulates (Kaufmann and Schaible, 2005) set out cri-
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teria for concluding that a microorganism is the cause of a partic-
ular disease. In the original form, the postulates were: A disease
is caused by a pathogen 1) if and only if it is present in a diseased
host, and absent in non-diseased hosts; 2) The microorganism can be
be isolated from an individual diagnosed with the disease, purified
and grown; 3) After isolating the microorganism, introducing it into
a healthy host causes the disease; and 4) from the experimentally in-
fected host, the microorganism can be isolated again, and identified
to be the same as the introduced organism. These postulates worked
to put the identification of organisms that cause a particular disease
on solid footing.
With respect to surveillance, the properties of a binary diagnostic
test for a particular pathogen can be summarised by the sensitivity
and the specificity of the test. The sensitivity refers to the probabil-
ity of getting a positive result from an individual infected with the
pathogen, while the specificity refers to the probability of getting a
negative result from an individual not infected with the pathogen
(the specificity). The terms of “Specificity” and “Sensitivity” were
first used in the context of a screening program for cervical cancer
(which we know now to largely be the consequence of an infectious
pathogen) in the 1940s as described in a publication of the CDC in
1961 (Morabia and Zhang, 2004).
Following Koch, microbial culture is commonly used as the gold
standard for diagnosis for infectious diseases (OIE, 2013), and treated
as being 100% specific, with no false positive results. A sample of tis-
sue or fluid is taken from the potential case, purified of substances
that may inhibit growth, and a culture of organisms is grown that
can be identified as a particular pathogen, via observation in mi-
croscope or some other approach through which it is possible to
identify features unique to that pathogen. This method will nearly
always (except in cases of sample contamination) be 100% specific,
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i.e. not show any false positives. However, growing a culture takes
time and is therefore resource intensive. Depending on the pathogen,
it might also be difficult due to biosecurity issues: only laborato-
ries with biosecurity classification level four are allowed to culture
highly pathogenic organisms such as Ebola or foot-and-mouth dis-
ease (US Department of Health and Human Services, 1999). For
other pathogens, it might be difficult to create the right conditions
of growth outside the host. For example, Mycobacterium spp. is no-
toriously difficult to culture, and if culture is successful, for taking
several weeks to grow before being identifiable (OIE, 2014). Viruses
and prions are even more challenging, requiring carefully prepared
environments with the correct cells and proteins present to replicate.
While culture is still used as a gold standard in studies of proper-
ties of new diagnostic methods, it is increasingly rare to use it as a
diagnostic tool in itself, for the above mentioned reasons.
Another method of diagnosis relies on the existence of genetic mate-
rial such as DNA or RNA from the pathogen in the test sample, as
a proxy for the presence in the sample of the pathogen itself. This
was made possible with the development of the polymerase chain
reaction (PCR) procedure in 1985 (Mullis et al., 1986). A small length
of a genetic sequence unique to the pathogen is used as a “primer”
to amplify any genetic material containing that primer to the point
where its presence can be easily detected. If amplified material is
then found, that is evidence for a diagnosis. A particular “primer”
tends to be unique to a particular pathogen; however, it is possible
to use a combination of primers to be able to detect and identify a
range of different pathogens simultaneously, including the identi-
fication of pathogen families, species, sub-species, or types. DNA-
and RNA-based methods tend to be highly sensitive, able to de-
tect concentrations of only a few tens or hundreds of organisms
per sample. Because of their sensitivity, however, they also tend to
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be prone to false positive results, and can easily suffer from cross-
contamination or cross-reactions with genetic material from non-
pathogen sources, resulting in low specificity.
A third approach to diagnosis is to look for effects of the pathogen
in the host (e.g. a detectable signature of the host responding to the
presence of the pathogen). At its core, this is exactly what medical
doctors do when diagnosing a patient in the traditional manner
based on a collection of symptoms indicative of a particular dis-
ease. . Whilst such symptoms based diagnosis at times has rather
low specificity i.e. several diseases may have similar symptoms, the
laboratory methods exploit the fact that the immune system of ani-
mals and humans respond to infections in specific and predictable
ways, generating antibodies that target a particular pathogen. These
antibodies can be isolated from e.g. a blood sample, and their ex-
istence detected by mixing the test sample with a preparation of
organic material derived from the pathogen that has been marked
for easy identification with e.g a fluorescent protein. If there are an-
tibodies in the sample that react with the organic preparation, this
can then be measured, for example via enzyme-linked immunosor-
bent assay (ELISA) (Wright et al., 1993). The existence of antibodies
are then taken as evidence for the individual having been infected
with the pathogen. However, since antibodies are not 100% specific,
there is usually a threshold concentration that the sample must dis-
play for the diagnosis to be reliable. A further complicating matter is
that there are several types of immune response that can be used as
a basis for a test. Some immune responses are specific to a particular
disease, while other immune responses (such as interferon-γ) can re-
act to a wide range of different infections. Some components of the
immune response, such as memory cells, remain in the body for a
long time, while others can subside quickly.
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The different approaches of diagnosis measure different aspects of
the host-pathogen interaction during the progression from initial
pathogen infection via subsequent host response to recovery. Be-
cause of this, they will show a case as positive under somewhat dif-
ferent conditions (Greiner and I. A. Gardner, 2000a). For a culture
approach to be feasible, there must still be live pathogens present
in the host, and thus a positive test is evidence of an ongoing infec-
tion. A genetics-based approach will be positive if DNA or RNA is
present; this mean that the pathogen could potentially have died
out, but dead organisms still remain in the body. A positive DNA or
RNA-based test is thus evidence of a recent infection, but not neces-
sarily one that is ongoing (the genetic remains can be present in the
body despite the infection having cleared). The presence of an im-
mune response indicates that the host has responded to an infection
at some point in the past. Some antibodies disappear quickly, and
so their presence indicates a recent infection. Other types of antibod-
ies can stay for weeks, months or years before their levels decline,
and so their presence would only indicate that the individual has
been infected at some point in the past. An additional complication
is that individuals can develop antibodies just by being exposed to
a pathogen, without developing an active infection. Using a positive
antibody test to indicate infection thus usually implies a broader
case definition than that based on using a culture test.
Knowing the details of what is being measured is thus important
for understanding exactly what any given test data represents, and
also for resolving possibly conflicting results between different tests.
Classically, a test result is reported as a binary positive/negative for
infection. More recent methods base such classifications on quan-
titative measurements of the indicator; concentration of antibodies
(Uttamchandani et al., 2009), number of copies of a particular gene
found (Caboche et al., 2014), or concentration of bacteria in a media
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(Hammes and Egli, 2010). In such cases if the test result is above a
certain cut-off value, it is classified as positive, but otherwise as neg-
ative.
However, quantitative results can also be analysed directly, in which
case the statistical properties of the measurement becomes impor-
tant. For example, many diagnostic methods use repeated dilutions
to bring concentrations into a range that can be measured, and then
the result is scaled by the dilution factor. If there is a constant error
in measuring the concentrations, the scaling will then introduce a
multiplicative error in the resulting data set. Such dilutions also fre-
quently mean that observations are clumped at different multiples
of the same number (2,4,8,. . . ), which can lead to under dispersion
which should be accounted for in any statistical analysis of the data.
The steps of the laboratory workflow can each introduce errors of
different sorts, which need to be taken into account in subsequent
statistical analysis (Greiner and I. A. Gardner, 2000b).
The use of the results of diagnostic testing can be approached from
at least two different viewpoints. From the clinician’s point of view,
a diagnostic test is a tool supporting decision-making and helps in
identifying appropriate treatment for the patient at the point of care.
From this clinical perspective, information on when to administer
treatment and when to abstain are the most important functions of
diagnostic testing, and this includes understanding the limitations
and strength of the available tests.
In order for a diagnostic test to be useful as a decision-support tool,
a clear result indicating the likely status of the individual is clearly
of great value: a message of “infected” or “not infected”, with a
known level of uncertainty. However, from a statistical or epidemi-
ological as opposed to clinical prospective, the interest lies in the
overall pattern of disease in the population. From these perspectives,
we have the luxury of not having to worry about what the test result
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is for any particular individual. Understanding these two differing
perspectives becomes important for the discussion of quantitative
test results instead of binary results, and the use of more than one
diagnostic test. For the clinician, a quantitative test response has lit-
tle value unless it can be translated to inform a particular course of
action, for instance by the use of a binary cutoff point. Likewise, in
most cases, the use of multiple diagnostic tests is only of relevance
to the extent that it can be used to pin down the appropriate diagno-
sis.
From a population perspective however, the overall distribution of
the quantitative test results within the population can be of use for
estimating test variability as well as variation in exposure and sever-
ity/response to pathogen infection between individuals. Multiple di-
agnostic tests, while providing limited additional information on the
individual level, can be used in the aggregate to provide a descrip-
tion of the how the pathogen is spreading, a problem we address in
this thesis (chapters 3 and 4). The increasing awareness of the high
proportion of subclinical infections that play an important role in
the epidemiology for a number of pathogens also complicates the
usage of a binary “infected”/“non-infected” dichotomy. The collec-
tion of test results pre-cutoff can thus be invaluable to statisticians
and epidemiologists, while being perceived as unnecessary by those
closer to the point of care e.g clinicians, and it is important to be
aware of this tension when conducting studies or setting up surveil-
lance systems, so that both perspectives are acknowledged.
1.4 the use of statistical methods in disease surveillance
This section will not attempt a review of all types of statistical analy-
sis used in the process of disease surveillance; there is far too much
to cover in just a few paragraphs. Instead, it will describe a few ex-
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amples of how statistical analysis can be used to extract important
signals from limit surveillance data that can then be used to inform
decisions on how to manage a particular disease.
At the most fundamental level, statistical analysis can be used to
highlight patterns in collected data. In 1854, the physician John Snow
identified the source of a Cholera outbreak by mapping the cases
and noticing that there was a cluster of cases around a particular
street pump, a study widely considered to mark the start of epi-
demiology (Hempel, 2013). Such cluster analysis has remained an
important research topic to this day. One of the most well-known
modern statistical tools for cluster analysis is the Kulldorf scan statis-
tic (Kulldorff, 1997), implemented in the SatScan program (Kull-
dorff et al., 1998), among other statistical software packages. Cluster
detection can look for either clusters in spatial dimensions with a
number of cases occurring in one area, clusters in temporal dimen-
sions where a number of cases occur within a short space of time
but not necessarily in the same place or clusters in both space and
time. Cluster analysis can also be based on metrics other than space
and time, e.g. age, to detect unusual aspects of data. Another promi-
nent type of pattern detection is to understand when reported cases
of some disease reaches an “unusual” level, due to an outbreak or
because of some other change in epidemiology, that might require a
public health intervention. One important approach for doing so is
known as a temporal scan statistic, first introduced in Farrington et
al. (1996), which described the Farrington Algorithm. This algorithm
continuously evaluates an incoming time series for statistically sig-
nificant changes, sounding an alarm if the cumulative change over a
specified time period reaches a significance threshold, according to
some statistic; many different statistics have been suggested for this
broad purpose (Unkel et al., 2012).
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Statistical analysis can also be used to extract trends from indirect
data sources. One example is the recent increasing usage of syn-
dromic surveillance. The main motivation for syndromic surveil-
lance is that there is a delay between infection and symptoms, and
between symptoms and health-care-seeking behavior (in humans),
symptoms severe enough to be noticed by a farmer or veterinar-
ian(in livestock) or to cause death and the resulting carcass to be
noticed by hunters or the general public (in wildlife). However, a
symptomatic individual has an effect on its surroundings or habitat,
and this effect can be tracked. Since symptoms occur before an in-
fection is diagnosed, syndromic surveillance has the potential to in-
crease the timeliness, sensitivity and robustnesss of existing systems
(Buehler et al., 2003; Dórea et al., 2011). Hulth et al. (2009) devel-
oped a statistical model using partial least squares regression to pre-
dict officially reported influenza case numbers from web searches
submitted to a medical web site. Google Flu Trends also predicts in-
fluenza levels, using a simple statistical regression model combined
with model selection procedures and using google search queries as
their data source (Ginsberg et al., 2009). Syndromic surveillance can
be used for animals as well; Warns-Petit et al. (2010) describe the use
of data mining to categorize recorded necropsy data pre-diagnosis
in wild animals, identifying clusters that could signify wildlife dis-
ease outbreaks of re-emerging or emerging pathogens.
An increasing use of statistical analysis is to integrate different sources
of information together with the surveillance data to make infer-
ence about the epidemiology of disease. For example, in the case
of a disease outbreak, it is possible to combine data analysis with
models of the epidemic process to, for example, predict the timing
of the peak based on the present rate of change, estimate the du-
ration of the outbreak, or the scale of the impact (Andersson et al.,
2008). Epidemic models informed by statistical analysis were heav-
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ily used during the 2001 foot-and-mouth disease outbreak in Britain
(Kao, 2002), and again during the 2007 bluetongue disease outbreak
(Szmaragd et al., 2009) to inform the decisions on suitable control
policies. Another approach is to combine information on diagnos-
tic test behaviour with data analysis to estimate historic patterns
of disease. For example, Giorgi et al. estimated the time of the start
of an HIV outbreak under assumptions of exponential growth of
viral load (Giorgi et al., 2010). Others have exploited information
on diagnostic test kinetics, i.e., the pattern of diagnostic test values
during the course of infection, to estimate average incidence rates.
Examples include the use of antibody test kinetics to estimate sero-
incidence rates forinfluenza (Baguelin et al., 2011), Salmonella in cat-
tle (Nielsen et al., 2011) and Salmonella in humans (Simonsen et al.,
2008). Interestingly enough, because of the delay in surveillance sys-
tems, it may sometimes be necessary to estimate what is happen-
ing “now”. Höhle and An der Heiden (2014) describes a Bayesian
model for “nowcasting” current levels of disease, based on the num-
ber of currently reported cases and the expected number of delayed
reports that will arrive in the coming weeks, and demonstrates its
use in the case of a large 2011 outbreak of Shiga toxin-producing E.
coli 0104 in Germany.
1.5 foundations for the statistical methods used in the
thesis
The following sections give a general overview of the statistical foun-
dations underlying the methods developed in the thesis, introducing
the core terminology and describes some of the specific assumptions
and approaches used.
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1.5.1 A brief introduction to Bayesian Statistics
This thesis adopts a Bayesian approach to the analysis of diagnos-
tic test data, instead of a classical, frequentist approach. The differ-
ence is partly in philosophy, but mostly show up as a difference
in how results are reported and which tools tend to be used. In a
Bayesian framework, probability distributions are encodings of our
knowledge of the world. The Bayesian methodology described be-
low provides a means to update these distributions when new in-
formation is available, and thus the Bayesian approach provides a
natural framework for the integration of data. Quantities that we
are interested in can be viewed as having probability distributions
that encode our original knowledge about them, with a modal value
representing the “best guess” for the true value, and the spread of
the distribution describing our uncertainty of that guess. Assume
that there are two quantities: A, which represents something you
want to know, and B, which represents a quantity that you have
some knowledge of e.g. via measurement or observation. As an ex-
ample, consider a person named Ainsley, with an unknown gender
but with the known height of 157cm. Then A would represent the
gender of Ainsley, and B would represent the height.
There are three important types of probability distributions in Bayesian
statistical analysis: prior distributions, posterior distributions, and
likelihoods. A prior distribution P(A) represents our knowledge
about A before (or prior to) observing some (new) data B. In the ex-
ample of Ainsley, it would be our best guess of the gender before
learning about the height. For example, in the wikipedia page on
the name “Ainsley”, there are links to 5 male and 3 female people.
Taking this information as our prior gives a binomial distribution
Bin(5/8, 3/8) for the outcomes (male,female).
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A posterior distribution P(A|B) represents the state of our knowl-
edge incorporating the data B. The notation P(x|y) refers to the
probability of x conditional on the value of y. In the case of our ex-
ample, the posterior distribution P(A|B) would refer to our knowl-
edge of Ainsley’s gender given that we know the height of 157cm.
A likelihood P(B|A), finally, describes the probability of observing
the data B given a particular value for A. It is often treated as a func-
tion L(x) of the possible values x of A, so that L(x) := P(B|A = x).
In our example, P(B|A) would refer to the probability of the height
being 157cm given that Ainsley was male/female, respectively. The
likelihood is typically based on a set of assumptions underlying our
model of the process of interest and describes how the data is gener-
ated.
The prior, the posterior, and the likelihood can be related to each
other via Bayes’ theorem:
P(A|B) = P(A)P(B|A)
P(B)
This equation can be interpreted as saying that what is known about
some object A given that we make some observation B is encoded
in the probability P(A|B), and that this can be expressed by multi-
plying the prior with the likelihood P(B|A) divided by the proba-
bility P(B). The probability P(B) is often called the normalization
constant for the posterior distribution P(A|B) and is the probability
of observing the data B under the assumptions underlying the like-
lihood irrespective of the value of A. In intuitive terms, Bayes’ the-
orem thus tells us how, under model assumptions encoded by the
likelihood, to modify our prior state of knowledge about the world
by how surprising (i.e how unlikely) newly observed data is.
It should be noted that the normalization constant P(B), the uncon-
ditional probability distribution of the data, is rarely known. The
posterior probability is therefore usually calculated as P(A|B) ∝
P(B|A)P(A). Since for most applications, only the relative probabil-
26 chapter 1 : introduction and overview
ity of different values of A are of interest (and in particular, finding
the values of A with the highest posterior probability), this is rarely
an issue in practice (e.g. see the section on Markov chain Monte
Carlo below).
Bayesian inference make use of Bayes’ theorem in the following way.
Assume that there there is some data that is believed to be relevant
to a quantity of interest. Set up a statistical model describing how
the data is expected to be distributed depending on the various pa-
rameters that might might affect the observed data. Then calculate
the likelihood (as defined in the previous section) of the observed
data under the statistical model. Assign a prior distribution for all
parameters representing our state of knowledge about them before
conducting the statistical analysis. Finally, calculate the posterior dis-
tribution from the product of the likelihood and the prior distribu-
tion. This posterior distribution can also be interpreted as the prior
distribution shifted in the direction of the data likelihood.
From the Bayesian perspective, the full posterior is of interest and
the posterior distribution is what tends to be reported, possibly
summarised, rather than point estimates of parameter values. An
Analytical solution of the posterior distribution is only possible in
fringe cases, and numerical algorithms are the only way to conduct
Bayesian inference in practice. For this reason the application of
Bayesian statistical analysis has expanded greatly with the advent
of cheap widely available computing resources.
1.5.2 Markov chain Monte Carlo
The posterior distribution is usually described with a complex mul-
tidimensional integral that is not solvable analytically, and so needs
to be approximated numerically. Many different algorithms have
therefore been developed that implement Bayesian inference by pro-
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viding approximate posterior distributions. The most common class
of algorithms, and the kind used in this thesis, are Markov chain
Monte Carlo (MCMC) type algorithms (Robert and Casella, 2011).
In very general terms, MCMC algorithms work by selecting an ini-
tial point in the parameter space, and then jumping from point to
point by calculating the value of the density at the current point
(up to a normalizing constant, e.g. P(B) in the example above), and
then calculating the density at a second point drawn from a pro-
posal distribution. The algorithm decides to move to the second
point or stay with the current point by taking into account proper-
ties of the proposal distribution and the relative value of the density
at the proposed second point compared to the current one. In this
way, the algorithm generates a sequence of samples from the pos-
terior, where each sampling point is only dependent on the preced-
ing sampling point. The type of conditional dependence that this
process exhibits is known as “Markov property”, and sequence of
samples having the Markov property is known as a Markov chain.
Because we are generating the sequence at random, the whole proce-
dure is thus known as Markov chain Monte Carlo(MCMC); MCMC
was preceded by so called Monte Carlo algorithms that propose in-
dependent samples from the distribution of interest but are typi-
cally much less efficient. It can be proven that by carefully specify-
ing the conditional jump probability, the distribution of the samples
of the MCMC converge to the posterior distribution of interest (As-
mussen and Glynn, 2011). There are many different implementa-
tions of MCMC , but the two oldest and most widely used are the
Metropolis-Hastings algorithm and Gibbs sampling.
The Metropolis algorithm was published in a seminal paper by Metropo-
lis et al. (1953). Using the Metropolis algorithm, sequential samples
are generated as follows: Assume a starting point Xt and an expres-
sion for the posterior density p(x) = p(A = x|B) ∝ p(B|A =
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x)p(A = x). Jump from Xt = xi to a new point xj randomly selected
in in the parameter space using an arbitrary transition probability
distribution T(x|Xt) that depends on the current point, and is sym-
metric so that T(xi|xj) = T(xj|xi). Compare the posterior density Xi
and Xj, and if the value at Xj is larger than that at Xi, set Xt+1 = Xi.
However, if p(Xj) ≤ p(Xi), then calculate the ratio α = p(Xj)/p(Xi),
and set Xt+1 = Xj as the next value of the chain with probability α.
If Xj is rejected, then set Xt+1 = Xi. Once a value for Xt+1 has been
chosen, set Xt+1 as the new point, and repeat the process. Metropo-
lis et al. proved in their paper that the distribution of samples gener-
ated in this way will converge to the distribution defined by p(). In
the Metropolis algorithm, the transition kernel T(x|Xt) is arbitrary
but must be symmetric, so that T(Xi|Xj) = T(Xj|Xi). A generaliza-
tion known as the Metropolis-Hastings (MH) algorithm that relaxes
this symmetry requirement was later described in a paper by Hast-
ings (1970), and it is this form that is most commonly implemented.
Gibbs sampling can be seen as a special case of the Metropolis al-
gorithm, introduced in Geman and Geman (1984), that can be used
if it is possible to sample from the conditional posterior distribu-
tion for each variable (holding the others fixed) but not necessarily
from the full joint posterior distribution. Assume a posterior den-
sity p() and a starting point in the parameter space Xt, with com-
ponents Xt = (x0, x1, . . . , xn). Fix all but the first component of Xt,
and generate a new value x′0 by sampling from the conditional pos-
terior distribution p(x|x1, x2, x3, . . . , xn). Then sample a new value
x′1 from p(x|x′0, x2, x3, . . . , xn), conditioning on the newly sampled
value x′0. Repeat the process for each component until a new vector
Xt+1 = (x0, x1, x2, x3, . . . , xn) has been generated. Repeat the process
from the beginning starting at Xt+1.
The use of MCMC algorithms is a computationally expensive pro-
cess, but the realisation of Moore’s law, other developments in CPU
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design, and improved design of proposal distribution such as Hamil-
tonian MCMC (Hanson, 2001) have made more and more problems
tractable using MCMC methods. The MCMC algorithm can itself
be implemented using different approaches. It is possible to code it
explicitly using a programming language of your choice, such as R,
C++ or Python. Alternatively, there are a number of computational
packages that have implemented an engine for the translation of sta-
tistical models to program code running an MCMC algorithm, al-
lowing the user to focus on encoding their model using the engine
syntax.
1.5.3 MCMC engines
One of the earliest implemented engines for MCMC was the BUGS
project, which was started in 1989, and popularized with the cre-
ation of the Windows software WinBUGS (Lunn et al., 2009). BUGS
is a declarative language for describing statistical models as Directed
Acyclical Graphs (DAGs) (Thomas et al., 1994). These are graphs
where each statistical component is a node. Edges between a pair
of nodes represent their conditional dependence. Hierarchical sta-
tistical models are well suited to a description in terms of DAGs,
and so with the increasing prominence of hierarchical modelling
(Steenbergen and Jones, 2002), BUGS and WinBUGS gained in pop-
ularity (though it may be that with the advent of WinBUGS, hierar-
chical modelling became easier and thus more popular). One down-
side of this approach, however, is that there is no concept of “order”
in a BUGS program file, and thus only limited possibilities to im-
plement if-then type statements. An alternative open source imple-
mentation of the BUGS language is JAGS (Just Another Gibbs Sam-
pler) by Plummer (2003), and after ongoing development of Win-
BUGS ceased, JAGS has become one of the dominant programs with
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which Bayesian inference is implemented. Like BUGS, it is based on
a declarative language describing DAGS, and as a result the kinds of
models that are possible to implement are somewhat restricted.
A relatively recent development is STAN (Hoffman and Gelman,
2014), a probabilistic programming language with more sophisti-
cated MCMC algorithm known as a “No-U-turn Hamiltonian MCMC”.
By adjusting the size of sampling steps based on information on the
gradient of the posterior, STAN can be more more efficient and in
general take fewer iterations to reach convergence, though each it-
eration requires more computations. For a wide range of models,
this translates into STAN implementations of a given Bayesian in-
ference problem being faster in terms of reaching a given effective
sample size compared with corresponding implementations in JAGS
or WinBUGS. As opposed to JAGS or WinBUGS, the language is not
based on DAGS; the program code is interpreted sequentially and
is therefore more expressive. As a side effect, the sequential nature
combined with a requirement to declare the type of variable upon
definition (continuous, integer, etc) makes for substantially easier
debugging of code.
The different engines described have different strengths and weak-
nesses. Coding your own model has the advantages of allowing
you to incorporate problem-specific information and shortcuts, and
that it can result in faster inference, especially when coding is car-
ried out using a lower-level language. A disadvantage is that the
coding itself can take considerable time, and that the resulting pro-
gram is more prone to bugs than using one of the higher-level lan-
guages that already has an MCMC engine implemented. WinBUGS
has been around for a long time, and there are a wide variety of ex-
amples and models implemented to take inspiration from. JAGS is
faster than WinBUGS, is portable across computing platforms, does
not rely on a DOS-based software, and is still being developed and
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improved. On the downside, Dr. Martyn Plummer is the sole devel-
oper, which means that bug fixes and improvements can take time.
STAN is faster, more expressive, easier to debug, and under very
active development by a four-person team. However, at the time of
this writing, there are some models that cannot be implemented,
and there are not a large numbers of previous examples for how
STAN can be used.
In this thesis, all the described models were implemented in JAGS,
with the exception of chapter 4, which made use of STAN.
1.5.4 Evaluation of convergence
Running an MCMC algorithm results in a series of sequentially cor-
related draws of parameter values. The proofs of convergence of
MCMC state that in the limit, i.e. after “enough” number of sequen-
tial parameter values have been drawn, the distribution of param-
eter values corresponds to the posterior distribution of interest. In
order to evaluate if “enough” draws have been made, one needs to
evaluate whether the MCMC procedure has reached a steady state.
To do so in a strict formal manner is only possible in some simple
analytically tractable special cases, but for the remainder of models
there are a number of heuristics that can be used for this purpose.
Summary statistics have been proposed that measure the amount of
convergence. The Gelman-Rubin statistic (Brooks and Gelman, 1998)
measures the within-chain variance of several (usually parallel) runs
of the same MCMC algorithm, with initial values in different parts
of the parameter space, and compares this to the overall variance
of all chains taken as a whole. If the ratio of the overall variance to
the within-chain variance is less than 1.15 (the original paper rec-
ommended 1.2 as a rough criteria for convergence), this is taken as
evidence that the different chains are sampling from the same distri-
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bution, and thus have converged. The GR statistics relies on the exis-
tence of several different chains, and that the different chains initial
values were chosen from sufficiently different parts of the parame-
ter space that their starting between-variance is high. In this thesis,
Initial starting values for the parameters in the various MCMC anal-
yses conducted were chosen at random, either sampled from the
prior distributions, or by selecting a central region of the support
and sampling uniformly for this region. In either case, initial values
independently sampled for each chain.
Another heuristic includes looking at autocorrelation plots for dif-
ferent parameters, as too high an autocorrelation indicates that the
chain is still shifting towards the true value. A high autocorrelation
can also indicate bad “mixing”, where the chains have converged
to the true posterior, but where the correlation between individual
draws is so high that you need to generate a large number of draws
to produce an unbiased estimate representative of the full poste-
rior distribution. In addition to any quantitative evaluations, it is
also essential to visualise the draws directly; obvious patterns over
time tend to indicate non-convergence, and other problems such as
parameters being correlated with each other also tend to show up
when plotting.
For the results presented in this thesis, the Gelman-Rubin statistics
has been used for the initial judgement of convergence and all par-
allel chains have GR values under the accepted threshold of 1.15. As
a rule of thumb, five chains have been run in parallel to provide suf-
ficient data on between-chain variability. After a draw passes this
value, additional inspection of trace plots and autocorrelation plots
have been used to further ensure that the estimated posterior is not
misleading.
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1.5.5 On the selection of priors
The choice of priors is a contentious one in the field of Bayesian sta-
tistical analysis, with many different schools, and the approach used
in this thesis has evolved over the course of the years of work. As
a general summary, there are three main categories of priors: infor-
mative priors, uninformative priors, and weakly informative priors
(Robert (2007), p 105ff).
Informative priors explicitly try to incorporate previous information
in a parametric form. This information might be results from previ-
ous studies or solicited from experts. This is a classic approach to
Bayesian statistical analysis, as it is strongly influenced by the view
that probability distributions should describe our state of knowl-
edge of the world. In the work for this thesis, informative priors
were used in the development phase of the hindcasting model for
the variance of test diagnostics. At a later stage, these priors were
changed to the uninformative kind. The hindcasting method is thus
robust to the choice of prior, and the data used was informative
enough to identify parameters without strong prior beliefs.
According to the “uninformative” school of thought, priors are cho-
sen in a way that attempt to influence the posterior estimates as lit-
tle as possible. A classic example of this is the use of a gamma(0.0001,0.0001)
prior for the reciprocal of the variance of a normal distribution, thus
putting approximately equal weight to a large subset of the positive
real number line. (This choice of prior was introduced as a recom-
mended choice in BUGS in 1994(Thomas et al., 1994), and subse-
quently gained popularity). This school is primarily governed by
an attempt to be as scientifically unbiased and objective as possible.
A category of priors that can be used in both an informative and
an uninformative setting is conjugate priors. These are priors cho-
sen so that the prior distribution P(A) and the posterior distribu-
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tion P(B|A)P(A) both belong to the same class of parametric dis-
tributions. For example, the Beta B(a, b)-distribution is the conju-
gate prior to the proportion parameter of a binomial distribution
Bin(a, p), in that the posterior distribution for p given a beta prior
B(a, b) and observed c success and d failures from a binomial distri-
bution is B(a + c, b + d). Because of this property, conjugate priors
simplify analytical calculations and were important for making nu-
merical calculations tractable in the early days of lower computer
power. In the case of Gibbs sampling (described above), using conju-
gate priors implies that the posterior conditional distribution of each
component follows a known parametric form, and so can be easily
sampled when updating the components. One reason the gamma
prior became popular was that the gamma distribution is the con-
jugate prior for the inverse of the variance parameter in a normal
distribution with unknown mean and variance.
The approach of weakly informative priors, championed by amongst
other, Andrew Gelman (Gelman et al., 2008), was used during later
phases of the thesis work, when investigating and trying to resolve
convergence issues. When using weakly informative priors, the prin-
ciple is to incorporate domain knowledge on as general a level as
possible. So, for example, it is known that the height of humans are
on the order of meters and not kilometers or millimeters, and so
a lognormal distribution of lognorm(1,
√
10) would be used to in-
corporate this knowledge ( a standard deviation of 101/2 implies
that 95% of the distribution lies within [1/(101/2∗2), 1x(101/2∗2)] =
[1/10, 10)]). This improves the behaviour of the numerical inference
by regularizing the likelihood surface, while at the same time avoid-
ing that posterior estimates are highly influenced by subjective ex-
pert judgements.
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1.6 thesis outline
The work conducted in this thesis is focused on ways to exploit
the full potential of diagnostic data, leveraging the continuous and
dynamic nature of test measurements, and the additional informa-
tion gained by combining multiple diagnostic tests. A key part part
of the argument put forward is that recording raw test data and
conducting multiple tests on samples typically collected in current
surveillance systems would make possible statistical analyses that
can produce valuable information on the epidemiology of diseases.
This is conceptualised as being of particular value where surveil-
lance data is limited, or for diseases where little is known, either
because they are emerging infections, or because they have been un-
detected or considered of low priority in the past.
The classical Hui-Walter latent class analysis (Hui and Walter, 1980)
makes it possible to estimate the unknown sensitivity and specificity
of two binary diagnostic tests by comparing their results in two set-
tings with differing levels of incidence. Chapter two applies this ap-
proach to evaluate the use of multiple diagnostic tests to estimate
sensitivity and specificity of diagnostic tests that can distinguish vac-
cinated and infected animals (DIVA tests) for Mycobacterium bovis,
producing recommendations regarding a potential vaccine trial in
cattle in the UK. It expands on the Hui Walter approach by showing
how to estimate vaccine efficacy in addition to sensitivity and speci-
ficity.
Chapter three also looks at the additional benefit of using two diag-
nostic tests, but in a more general fashion by treating the diagnos-
tic test response as continuous with known kinetics over the time
since infection. The concept of “hindcasting” (inferring the histori-
cal trend of) historic disease dynamics from cross-sectional data is
introduced, and applied to the situation of endemic diseases which
36 chapter 1 : introduction and overview
exhibit linear trends. In this way, it is possible to estimate the long-
term trends of pathogen incidence, for example to evaluate the im-
pact of policy implementations using cross-sectional data.
Chapter four is primarily aimed at improving the early phase of dis-
ease surveillance, during the initial phase of an outbreak, or when a
new pathogen has been introduced to a region or country. The focus
is on emerging or epidemic pathogens where the interest is on find-
ing out information on the dynamic of an outbreak. The approach
is illustrated by application to two case studies, one based on a blue-
tongue outbreak in the UK in 2007, and one based on a whooping
cough outbreak in Wisconsin in 2003..
Chapters three and four highlight the benefits gained by utilizing
knowledge of test kinetics in disease surveillance, and thus make a
case for considering ways to ensure greater access to such informa-
tion. Chapter five is thus an exploration of strategies for improving
estimation of test kinetics using observational data, with a particu-
lar focus on the potential advantages of estimating two or more test
kinetics simultaneously.
Chapter six provides an overview of the results presented in the
thesis, highlights potential avenues of research and argues for the
greater utilisation of multiple testing in the field of disease surveil-
lance.


2C H A P T E R 2 : A L AT E N T C L A S S A N A LY S I S O F B T B
D I VA T E S T S
Abstract The practice of disease surveillance covers the process from
discovering potential cases, via taking samples and testing these for
disease with different diagnostic tests, to collecting the test results in
databases, analysing the patterns of disease, and deciding on appro-
priate responses and policies. As a part of this process, establishing
the properties of the diagnostic tests used is of critical importance.
This chapter describes an application of classical binary diagnostic
test analysis for estimating sensitivity and specificity in a setting of
vaccinated individuals tested using two diagnostic tests with dif-
ferent properties in vaccinated and unvaccinated animals. Starting
from the definitions of sensitivity and specificity of a diagnostic test,
it discusses an approach to estimate these using a Bayesian Latent
Class Analysis. The approach is then applied to estimate the effect
of study size on sensitivity and specificity estimates for a trial of a
test for bovine Tuberculosis that is able to distinguish between vac-
cinated and infected animals, a so-called DIVA (”Distinguishing
Infected and Vaccinated Animals”) test. The sample size analysis
was commissioned by the Welsh Government and the British Depart-
ment for Environment, Food and Rural Affairs (Defra). The result
of the analysis shows that the sample size required to demonstrate
that the test specificity is above the previously established thresh-
old for cost-effectiveness, is in excess of 30 000 animals, even under
the assumption that the real specificity is 99.9999%, and including a
pilot study of animals tested with a gold-standard approach. The de-
scribed framework expands on published studies by estimating vac-
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cine efficacy in addition to diagnostic test properties, allowing for
the application of latent class analysis in a wider range of settings
than previously possible.
2.1 introduction
Diagnostic testing plays a crucial role in the surveillance and detec-
tion of infectious diseases. In its simplest form, we take a sample
from an individual, and use our test, for example an antibody test,
to say whether the individual is infected. As all tests are imperfect,
knowing the behaviour of the diagnostic tests used for surveillance
is fundamental to evaluate collected surveillance data; of particular
importance is the reliability and error rates of the tests used.
Classically, diagnostic tests have been treated as having a binary re-
sponse, producing either a positive or a negative result. The diag-
nostic test gives a result that can be classified as “positive” if the
individual is infected, and a result that can be classified as “nega-
tive” if the individual is not infected. Denote by D+(D−) a infected
(non-infected) individual, and t+ (t−) a positive (negative) test result.
The probability that a test of an infected animal produces a positive
result , Se = P(t+|D+) is commonly referred to as the sensitivity
of the test, and the probability that a test of a non-infected animal
produces a negative test, Sp = P(t−|D−) is commonly referred to as
the specificity of the test. This terminology was first introduced in
1961 by Thorner and Remein (1961) in a US dept. of Health publica-
tion. Together, sensitivity and specificity fully describe the expected
behavior of a binary test, when used in a population and on a dis-
ease where both sensitivity and specificity can be assumed to be the
same for all individuals.
In order to estimate the specificity of a test, the ideal situation is to
test a population that is known to be free from disease, and produce
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statistical estimates and confidence intervals of the specificity from
the proportion of negative test results and the number of individu-
als in the population. Similarly, in order to evaluate the sensitivity
of a test, the ideal situation is to test a population where all individ-
uals are known to be infected, and estimate the sensitivity from the
proportion of positive test results. However, such ideal situations
are rare, as it requires either a perfect test or a controlled infection
study.
A somewhat more realistic approach is to test a population with un-
known prevalence with two tests, one reference test where the sensi-
tivity and specificity is already known, and another test that is being
evaluated. In such a situation, it is possible to estimate the unknown
sensitivity and specificity of the new test. However, this creates a bit
of a catch-22 situation, as the properties of the reference test would
have to have been evaluated at some point in the past.
A statistical method for estimating the properties of two diagnostic
tests at once was pioneered by Hui and Walter (1980). In this sem-
inal paper, they show that it is possible to estimate the unknown
sensitivity and specificity of two different diagnostic tests simulta-
neously if both tests are used on all individuals in two populations
with different (but unknown) prevalences of disease. The approach
used in their paper is known as ”Latent Class Analysis”.
This chapter extends such latent class analysis to a situation where
a vaccine can be expected to interfere with the diagnostic test per-
formance. The assumptions are that two populations with different
prevalences of disease are available, each population is split up into
one vaccinated and one unvaccinated subpopulation, and two diag-
nostic tests are used on all four subpopulations. We allow sensitivity
and specificity to vary for vaccinated and unvaccinated individu-
als. It is demonstrated that it is possible to extend the latent class
framework to estimate unknown vaccine efficacy in addition to the
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unknown test parameters, and population prevalences. The frame-
work is applied to estimate the effect of study size on sensitivity and
specificity estimates for a trial of a test for bovine Tuberculosis that
is able to distinguish between vaccinated and infected animals, a
so-called DIVA (”Distinguishing Infected and Vaccinated Animals”)
test. The results of this study are currently being considered by the
Welsh Government and the British Department for Environment,
Food and Rural Affairs) (Defra).
2.2 a latent-class analysis of vaccinated populations
In this section, the notation follows that of Johnson et al. (2001) closely,
with the addition of vaccinated and unvaccinated subpopulations,
and a vaccine effectiveness parameter.
Consider two populations in which there are cases of the pathogen
of interest; one ”high prevalence” population and one ”low preva-
lence” population, but where the exact prevalences are unknown in
both populations. Each population is split into two subpopulations;
one consisting of vaccinated individuals, and one consisting of non
vaccinated individuals. Assume there are two different tests, with
possibly differing sensitivity and specificity. Assume that the results
of the tests are independent conditional on the status of the animal,
and that sensitivity and specificity are affected by the vaccination
status of the individual.
Ignoring vaccination, we would define P(t = +|D = +) as the
probability of a test t being positive given that the true status D is
positive. We would also have P(t = +|D = −), P(t = −|D = +),
and P(t = −|D = −) denote the probabilities of the different
combinations of test results and true status. However, here we as-
sume that each test t can have different sensitivity Setv, defined as
Setv = P(t = +|D = +, v) when used to test animals with vaccina-
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tion status v (i.e. vaccinated or unvaccinated). Likewise, we assume
that the specificity Sptv = P(t = −|D = −, v) can differ between
tests and between vaccinated and unvaccinated animals. Setv and
Sptv are treated as unknown properties of the tests in the model. De-
note the prevalence in each unvaccinated population p by Ip1, and
the prevalence in each vaccinated population by Ip2 = λ ∗ Ip1, where
λ denotes the vaccine efficacy defined as the relative reduction in in-
cidence in vaccinated animals. Assume that the relative reduction of
incidence is the same regardless of the original incidence rate.
Finally, consider the event that a particular individual is tested with
the two diagnostic tests. Denote by ++ the event that the two tests,
according to a specified ordering, are positive. In a similar fashion
+− denotes the event in which the first test is positive and the sec-
ond negative, etcetera. Note that that a test can be positive either
because the true status of an animal D = + and the test gives the
correct answer (with probability Setv), or because the true status is
negative, D = −, and the test gives the wrong answer (with proba-
bility 1− Sptv).
Using this, it is possible to write the probability for a combined test
result given population and vaccination status as:
P(+ + |p, v) = (Se1v ∗ Ipv)(Se2v ∗ Ipv)+
(1− Sp1v) ∗ (1− Ipv)(1− Sp2v) ∗ (1− Ipv)
P(+− |p, v) = (Se1v ∗ Ipv)((1− Se2v) ∗ Ipv)+
(1− Sp1v) ∗ (1− Ipv p)(Sp2v) ∗ (1− Ipv)
P(−+ |p, v) = ((1− Se1v) ∗ Ipv)(Se2v ∗ Ipv)+
(Sp1v) ∗ (1− Ipv)(1− Sp2v) ∗ (1− Ipv)
P(−− |p, v) = ((1− Se1v) ∗ Ipv)((1− Se2v) ∗ Ipv)+
(Sp1v) ∗ (1− Ipv)(Sp2v) ∗ (1− Ipv)
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When tabulating test data, denote by N++,pv the number of observa-
tions where both tests were positive in population p with vaccina-
tion status v, and similarly for the number of observations with only
the first test positive, only the second test, or neither test positive.
Then the vector
N = {N++,pv, N+−,pv, N−+,pv, N¯,pv}
is multinomial-distributed with probability vector
{P(+ + |p, v), P(+− |p, v), P(−+ |p, v), P(−− |p, v)}
There are four counts for each subpopulation, and four subpopu-
lations, giving a total of 16 data points, and 12 degrees of freedom.
The probability vector is a function of {Setv} and {Sptv}, with four
distinct values each, Ip, with two values, and by λ, giving a total of
of 11 parameters. We therefore have one degree of freedom when
estimating the parameters.
Given observed counts {N}, the data likelihood for the parameters
in the model is then simply:
∏
∀p,v
(
P(+ + |p, v)N++,pv × P(+− |p, v)N+−,pv×
P(−+ |p, v)N−+,pv × P(−− |p, v)N−−,pv))
We evaluated the likelihood using a Bayesian Markov Chain Monte
Carlo (MCMC) approach implemented in the JAGS language (Plum-
mer, 2003) using beta priors for Sepv and Sppv, with parameters de-
rived from the results of ”gold standard” tests. Specifically, if the
number of true positive animals, as detected by a gold standard
test that were detected by test 1 was s1, and the number incorrectly
tested as negative was n1, then a β(s1 + 1, n1 + 1) prior was used
for the sensitivity of test 1. A similar approach was used to define
beta priors for the sensitivity of test 2 and the two specificities. Start-
ing values for the parameters in the MCMC were chosen at random
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from the prior distributions, independently sampled for each chain.
Inspection of trace plots indicated that for all scenarios, the chains
had fully converged after a burn-in of 1000 iterations. The following
1000 iterations were then used as basis for the presented results.
There is a potential technical issues with the implementing the above
approach, known as label switching. In the expressions above, swap-
ping Se for 1− Sp, and Sp for 1− Se would give the exact same re-
sult, and so the posterior could converge to either of these interpre-
tations, leading to a bimodal distribution. One solution for both of
these problems to require that Sensitivity plus Specificity is above 1
(as otherwise swapping the interpretation of the test around, treat-
ing positive test response as a negative result and vice versa, would
result in a better test) (Toft et al., 2004). In the case of this study, the
use of prior information from gold standard tests proved enough to
resolve the potential bimodality, so constraining the sensitivity and
specificity was not needed.
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The use of widespread vaccination is one of the most powerful meth-
ods available for the control of endemic and epidemic infectious
diseases. The success stories are many, including polio, smallpox
(WHO and Global Commission for the Certification of Smallpox,
1980), and rinderpest (FAO, 2013). In some cases however, the use of
vaccination can be complicated by diagnostic tests failing to distin-
guish between infected and vaccinated individuals. Unless the vac-
cine is perfectly efficacious, this means that any breakthrough cases
that occur despite vaccination would go undetected. In the case of
an outbreak of cases, the lack of a functioning test would severely
hamper control efforts.
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In the case of bovine Tuberculosis (”bTB”), the standard test recom-
mended for screening by the World Organisation for Animal Health
is the so-called tuberculin skin test (OIE, 2009), which consists of
injecting purified tuberculin proteins in the neck of the animal and
looking for the resulting inflammation that indicates the presence
of antibodies against M.bovis. Vaccinated animals will show the
same reactions, and so the tuberculin test is unable to distinguish
between vaccinated animals without infection, and vaccinated ani-
mals where breakthrough infections have occurred. Because of this,
the European Council have made it mandatory for countries to ab-
stain from vaccination if they want to retain an export classification
(EEC, 1977). The concern is that infected animals will be exported
and thus spread the disease to countries that are disease free.
Bovine Tuberculosis is endemic in the UK and there has been a steady
increase in incidence since 1984 (Gilbert et al., 2005). This increas-
ing incidence has resulted in a similarly increasing cost to farmers
and society (DEFRA, 2014). Suitable policies for the control of bTB
has been the subject for intense debate (Schiller et al., 2011), includ-
ing the controversial proposals for the culling of badgers which can
transmit infections to cattle (Godfray et al., 2013), and which many
believe represent a reservoir for bTB. One option is the large-scale
vaccination of the cattle population (Waters et al., 2012). However,
because of the EEC regulation, this has so far not been an option.
Recently, new tests for bTB have become available that can diagnose
infection in vaccinated animals. These tests are able to distinguish
between antibodies produced in response to vaccination, and anti-
bodies produced in response to a natural infection, so-called DIVA
tests. They have been evaluated in lab settings as well as in con-
trolled experimental infections, and have been found to have a very
high specificity, as well as a good sensitivity (AHAW, 2013; Conlan
et al., 2015). The next step in the evaluation is to test their perfor-
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mance in realistic field conditions, necessitating a large, long-term
trial involving production farms in the UK.
This section describes the effect that design choices, vaccine efficacy,
true test sensitivity and true test specificity have on the sample size
required to attain a certain level of precision for the estimated test
sensitivity and specificity, using the latent class analysis framework
described above. A particular goal for the analysis is to estimate the
sample size needed to able to be able to reliably prove that the novel
DIVA test reaches a 99.85% threshold.
This threshold was established in (Conlan et al., 2015) by using individual-
based modelling to investigate the cost-effectiveness of introducing
vaccination of bTB in the UK under a range of different scenarios.
False positive tests incur a large cost in terms of unnecessary use of
containment efforts and full-herd tests. Conlan et al. thus concluded
that a DIVA test would need to be reach 99.85% specificity, for the
balance between a reduced clinical burden and an increased cost of
false-positive diagnosis (with subsequent actions) to be beneficial.
The previous studies of the DIVA test indicate that the true speci-
ficity is likely above 99.9%, making it likely that it would be possible
to begin routine vaccinations. However, in order to provide reliable
evidence that this is the case in real-world conditions, any estimates
of specificity produced by the trial should ideally indicate that the
95% credible interval for the posterior estimate is above 99.85.
2.3.1 Data simulation
As in the description of the framework, the following assumptions
were made when analyzing the potential outcomes of a DIVA trial:
• The study is composed of one ”high prevalence” population
and one ”low prevalence” population, but the exact preva-
lences are unknown.
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• Each population is then split into two subpopulations; one con-
sisting of vaccinated individuals, and one consisting of non
vaccinated individuals.
• It is assumed that there are two different tests used in the trial,
both DIVA capable. It is further assumed that these tests had
differing sensitivity and specificity, but that sensitivity and
specificity was not affected by the vaccination status of the an-
imal. The analysis used a balanced design, with equal number
of individuals in each subgroup, as it was believed that this
represented the most likely protocol to be adopted for the field
trials.
Data were simulated using the R software package (R Core Team,
2012). During data generation, it was assumed that the trial was
run on four groups of equal size: vaccinated and unvaccinated cat-
tle from either a high prevalence (modelled as a prevalence of 5%),
or a low prevalence (modelled as 2%) population. In addition to this
data, it was also assumed that there would be a number of animals
taken from breakdown herds that had been tested positive using
the established skin test and could be considered ”gold standard”
positive, as well as a number of animals taken from certified bTB-
free farms that could be considered ”gold standard” negative. These
smaller populations of known positive and known negative animals
was included because the results from animals with known disease
status could be expected to provide information on sensitivity and
specificity that could replace test results from a large number of
tests from animals with unknown status, thereby decreasing the
required size of the study. The other reason for including such ani-
mals is to provide a safe lower bound for the specificity, estimated
in a way that is incontrovertible; an additional safeguard to guaran-
tee a baseline of useful results. Finally, it was felt that having prelim-
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inary estimates of the test properties would be useful for farmers to
be convinced of the benefit to being part in the vaccination study.
Data was generated from scenarios with different combinations of
parameters: eight different values of sample size were used between
30 000 and 100 000 animals in 10 000 step intervals; 10 different val-
ues for true specificity between 0.9990 and 0.9999, and for the gold
standard combinations of either 30 positive and 100 negative ani-
mals, 300 positive and 1000 negative, or 1500 positive and 5000 nega-
tive animals were used. 100 different data sets were randomly gener-
ated for each unique combination of parameter values.
2.3.2 Results
Recall that we assume that the true specificity of the DIVA test is
above 99.9%, and that the 95% credible interval for the posterior of
the estimates of specificity produced by the trial should be above
99.85%.
In order to provide a context for the results of the sample size calcu-
lations, one can consider a hypothetical scenario where a perfect test
is available for use on all animals in the study. Table 2.1 shows the
relationship between sample size and width of the confidence inter-
val for four different specificities, assuming that the imperfect DIVA
test could be tested on gold standard negative animals.
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Table 2.1: This table indicates the relationship between sample size and precision
for evaluating specificity of a diagnostic test with a gold standard ap-
proach. Numbers are taken from the appendix written by Innocent,
McKendrick, and Rydevik of the Triveritas Ltd for a consortium (2015)
report to Defra and the Welsh Government. These are based on an ex-
act formula for sample size calculations of binomial distributions (Ar-
mitage et al. (2008), p117), and gives the lowest sample size for which
there is an 80% probability that a random sample would produce a con-
fidence interval of equal to or less than the required width.
true sensitivity width of credible interval sample size
70% +/-5% 353
70% +/-1% 8230
75% +/-5% 320
75% +/-1% 7382
99.5% +/-0.5% 1226
99.5% +/-0.2% 5974
99.85% +/-0.5% 696
99.85% +/-0.2% 2508
99.99% +/-0.3% 1162
99.99% +/-0.2% 2034
99.99% +/-0.1% 6150
99.99% +/-0.05% 20320
While in reality there are no true gold standard tests available for
bovine tuberculosis, post mortem identification of lesions with sub-
sequent identification of the causal agent is considered to have 100%
specificity. One approach would therefore use the results from post-
mortem examinations to identity assuredly positive animals. An-
other approach to ensuring that the test is evaluated on guaran-
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teed negative animals, instead of using a gold standard test for clas-
sification, is to apply the test to animals that are highly unlikely
to have been exposed to bTB. One example would be a low-risk-
classified farm in Scotland (which is classified as officially bTB-free
since 2009). While these approaches are too expensive to carry out
on a full scale, we can use both approaches on a smaller scale and
use the results to inform our priors for the latent class analysis.
Figure 2.1 shows the effect of sample size on the credible interval of
the estimated specificity of one of the DIVA tests. Each box repre-
sents the results from fitting the latent-class model to 100 different
randomly generated data sets with a varying number of tested an-
imals, assuming that the true specificity of the test was 0.999, and
that in addition to the main study, 30 animals that were gold stan-
dard positive and 100 animals that were gold standard negative
were tested to derive priors for the specificity and sensitivity of the
DIVA test (see methods for details). We would desire that the study
has at least 80% power, i.e. at least 80% chance that the posterior es-
timate would show the result desired if the hypothesis that is being
tested is true. In the case of the current study, this translates to be-
ing able to have at least an 80% chance to prove that the DIVA tests
are good enough (i.e. better than 99.85% specificity). For the figure,
this translates to the lower end of the box being above the 99.85%
line. Clearly, even with 100 000 animals, the study does not reach
sufficient power.
Figure 2.2 shows how distribution of the lower bound of the credi-
ble interval change under different assumptions of true specificity
and the number of gold standard tested animals used to inform the
prior distribution for specificity and sensitivity. This figure clearly
indicates that the most crucial parameter is the true specificity, which
has to be much higher than the threshold efficacy in order to pro-
duce data that can reliably demonstrate that the specificity is, in-
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Figure 2.1: The above box plots describes the distribution of the lower bounds of
the credible intervals for the estimated specificity of the DIVA tests.
Each box represents the results from fitting the latent-class model to
100 different randomly generated data sets with a varying number
of tested animals, assuming that the true specificity of the test was
0.999, and that in addition to the main study, 30 animals that were
gold standard positive and 100 animals that were gold standard neg-
ative were tested to give a baseline indication of the sensitivity and
specificity (analysed as described in the methods). The box plot param-
eters were modified from a standard box plot to display 80% and 95%
quantiles. Thus, the box represents the central region in which 60% of
estimate lower 95% bounds of the estimated specificity Sˆp from 100
simulations falls. The whiskers indicate the extreme 95% range of the
lower 95% credible interval, and the middle mark indicate the median.
The red horizontal line indicate the 99.85% threshold above which a
DIVA test would be cost effective when implemented - the lower edge
of a box above this line would thus indicate a power of more than 80%
for demonstrating that the test used is cost effective, based on data
with the number of samples indicated.
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Figure 2.2: This figure shows how the credible interval is affected by different
conditions, and which conditions are required to reach 80% power.
As in figure 1, the lower edge of the boxes signify the threshold for
which 80% power is reached. The red line indicate the 99.85% speci-
ficity threshold - Columns indicate varying specificity; rows indicate
varying sizes of a gold standard pilot study. The blue line indicate the
trend of the medians as a function of sample size.
54 chapter 2 : a latent class analysis of btb diva tests
deed above the threshold. From the results shown in the figure, it
is possible to say that if the true specificity is high enough, above
0.9995, sufficient power can be reached with a combination of a pi-
lot study using 1500 gold standard positive and 5000 gold standard
negative animals; and a study on production animals including a
total of 50 000 animals. If the DIVA test has near perfect specificity
, >0.9999, and only on very rare occasions give false positive results,
then sufficient power can be reached with a pilot study on 300 posi-
tive and 1000 negative animals, and a study on production animals
including 30 000 individuals.
As described in the methods section above, in addition to estimat-
ing sensitivity and specificity for the two DIVA tests, the vaccine
efficacy parameter is also estimated. For the middle-of-the-road sce-
nario with an assumed true specificity of .9999, a sample size of 30
000 animals, 300 positive and 1000 negative gold-standard tested an-
imals, and a true vaccine efficacy of 0.6, the mean posterior estimate
of the vaccine efficacy had a root mean square error (RMSE) of 4.7
percentage units based on 100 different simulated data sets, a rela-
tive error of about 8% . The mean width of the 95% credible interval
was 20.6 percentage units. The true sensitivities and specificity of
the diva tests have little influence on these estimates (with an as-
sumed true specificity of 0.999 , the RMSE was 4.3 percentage units,
a 7% relative error, and the mean width was 21.8 percentage units);
similarly for the number of gold standard tested animals used. How-
ever, the true vaccine efficacy has a strong influence on the width of
the credible intervals. Figure 2.3 shows how the 95% posterior credi-
ble interval varies for different sample sizes and different true levels
of vaccine efficacy.
As the true vaccine efficacy increases, so does the absolute size of
the confidence interval. To estimate a 90% vaccine efficacy to within
+/- 10 percentage units, a sample size of at least 70 000 animals
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Figure 2.3: Each vertical line represents the 95% posterior credible interval of the
inferred vaccine efficacy parameter for different sizes of the pilot study,
and for different true values of the parameter. The true specificity of
the DIVA test was fixed at 0.9999, and the number of gold standard
tests were fixed at 300 positive and 1000 negative animals. For each
combination of sample size and true vaccine efficacy, ten different data
sets were simulated. The horizontal axes are thus on on a categorical
scale that indicate the level of true vaccine efficacy, ranging from 10%
to 90%. The grey lines indicate the 95% posterior credible interval
of the efficacy parameter for each data set, with the dots indicating
the posterior mean, coloured according to the level of assumed true
vaccine efficacy. The dashed horizontal lines indicate vaccine efficacy
levels in 10%-unit intervals
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would be needed, while a 50% vaccine efficacy could be estimated
to within 10 percentage units with 50 000 animals. For less effective
vaccines, 30 000 animals would be more than enough to estimate
efficacies of less than 30% to within 10 percentage units. The increas-
ing size of the confidence interval is likely due to higher vaccine ef-
ficacy leading to fewer positive animals, making the evaluation of
test sensitivity and specificity more uncertain, and thus as a conse-
quence all parameters of the posterior.
2.4 discussion
This chapter has expanded on previous work on the Hui-Walter
paradigm by demonstrating how to estimate the sensitivity and
specificity of two tests with different properties in vaccinated and
unvaccinated populations. In addition, it demonstrates that this can
be done for a vaccine with unknown efficacy, using two populations
with different levels of disease, each population divided into vacci-
nated and unvaccinated subpopulations.
Results from the sample size evaluation highlight that the ability to
prove that the DIVA tests have a specificity high enough to pass the
cost-effectiveness threshold of 99.85% established by Conlan et al.
(2015), is highly dependent on the actual specificity of the tests. It
is a challenging criteria that will require either a very large trial, or
that the DIVA test is better than the required threshold by a large
margin, or some combination of the two. A sample size of 50 000 an-
imals in the trial would only be likely to clear the 99.85% threshold
if the true specificity is above 99.99%, with sample sizes of 500 000
animals required if the test is ”only” 99.9% sensitive, equivalent to
5% of the UK cattle population which would be a very large trial.
Moreover, without the addition of animals with known true infec-
tion status the required sample sizes are even larger.
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Note that these study sizes were calculated under the assumption
that it is needed to prove “beyond reasonable doubt” that the vac-
cine is cost effective. It could be argued that the decision of whether
to vaccinate or not should be decided based on which course of ac-
tion is “most likely” to be economically beneficial; there is a cost
to vaccinating, but there is likewise a cost to not vaccinate. By as-
suming that evidence “beyond reasonable doubt” is needed, the im-
plicit assumption is that the status quo is preferable in the absence
of considerable evidence to the contrary. If, instead, a “most likely”
approach to the decision were taken, this would allow each option
to be chosen based on their own merit. In technical terms, such an
approach would be translated to requiring that at least 50% of the
mass of the posterior probability distribution fall above the 99.85%
threshold. If such a decision criteria would be seen as sufficient, the
required study size to reach 80% power could be reduced consider-
ably (preliminary investigations indicate that the study size could
potentially be reduced by a factor between 5 and 10, assuming other
study parameters remain the same).
The Hui-Walter paradigm is well established for estimating the prop-
erties of diagnostic tests in the absence of a gold standard. By us-
ing vaccinated and non-vaccinated individuals as two distinct pop-
ulations, it becomes possible to estimate the efficacy of a vaccine
in addition to the properties of the diagnostic tests. To our knowl-
edge, no previous paper has made use of Hui-Walter type models
in this way before. This could be useful in situations where novel
vaccines and diagnostic tests are used to control a disease, where
the vaccine effect has been tested in controlled studies, but the field
efficacy of the tools is unknown. Such a situation is likely to occur
for rapidly developing outbreaks, such as the recent Ebola outbreak
(WHO Ebola Response Team, 2014), where both vaccines and new
diagnostic tools are developed in response to the occurrence of the
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outbreak. While the resulting efficacy estimates are not as precise as
those from a study designed for efficacy evaluation, the simulation
results presented above indicate that they would still be sufficient to
evaluate usefulness to within +/- 10 percentage-units.
An important assumption made in the use of the Hui-Walter paradigm
is the assumption of independence between the results of the two
different diagnostic tests, conditional on the true status on the ani-
mal. The conditional independence assumption is necessary in the
case of two tests and two populations, or as in our case, between
four subpopulations with four unknown sensitivity/specificity pa-
rameters. However, if the tests in question both measure the same
type of response to infection, this assumption can be questioned.
In Toft et al. (2007), it is suggested that if the assumption of condi-
tional independence is unreasonable, one can consider the use of
three different tests. In the DIVA situation, this would be difficult,
but a possible strategy is to conduct post-mortem evaluations on an-
imals which have been indicated as positive. In such a situation, it
is enough if one test is conditionally independent from the others.
Clegg et al. (2011) used a three-test latent class approach to evalu-
ate the performance of the interferon-γ test, the SICCT test, and a
multiplex antibody assay for detecting bovine Tuberculosis (all tests
described in OIE (2009)), assuming that the SICCT test was condi-
tionally independent from the two others. Unfortunately, in our sit-
uation the SICCT test would show vaccinated animals as positive;
however, should another DIVA test be developed based on another
principle from the two tests used in this study, a three-test approach
could be used to estimate possible dependencies between the exist-
ing tests.
An additional consideration is the time between testing animals.
While the analysis in this chapter assumes that all animals are in-
fected randomly and independently from each other, and that there
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is a dichotomy between ”infected” and ”non-infected” animals, it is
likely that test sensitivity is dependent on the time since infection.
The disease progression after infection with M.bovis can take up to a
year (Domingo et al., 2014), and can be usefully considered to pass
through several distinct stages. A diagnostic test is likely to have
different sensitivity at each stage in the disease. Therefore, if an an-
imal is infected and tests negative, it is likely that subsequent tests
close enough in time will also be negative, and the nominal sensi-
tivity would therefore overestimate the herd-level sensitivity. A pos-
sible way to circumvent this would be to model the measured test
response as a continuous variable instead of using the infected/non-
infected classification. This could be done using either a mixture
model approach, or by incorporating information on how the test
response would depend on the time since infection.
The work in this chapter has shown that with the introduction of a
vaccine for a disease, it is possible to estimate the vaccine efficacy
using two tests with unknown sensitivity and specificity, demon-
strating that tests that have not yet been assessed against a gold
standard can still be used in a situation where a vaccine is expected
to interfere with the test results. It has further been shown that such
tests can be used even if the vaccine efficacy is unknown. In this sit-
uation, a trial of diagnostic tests would also produce estimates of
a vaccine efficacy. Finally, in regards to the DIVA tests for bovine
TB, the results indicate that attempting to establish confidence in-
tervals for the sensitivity and specificity of new diagnostic tests is
likely to only provide partial evidence for demonstrating that a test
has reached a particular specificity threshold, when the required
specificity is close to 100%. In such situations, the evidence from
field studies of test properties needs to be combined with labora-
tory studies, the fundamental science underlying the tests and other
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sources of information to determine whether the true specificity is
sufficiently high for the intend ended use.
2.5 from binary to continuous tests
In this chapter, the assumption has been that diagnostic tests pro-
duce binary results, and implicitly that each individual is either in-
fected or noninfected. Often, a binary diagnostic test is generated
by taking a continuous measurement of some quantity, such as the
level of antibodies in the blood, and checking to see whether it is
above a pre-defined cutoff value. By converting a continuous mea-
surement to a true/false value, we are in essence throwing away
information (Fig 2.4). However, knowing the quantitative value of
the test measurement can tell us more than a binary test result can.
A quantitative test result can allow us to estimate the overall distri-
bution of test values in the population, evaluate the variability of the
binary classification for a given test value, and increase the precision
of population incidence or prevalence estimates.
Figure 2.4: This figure shows a typical curve for the development of viral load
test measurements over time . A positive or negative test result can
be generated by setting a cut-off value (black line). Above the line, the
test is “positive”; below the line, the test is “negative”.
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The binary classification is useful and straightforward. In clinical
practice, such an approach makes perfect sense in order to decide
on appropriate treatments. In modelling, the simplicity of the bi-
nary classification allow for tractable expressions for the disease dy-
namics. This is embodied by the basic SIR model where individuals
move from uninfected/susceptible, to infected, to non-infected and
recovered/removed. This type of model has a long history as a tool
for understanding the dynamics of infectious diseases (Hethcote,
2007).
However, in several cases, this categorization is too simplistic. As
a simple example, consider chickenpox, which lie dormant after
the disease has run its course, kept in check by antibodies. If these
wane, the virus may re-emerge as shingles. For bovine tuberculo-
sis, as discussed in the previous section, the disease progresses via
several stages, and many individuals carry the mycobacterium in-
definitely without suffering ill health. Such processes are impor-
tant aspects of disease dynamics and host responses, but the binary
paradigm lacks the expressive power to capture such nuances. In
mathematical modelling of disease dynamics, an approach is to
include more stages representing recovered-but-immune, asymp-
tomatic, asymptomatic but infectious, etc. In statistical inference, the
diagnostic test can be modelled as a categorical response variable, or
as a continuous response following some kinetic curve.
The following chapters in this thesis continue to model situations
where each individual has been tested using multiple diagnostic
tests. However, as we will see, instead of binary tests, tests with a
continuous, quantitative response are considered. In this way, much
richer types of analyses can be conducted. Chapter 3 describe how
historic linear incidence trends can be estimated from cross-sectional
data. Chapter 4 describes how it can be applied in an epidemic set-
ting. These two chapters serve to demonstrate the potential analyses
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that can be done when going beyond the classical terminology of
binary diagnostic testing of disease. Finally, chapter 5 suggests an
approach to estimating test kinetics of multiple given observed data,
which can be considered an extension of the estimation of sensitivity
and specificity described in this chapter.
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Abstract
This chapter describes a novel statistical approach to combine data
from multiple diagnostic tests with different temporal characteristics
to hindcast the historical unobserved trend of an endemic infectious
disease. Assuming a cross-sectional sample of individuals infected
with a pathogen, a Bayesian MCMC approach is used for estimating
time of exposure and the overall epidemic trend in the population
prior to the time of sampling. It is demonstrated how to utilize this
approach to distinguish between decreasing and non-decreasing
trends. Further, the chapter describes results of applying this for ide-
alised pairs of diagnostic tests, based on different host-pathogen
dynamics. Finally, we discuss the benefits of this novel methodol-
ogy for the management of infectious diseases, and for evaluation of
policy interventions.
3.1 introduction
Pathogens are one of the major contributors to the burden of disease
in humans (Lopez et al., 2006), have a substantial economic impact
on the livestock industry (Stott, 2003), and can be a serious threat
to conservation and management of wildlife populations (Daszak
et al., 2000). A crucial component of efforts to control endemic dis-
ease is the use of infectious disease surveillance for tracking trends
and evaluating the effect of control measures. The current state of
human disease surveillance has been characterized as deficient in
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terms of both coverage and reporting speed (Butler, 2006). The more
complex settings typical of livestock and particularly wildlife sys-
tems tend to result in available surveillance data being sparser still
for animal disease (Mörner et al., 2002; Perez et al., 2011; The Royal
Society, 2002)
The structure of a functioning disease surveillance system is com-
plex, with a string of tasks that need to be accomplished before a
case is recorded in a database and becomes available to epidemiol-
ogists and policy makers. However, a crucial part is the use of diag-
nostic tests to identify and confirm the type of pathogen that caused
infection. This and the following chapter will argue that combin-
ing two or more quantitative diagnostic tests with trajectories of the
development of average test measurements following infection pro-
vide substantial additional information that can be used to estimate
historic patterns of infection. Current analyses typically treat diag-
nostic tests as binary classifiers of infected/non-infected individu-
als. However, the behaviour of diagnostic tests are more complex as
they typically return a result in terms of a non-binary response level.
Moreover, the expectation of this test response varies as a function
of time since infection. To make use of such data and realise these
benefits, a novel statistical approach is introduced for recovering
population-level trends of infection even from only cross-sectional
data by combining knowledge of the dynamic characteristics of mul-
tiple diagnostic tests to infer the timing of infection events for indi-
viduals. The process of recovering such trends will be referred to
as “hindcasting”, following terminology established in other papers
(Banakar et al., 2011; Kleczkowski and Gilligan, 2007; Wethey and
Woodin, 2008) for reconstructing historical trends from currently
available data. This chapter will focus on the potential use of hind-
casting in the case of endemic diseases, while chapter four describes
the potential for hindcasting in an epidemic setting.
3.1 introduction 67
Changes in the epidemiology and/or incidence of endemic pathogens
are ideally tracked through the use of routine, ongoing surveillance.
However, in a number of situations and for a number of pathogens,
such ongoing surveillance is either non-existent or limited in its abil-
ity to provide a full, unbiased view. For some diseases, the epidemi-
ology is known and the disease is considered important, but surveil-
lance relies on diagnostic measures which are either expensive and
underutilized, or lacking in sensitivity and/or specificity. One such
example is the disease scrapie in sheep. Scrapie is a prion-spread
disease with a very long incubation period, and difficult-to-detect
symptoms. In the USA, scrapie has decreased from a 0.2% preva-
lence to less than 0.05% between 2003 and 2009 thanks to introduced
policy measures (United States Department of Agriculture, 2010).
However, there are substantial biases in reported prevalence num-
bers, raising the need for additional surveillance measures (Del Rio
Vilas and Pfeiffer, 2010). Another pathogen, endemic in most of Eu-
rope, is Mycobacterium avium subsp. Paratuberculosis, also known as
”Johne’s disease”. Paratuberculosis infections are asymptomatic for a
long period of time, only detectable after some period and with the
use of specifically targeted tests (OIE, 2014). Reported prevalences
across Europe vary widely, from 0.1% to 20%, largely owing to the
difficulty of diagnosis (Nielsen and Toft, 2009). With these kinds of
so-called iceberg disease systems (see Section 1.2), where routine
surveillance only captures a small proportion of actual cases, there
is a strong need for alternative strategies that can ensure that the
trend measured by routine surveillance systems is representative of
the full epidemiology of the targeted disease system.
There are a number of endemic diseases considered to be of low
importance and therefore not targeted by surveillance. When such
a disease suddenly gains importance, because of increasing preva-
lence induced by changes such as mutation of the pathogen, or due
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to realizations of the extent of its economic impact, the ability to
rapidly gain an understanding of the historic trends would be ex-
tremely useful in prioritizing and targeting interventions. This can
be the case even for high profile pathogens such as the H5N1 flu
virus, where the threat of silent spread in poultry flocks is a seri-
ous concern (Savill et al., 2006). Some pathogens have a very high
incidence of undiagnosed infection, where the pathogen circulates
widely in the population causing non-specific disease. Salmonella
(Simonsen et al., 2011) and Pertussis (Hallander et al., 2009) are two
examples of human diseases where the true extent of infections have
been unknown until fairly recently. Sexually transmitted infections
are also often under diagnosed because of social stigma associated
with testing. Chlamydia is a disease with a significant disease bur-
den in most parts of the world (WHO, 2012a), and where the preva-
lence in women is much better known, and often reported to be
higher, than in men for whom the testing rate is much lower(see
e.g. the introduction of Götz (2005) ).
For many endemic diseases, policies are put in place to reduce inci-
dence or eradicate the disease - either locally, as with bovine viral di-
arrhea(BVD) in Scandinavia and Scotland (Ståhl and Alenius, 2012);
or globally, as happened with Rinderpest in Cattle (FAO, 2013) and
smallpox in humans (WHO and Global Commission for the Certifi-
cation of Smallpox, 1980). Measuring the impact of implementation
of such policies is needed to ensure that eradication efforts are on
the right track. High costs restrict implementation of longitudinal
surveillance programmes whereas cross-sectional studies of disease
are more common. Therefore, methodology that could infer tempo-
ral trends from cross sectional data would be extremely beneficial.
The application of the hindcasting techniques introduced here could
be used to extend the utility of such cross-sectional studies to fulfil
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some of the objectives of an ongoing surveillance system (see Sec-
tion 1.2 for a discussion of such objectives).
Several papers have recovered limited historical characteristics of
the spread of pathogens from cross-sectional data using a single di-
agnostic test, typically an antibody test. For example, Giorgi et al. es-
timated the time of the start of a local HIV outbreak under assump-
tions of exponential growth of viral load (Giorgi et al., 2010). Others
have exploited information on diagnostic test kinetics, i.e., the pat-
tern of diagnostic test values during the course of infection, to esti-
mate average incidence rates. Example includes the use of antibody
test kinetics to estimate sero-incidence rates for influenza (Baguelin
et al., 2011), salmonella in cattle (Nielsen et al., 2011) and salmonella
in humans (Simonsen et al., 2008). One challenge in these kind of
studies is that the relationship between the magnitude of signals
from diagnostic tests and time since infection is usually not mono-
tonic; the signals tends to increase and then decrease. This means
that the inverse problem of estimating time since infection given a
test value is non-unique and although this can be framed as a statis-
tical problem the resulting inference is highly uncertain (Giorgi et
al., 2010; Simonsen et al., 2009), limiting what can be estimated from
test data. However, there are often several diagnostic tests available
that target different aspects of the multi-faceted dynamic interac-
tion between host and pathogen (Casadevall and Pirofski, 2001), and
would thus exhibit different test kinetics. That is, the profile of test
responses, as a function of time since infection, will differ depend-
ing the underlying diagnostic used. This means that, in principle,
we can generate a unique signal for a given time since infection by
combining results of several diagnostic tests that respond on differ-
ent time scales. Here, this fact is exploited to develop a more robust
statistical approach for analyzing cross-sectional field data from two
or more diagnostic tests. Empirical infection models that character-
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ize test kinetics are used to infer the time since infection for each in-
dividual. While there is large uncertainty in the estimated infection
time for each individual, the combined estimates from multiple indi-
viduals describe the overall population-level distribution of infection
times, which can be used to estimate the overall trend of incidence.
In an endemic setting, trends of infection are often gradual, and can
be approximated by a constant change per time unit (month, year,
decade). The chosen approach in this chapter was thus to posit that
the incidence follows a linear trend with some slope. Section 3.2 de-
velops the statistical framework for hindcasting in general, while
section 3.3 details the mathematical consequences of assuming a
constant linear trend with reinfections on inference of the trend
from cross-sectional data. Section 3.4 details the choice and imple-
mentation of test kinetics. Section 3.5 details results from applying
the framework to data simulated under a range of different scenar-
ios. Finally, section 3.6 discuss the implications of the results and the
hindcasting framework.
3.2 statistical framework
The statistical framework used for hindcasting in this thesis assumes
test data ynk from multiple disease diagnostics indexed by k = 1, . . . , K
on individuals i = 1, . . . , N. Each individual is assumed to have
been tested at some time ti, after having been exposed to the pathogen
at some earlier time ei. It is further assumed that these individuals
are chosen in an unbiased, random manner from a larger popula-
tion. Each diagnostic test is assumed to return a value measured on
a continuous scale, which might, for example be the highest dilution
at which antibodies are detected in a serological test. Without loss of
generality, these values are assumed to be rescaled to the unit inter-
val [0,1].
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Initial exposure to a pathogen is the start of a complex dynamical
process within the host. Such internal host-pathogen interactions
can be conceptualised as a multivariate process that depends on the
time since initial exposure. Each diagnostic test is assumed to tar-
get the state of a different component of this process so that each
test k carried out at time ti on individual i can be modelled as a la-
tent variable lik(ti, ei) = lik(di), with each test having differing but
correlated response patterns over the time since initial exposure
di = ti − ei. these latent variables are modelled using results from
experimental infection studies for a given host-pathogen system,
where the length of time since initial infection di is known.
The known data, across all individuals in the sample, comprises a
set of test results denoted by Y = {yik} with sampling times T =
{ti}. The aim is to infer the unknown set of exposure times E =
{ei}, using information on the behaviour of the latent processes L =
L(T, E) = {lik(ti, ei)} generating the test results. In the hindcasting
model used here, L represents the expected value of the test results
given ei and ti. Note that when describing these sets the limits of
each index k = 1, . . . , K and n = 1, . . . , N are implicit.
Assume that the sampling times T and the observed test values
Y,are known whereas the quantities L and E are assumed to be sub-
ject to uncertainty and variation. There are thus three components to
the statistical model: a latent process model P(L|T, E, θL) describing
uncertainty and variation in the host-pathogen interaction process
within the host in terms of the time since initial exposure; a testing
or observation model P(Y|L, θY) describing the distribution of re-
sults from tests carried out on the hosts conditional on the internal
latent process; and an epidemic trend model P(E|T, θe), describing
the historical development of the epidemic in terms of the distribu-
tion of exposure times in the sampled host population, at the time
of sampling. The specific implementations of each of these compo-
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nents in the linear trend setting is described in the next two sections.
Combining the three parts of the model, the full data likelihood
given an observed data set {Y, T} is written as P(Y, E, L|T, θ) =
P(Y|L, θY)P(L|T, E, θL)P(E|T, θE), where θ = {θY, θL, θE} Thus the
likelihood combines models for testing with those for within and
between host pathogen interactions.
According to Bayes’ theorem, the so-called posterior distribution for
the unknown parameters is proportional to the data likelihood and
prior P(θ). Using the parameters of interest θ, the latent process L,
the exposure times E, given the observed test data Y and sampling
times T, the posterior distribution can be described by the equation
P(L, E, θ|Y, T) = (P(Y, E, L|T, θ)P(θ))/(P(Y, T))
Within the Bayesian framework all inference is based on the poste-
rior. The prior P(θ) can result from previous measurements or ex-
pert opinion, and represents knowledge about the values of the pa-
rameters before any of the data used in the likelihood is observed.
In what follows, the simplifying assumption will be made that the
latent process L is modelled by a known deterministic function of T
and E. This means that the term P(L|T, E, θL) drops out of the likeli-
hood which then simplifies to
P(Y, E|T, θ) =
P(Y|L(T, E), θY)P(E|θE)
, and the posterior becomes
P(E, θ|Y, T) = P(Y|E, T, θY)P(E|θE)P(θY)P(θE)
P(Y, T)
Note that under this notation any parameters defining the determin-
istic latent process L(T, E) = lnk(tn, en) are suppressed since they are
not inferred i.e. θ = {θY, θE}.
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In both cases above the normalization factor P(Y, T) is typically un-
known and computationally expensive to calculate. However, stan-
dard Markov Chain Monte Carlo (MCMC) methods circumvent this
problem and are able to generate samples from the posterior even
though the normalization is unknown (see Section 1.5.2).
3.3 parametrization of a linear trend of incidence
3.3.1 Distribution of times since infection (tsi) under linear trend
The hindcasting framework estimates the historic trend of infection
f (t) in the population from cross-sectional data. The trend f (t) de-
scribes the incidence over time if the cases are reported continuously.
If, instead, infected cases are sampled at a single point in time, this
sample will consist of individuals that have been infected some time
in the past. The objective is then to estimate the distribution of these
times since infection(”tsi”), based on collected test measurements.
The probability density function distribution is hereafter denoted
ftsi(t). In order to simplify calculations, the time is measured back-
wards; the time of the cross-sectional sample is defined as t = 0, and
an infection that occurred 10 time units ago is denoted t = 10.
It should be noted that because we only have one observation per in-
dividual, it is only possible to estimate one time since infection, and
the population level distribution of times since infection is in effect
the distribution of times since last infection. Thus, this modelling
approach implicitly assumes that any reinfection of an individual
resets the “clock” of the infectious disease dynamic to zero.The most
basic scenario used for hindcasting a disease trend represents an en-
demic disease, with cases occurring at a constant rate. Formally, this
scenario can be defined by assuming that the entire population is
exposed to a constant force of infection λ. For a randomly observed
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infected individual, it can then be shown (Muench, 1934) that the
time since infection ftsi is distributed according to an exponential
distribution with rate parameter λ, ftsi(t) = λe−λt.
The assumption of “last infection resets the clock” implies that later
infections hide earlier infections, which leads to an apparent increas-
ing incidence, captured by the above expression. If, instead, it is as-
sumed that the first infection confers immunity, as so only the first
exposure to the pathogen is observed, this will mean that later infec-
tions are blocked or invisible, leading to an apparent decrease in in-
cidence. This can be described by changing the sign of the exponent
in the above expression so that the equation becomes f ?tsi(t) = λe
λt.
However, note it is now necessary to explicitly include an upper
limit on time (such as the year of birth of each individual), as f ?tsi(t)
will otherwise have an infinite integral and not be a probability dis-
tribution.
This basic scenario assuming that only the last infection is visible
was modified to a scenario in which the force of infection changes
over time according to a linear trend. In this, the force of infection
λ at a time t is equal to λ(t) = α+ βt as mentioned above. Because
of the linearity of the trend, the probability of having been infected
during a time period from 0 to T is equivalent to the probability of
having been infected under a constant trend of the mean incidence
over the period, λˆ(t) = α+ βT/2 (See Figure 3.1).
In the constant case, the probability of having been infected during
the time period T can be written as
∫ T
t=0 λe
−λtdt = 1 − e−λT. By
analogy to the constant case, we can thus write the probability of
having been infected by time t assuming a linear trend as P(I <
t) = 1− e−(α+β∗t/2)∗t. By taking the derivative of this, the probability
density function for the times since infection can be calculated as
ftsi(t) = d(P(i < t))/dt = (α+ βt)e−(α+βt/2)t.
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Figure 3.1: The cumulative force of infection an individual is exposed to over a
time period from 0 to T for a linear trend λ(t) = α + βt (shown by
the total area shaded yellow plus that shaded purple), is the same as
the cumulative force of infection for a constant force of infection at the
intensity equal to that of the linear trend at T/2; ˆλ(t) = α+ βT/2
(shown in blue and purple).
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Furthermore, In the implementation this distribution was assumed
to be censored at some time point in the past C, and it was further
assumed that it was possible, a priori, to distinguish individuals
that had been infected at some point during this time period, from
naive individuals. When implementing such a censoring, the equa-
tion above needs to be modified by an additional scaling factor 1/(1−
e−(α+βC/2)C), equal to one over the integral of ftsi(t) over the time
span (0, C). The full equation used to represent the distribution of
exposure times was thus
ftsi = (α+ βt)e−(α+βt/2)t/(1− e−(α+βC/2)C)
As the model is implemented in the Bayesian framework, priors for
both the prevalence (α) and trend (β) parameters needs to be speci-
fied. In order to provide a prior for the incidence, information about
the population size needs to be incorporated. This was done by not-
ing that the number of positive and negative individuals in a pop-
ulation can be approximately described by a binomial model, pa-
rameterised by the probability of infection p. Then denote by N+
the number of positive individuals known to have been infected be-
tween the time of censoring C and the time of sampling (defined as
t = 0), from a population of size N. With an uninformative Beta(1, 1)
prior for the probability of infection p the distribution of the prob-
ability of infection given the number of positives and negatives ob-
served is p ∼ Beta(N+ + 1, N − N+ + 1). Under the assumption of
a linear trend, the mean incidence over the time period C is equal to
the incidence at time C/2, λˆ = α+ β× C/2. The proportion p of ob-
served positive individuals are exactly one minus those that had not
been infected during any of the time periods up until the time of
censoring C. From this observation, the mean incidence λ¯ per time
unit can be derived from the proportion of positive individuals over
the time period C by the relationship:
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p = 1− (1− λ¯)C → 1− λ¯ = (1− p)1/C → λ¯ = 1− (1− p)1/C
For the trend parameter β, note that if the linear trend model is as-
sumed to hold over the time period C, then the incidence is not al-
lowed to become negative over this time. Using this, the restriction
for the trend becomes:
λ¯± β× C/2 > 0→
λ¯ > β× C/2 > −λ¯→
λ¯2/C > β > −λ¯× 2/C
Following this, the trend was assigned a uniform prior, β ∼ U(−λ¯×
2/C, λ¯ × 2/C). The intercept parameter α was then simply calcu-
lated from trend and λ¯ via α = λ¯− β× C/2.
3.3.2 Properties of the linear-trend-induced distibution of times since infec-
tion
The properties of the distribution ftsi(t) of times since infection are
somewhat counterintuitive. Figure 3.2 shows its shape for decreas-
ing (β = 0.05), constant (β = 0), and increasing (β = −0.05) pa-
rameter values, holding α constant to 0.1. The first thing to note is
that because we are looking backwards in time, coefficients have op-
posite sign to what at first might seem intuitive . β = 0.05 denotes
that the incidence rate has been decreasing by 0.05 per time unit,
whereas β = −0.05 denotes that the incidence rate is increasing.
The second thing to note is that all three curves have a similar up-
wards slope. The further back in time we look, the less likely we are
to find a case that occurred at that time. This is the consequence of
the implicit assumption mentioned above that only the time of latest
infection for each individual is taken into account, which means that
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Figure 3.2: Time since infection vs the value of ftsi(t), when assuming a linear
trend of incidence that is either decreasing, constant, or increasing.
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more recent infections can hide infections that occurred further back
in time. However, it will be demonstrated that it is still possible to
estimate the incidence trend from the parameters of the exponential
distribution.
The aim of this chapter is to recover the population-level trend of
incidence from test measurements taken from individuals that have
been infected at a some point in the past in a population where the
time-since-infection (tsi) distribution is assumed to follow the equa-
tion under a linear trend defined above. In order to study the prop-
erties of this inference problem, a first approach is to investigate the
simplified situation where the times of infection are known and gen-
erated using ftsi.
Including the priors described in the previous section, the expres-
sion for the log posterior of ftsi given observations of time since in-
fections X (denoted by LPf ), becomes
LPf (α, β|X) = log(U(α| − 2× λ¯/C, 2× λ¯/C))+
log Beta(λ¯|N + 1, N − N+ + 1))+
∑
∀i
log[(λ+ β× Xi) e
−(λ+β×Xi/2)Xi
(1− e−(λ+β×C./2)×C)) × I(X < C)]
Figure 3.3 shows the resulting log-likelihood surface of LPf . Times
of infections X = {xi} were simulated from the probability distri-
bution of ftsi, and the value of the log posterior LPf given the sim-
ulated data was calculated over a grid of values for α and β. Note
that this is assuming that the times of infection were exactly known.
. There are two things to note in this image: the first one is that the
region of highest likelihood is that surrounding the black line. This
black line is the line for which the combination of α and β results
in the same average incidence λ¯, which indicates that the Beta prior
on λ¯ has a strong influence on the curvature of the log-likelihood
surface. Another thing to note is that the estimated log-likelihood
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Figure 3.3: Density surface of the log posterior distribution LPf over α (x-axis)
and β(y-axis), conditional on a collection of 1000 times since infec-
tion generated from the probability distribution defined by ftsi =
(α + βT)e−(α+βT/2)T/(1 − e−(α+βC/2)C). Yellow indicates a den-
sity value in the highest quantile, blue a density value in the lowest
quantile. Note that this assumes that times since infection are known
exactly; the full inference procedure includes estimating these times
since infection from test data.
3.4 test kinetics 81
changes little along the line of equal mean incidence c, but drops off
quickly with increasing perpendicular distance to the line. There is
little distinguishing the region surrounding the true value (noted
by the black dot), from the rest of the likelihood along the line of
constant incidence. This indicates that while it will be relatively easy
to recover the value of λ¯, finding the correct combination of α and β
is more challenging.
3.4 test kinetics
The hindcasting framework incorporates knowledge of the kinetics
of diagnostic test responses after infection in the form of a latent
process model P(L|T, E, θL). This latent process model describes
(stochastic or deterministic) aspects of the dynamic process that de-
velop following the introduction of a pathogen to a host. This pro-
cess is complex, with a wide variety of factors. However, as pointed
out by Pugliese and Gandolfi (2008), for many applications it is
enough to describe this dynamic as a two-part interaction, with one
variable representing the overall level of immune response, and a
second variable representing the total pathogen burden. Formalis-
ing the interaction of these two variables over time by simple paired
differential equations, it is possible to capture many of the quali-
tative patterns of interest for disease modelling, as will be demon-
strated here, this approach proves useful as the basis for statistical
inference.
It will be assumed that the kinetics of antibody test response after
infection reflects an underlying development of the host immune
response. Similarly, when looking at the kinetics of e.g. a quantita-
tive PCR test, the development of the measured quantity of nucleic
acid will be assumed to reflect the pathogen burden in the host. In
other words, it is assumed that observed test measurements are pro-
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portional to host immune response and pathogen load, respectively.
Under these assumptions, a paired differential equation approach
can be used to generate realistic paired test kinetics reflecting under-
lying host-pathogen interactions.
For the purpose of evaluating the framework, example test kinetics
were generated using a Lotka-Volterra predator prey type model.
This type of model is usually defined in terms of the growth rates of
two populations, a “predator” population, and a “prey” population,
where the “predator” eats eats the “prey”. For more details on the
properties of such models, see e.g. Wangersky (1978). In our case,
the pathogen fills the role of the “prey” which is being hunted by
the immune response, our predator. Denoting pathogen levels at
time t by Na(t) and immune response levels at time t by Ab(t) the
model can formally be written as:
dNa/dt = (bNa − h× Ab(t))× Na(t)
dAb(t)/dt = bAb × Na(t)− dAb Ab(t)
In these equations, bNa can be interpreted as the growth rate of the
pathogen in the host in the absence of an immune response, and h
can be interpreted as the proportion of pathogens that dies per time
unit for each unit level of immune response (i.e. the predation rate).
bAb is the the unit level of increase in immune response generated
per time unit for each single pathogen organism present in the host,
and dAb indicates the rate of decline of the immune response per
time unit in the absence of stimulation by presence of the pathogen.
The equations can be solved for a given set of parameter values us-
ing any generic linear ordinary differential equation (ODE) solver
to generate a bivariate function LV(t) = (Ab(t), Na(t)) describing
the mean trajectory of antibodies and pathogen load over time (see
figure 3.4). In practice, the values of LV(t) were pre-calculated for a
range of time points and stored in a lookup-table.For the purpose of
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evaluating the hindcasting framework, LV(t) was assumed to be be
known and used to define the latent process model.
Figure 3.4: Graph of a typical Lotka-Volterra curve. X-axis indicates time, y-axis
indicates “population size”/antibody level/pathogen load. Red line
indicates the trajectory for the prey (pathogen), blue indicates the tra-
jectory of the predator (antibody level).
Given a particular time since infection t, and using LV(t) as the la-
tent process model LV(t), the observation model P(Y|L(t), θY) can
be defined by assuming that observed test measurements are then
log-normally distributed around LV(t). Specifically, it is assumed
that test measurements come from a bivariate lognormal distribu-
tion around LV(E), where E are the times of exposure, with zero
correlation and independent standard deviation for the two tests:
log N(Y|µ = log(LV(E)),Σ = ( σ21 0
0 σ22
)
)
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The exact combination of tests used could have an impact on the
performance of the hindcasting procedure. By varying the parame-
ters of the Lotka-Volterra equations, three different combinations of
tests were generated, representing three disease types, or canonical
patterns of host-pathogen interaction in terms of test responses as a
function of time since exposure. Table 3.1 shows the parameter val-
ues used for each of these disease types; however it is the relative
response times of the two tests which determine the disease type.
Figure 3.5 shows development over time together with phase plots
for the three different canonical patterns. The set of parameters la-
belled a type 1 disease correspond to an incubating pathogen and
capture the type of interaction one would see for a pathogen which
has an incubation period during which it is reaching full strength,
followed by an immune response and a decline of pathogen levels,
until the host is completely cleared. This is modelled by assuming
a high growth rate for the pathogen, a moderately high number
of antibodies generated per pathogen, antibodies being efficient at
killing the pathogens, and a slow die off of antibodies. This results
in an initial high pathogen growth, until the antibodies have caught
up, bringing the pathogen load under control. Influenza is a classic
example of a disease where incubation plays a major role in its epi-
demiology and pathogenesis (Carrat et al., 2008).
The set of parameters labelled a type 2 disease correspond to a fast-
acting pathogen and assume that the growth phase of the pathogen
has already been completed at t=1. This is modelled by having a
high starting value for the nucleic acid values. It then models the dy-
namic with a slow pathogen growth, the antibody kill rate being ten
times the pathogen growth, and a low growth and die-off rate for
the antibodies, so that it takes some time for the pathogen load to
be brought down to zero. This pattern models rapid-acting diseases
such as norovirus infection (Lessler et al., 2009).
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Figure 3.5: Graphs of the three types of LV dynamics used, development over time
and phase plots. Left hand side shows kinetic curve over time (red in-
dicates pathogen load, blue indicates antibody response). Right hand
side shows phase plots in terms of locations over time in the space of
Antibody response (x-axis) versus pathogen load (y-axis). The graphs
on the right hand side also display 1000 example test results, gen-
erated by assuming 25% lognormal noise around the mean curves.
Dashed line indicates where on the the kinetic curve each point origi-
nate from.
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The set of parameters labelled a type 3 disease, models a ”chronic
infection with acute phase”, and assumes that the growth rate of
the pathogen is equal to the die-off rate of the antibody, an antibody
growth of ~1 antibody/pathogen and time unit, but that each an-
tibody is relatively ineffective in killing pathogens. In this way, the
pathogen load and the antibody levels reach a slowly declining equi-
librium after an initial growth phase, resulting in high levels of both
antibodies and pathogen load remaining for some time after the
pathogen has peaked. Scrapie and Tuberculosis are two diseases that
follows this pattern.
Table 3.1: Table of parameter values for different types of LV curves.
Pathogen
type
Prey
growth Pred
kill %
Pred.
growth
prey
death Starting
state
Prey
peak
time
Type 1 3 0.15 0.6 0.3 na=1,ab=0 2
Type 2 0.06 0.6 0.06 0.06 na=20,ab=01
Type 3 0.6 0.3 0.9 0.6 na=1,ab=0 2.5
The time scale over which these kinetics develop varies depending
on the type of pathogen modelled. As mentioned earlier, scrapie
(which would be a type 3 disease) is a a very slow-developing dis-
ease, where the expected development of the pathogen level would
be on the order of several years (United States Department of Agri-
culture, 2010). Similarly, Paratuberculosis (also type 3) can take up
to a year of in-host replication before it starts showing symptoms
(OIE, 2014). On the other hand, bluetongue virus (a type 1 disease,
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with a 10 day incubation period) in sheep has a time period of 2-
7 weeks from infection, through incubation and showing of symp-
toms, to potential clearing of the disease (Sperlova and Zendulkova,
2011). In humans, Chlamydia (also resembling a type 1 disease)
takes around a month to show symptoms, but the bacteria can then
remain persistent at a low level for months or years after that, caus-
ing damage to the patient (Hogan et al., 2004). Norovirus infection
(a type 2 disease) has a very quick course of action with only about
4 days from infection to clearance (Patel et al., 2009).
In general, we can only expect to estimate times since infection ac-
curately while the infection process is ongoing, i.e up to the time it
takes for the infection dynamic to go from exposure to clearing the
infection and removing all antibodies. Fortunately, antibodies often
remain for extended periods of time; however, once the pathogen is
cleared, the benefits of multiple tests are lost. If the dynamic reaches
a more-or-less steady state with only minor changes after T = 5
(whatever the unit of T is), then we can only reasonably expect to
distinguish times since infection up until time 5, and by extension
only expect to hindcast population-level dynamics of the disease
that occurred within that time frame. The important characteristic
of multiple diagnostic tests for the purpose of hindcasting is that
the different tests have different dynamics over time. Looking at the
test kinetic phase plots in Figure 3.5 (right column), we can see that
the bivariate trajectories give more information than if we were to
project them onto either axis (i.e. take only a single measure of infec-
tion). With differing test kinetics it is, in principle, possible to com-
bine the test results into as close-to-unique signatures of times since
infection as possible. The greater the difference between test tra-
jectories, the more precision is gained from combining them. Even
with two tests with identical kinetic trajectories, the combined mea-
surement will reduce measurement error and increase precision.
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However, with increasing separation of timescales, the ability to dis-
tinguish early from late infections becomes both more robust, and
more sustainable under higher levels of measurement error.
From these observations, and looking at the three categories of paired
kinetics displayed above, we would expect combined test data from
a type 1 disease to give precise levels of estimate under moderately
high levels of noise up until T = 5, since both test kinetics are
changing and providing information up that point. A type 2 disease
reaches a slow-changing state after T = 7 for both antibody levels
and pathogen load, and would thus have difficulty providing infor-
mation beyond this time horizon. The final type 3 disease exhibits a
well-defined separation between the two curves and a strong interac-
tion occurring up until T = 15, indicating that such an infection may
provide useful information at least up until that time.
3.5 implementation
3.5.1 Describing endemic trends using the hindcasting framework
The test kinetics and the distribution of times since infection are
combined to make use of the hindcasting framework. Recall that
in general, the posterior probability P(E, θ|Y, T) of a set of exposure
times E and model parameters θ given observed data Y and obser-
vation times T, can be written as a combination of a deterministic
process L(T, E) of expected test results at a given time point , an ob-
servation process P(Y|L(T, E), θY), and a distribution of exposure
times P(E|θE), forming the expression
P(E, θ|Y, T) = P(Y|L(T, E), θY)P(E|θE)P(θ)/(P(Y, T))
∝ P(Y|L(T, E), θY)P(E|θE)P(θ)
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In the linear trend scenario, the distribution of exposure times is
defined as P(E|θE) = ftsi(E|α, β) = (α + βE)e−(α+βE/2)E/(1 −
e−(α+βC/2)C), with the priors for α and β defined in section 3.4. The
deterministic function L(T, E) describing expected test levels was
set as the solution LV(t) to the Lotka-Volterra equations defined in
section 3.5, with values over time included in the JAGS model as a
lookup table.
Finally, the observation process P(Y|L(T, E), θY) giving the distribu-
tion of observed test data was set as a bivariate lognormal distribu-
tion around LV(t) with zero correlation and independent standard
deviation for the two tests:
P(Y|L(T, E), θY) = log N(Y|µ = log(LV(E)),Σ =
( σ21 0
0 σ22
)
)
Defining suitable priors for the lognormal distribution proved chal-
lenging - in the traditional parametrisation of the lognormal dis-
tribution, standard deviation σ is defined on the log scale. How-
ever, in terms of interpretability, it is easier to work on the observed
scale, using (σ?1 , σ
?
2 ) = exp((σ1, σ2)). In this way, σ
? > 1, and in-
terpretable as the multiplicative variation around the mean; e.g.
σ? = 1.5 implies a relative standard deviation of 1.5, and ~68% of
the mass of the distribution fall within mean/1.5, mean ∗ 1.5. How-
ever, when putting a prior on σ?, and generating posterior samples,
the MCMC chains proved to be mixing very slowly. This was likely
due to the sampler having a fixed step length despite the fact that
a step change of size δ when σ? is close to one has a much larger
effect on the likelihood than the same δ step when σ? is large. To
counter this slow mixing, the prior was instead set for σ?? = eσ
?−1
and given an exponential distribution P(σ??) = λe−λ(σ??−1), shifted
to account for σ?? always being above 1 (since σ? − 1 > 0). The full
expression of the prior is thus P(sigma?? = x) = λe−λ(x−1). After ex-
perimentation, λ was chosen to be 20, which gave a posterior where
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the majority of the mass was under σ? < 1.5, and only an infinitesi-
mal mass above σ? > 2.0.
Given the priors and the model for times since exposure, the full ex-
pression for the posterior distribution of P(E, θ|Y, T) thus becomes
P(E, θ|Y, T) = P(Y|L(T, E), θY)P(E|θE)P(θ) ∝
∏
∀i
[log N(Yi|µ = log(LV(Ei)),Σ = (σ?1 , σ?2 ))]×
∏
∀i
[(λ+ β× Ei) e
−(λ+β×Ei/2)Ei
(1− e−(λ+β×C/2)×C)) × I(Ei < C)]×
λe−λ(e
σ?1−1−1) × λe−λ(eσ
?
2−1−1)×
U(α| − 2× λ¯/C, 2× λ¯/C)×
β(λ¯|N + 1, N − N+ + 1))
3.5.2 Simulated data for framework evaluation
In order to determine the feasibility of the approach laid out in the
previous section, the ability of the hindcasting framework to detect
the direction of change in the incidence of infections in a population
was evaluated. The impact and interactions of a number of differ-
ent factors on the performance of the hindcasting procedure were
investigated by generating data under a sequence of scenarios that
is described below. For all the scenarios used to evaluate the per-
formance of the hindcasting framework, data were generated by
sampling the specified number of times since infection from the dis-
tribution ftsi of times since infections under a linear trend. Given
these sampled times of infection, sample data was generated using
a lognormal observation error around the expected mean test val-
ues defined by specified test kinetics associated with the scenario.
The multiplicative standard deviation for the lognormal observation
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term P(Y|L(T, E), θY) was set to a relative variation of 1.25 around
the mean kinetic curve. The overall population size that was sam-
pled was chosen so that the expected number of positive samples
would be constant across the scenarios which have different levels
of incidence. By fixing the number of positive samples, rather than
sample sizes of positive and negative individuals, the effect of differ-
ing trends and levels of incidence could be evaluated without being
confounded with sample size effects.
The initial exploration of decreasing, constant, and increasing trends,
was conducted using a single data set for each type of trend. Subse-
quent scenarios were evaluated repeatedly, each time with indepen-
dently generated identically distributed data sets. The total number
of different scenarios was 193, with each scenario being run 11 times.
The JAGS code for evaluating these scenarios was run on Amazon’s
cloud computing service EC2 (Juve et al., 2009). Running all 2213
scenarios took 72 hours using a 32 core computation-optimised
linux instance.
Scenarios with increasing, constant, and decreasing trends
In a first step, the framework was applied to three data sets gener-
ated under different scenarios: a scenario with decreasing incidence
trend (50% decrease in the level of incidence over the time span), a
scenario with constant incidence trend, and a scenario with increas-
ing incidence trend (50% increase in the level of incidence over the
timespan). For all of these initial scenarios, an incubating disease
(type 1) was assumed, a sample size of 5000, an incidence at the
time of sampling of 0.05 per individual and time unit, and a time
span of 20 time units. For all three trends, it was assumed that two
diagnostic tests were used.
Scenarios with different test kinetics and trends of different magnitude
In the second set of scenarios, the effect of trend and sample size on
the ability of the hindcasting framework to recover trends was con-
92 chapter 3 : hindcasting trends of infection from multiple test data
sidered. Data sets were generated with different trends (50% increas-
ing or decreasing, 25% increasing or decreasing, or constant), dif-
ferent assumed sample sizes (100, 250, 500, 1000 and 2000 samples),
and different test kinetics (using disease types 1, 2, and 3 as defined
in section 3.4). For all scenarios, it was assumed that the incidence at
the time of sampling was 0.1 per individual and time unit, and that
two diagnostic tests were used.
Scenarios comparing different test kinetics and number of tests
In the third set of scenarios, the trend was fixed to a 50% increasing
trend, with an incidence of 0.1 per individual and time unit. Instead,
it was assumed that either two diagnostic tests, only an antibody
based test, or only a Nucleic acid (or antigen) based test were used
for testing collected samples. Sample sizes again varied between 100,
250, 500, 1000 or 2000 samples.
Scenarios modelled after real-world settings
Finally, the performance of the framework was also evaluated for
three case studies based on plausible parameter values, to produce
a first indication of the real-world usefulness of the hindcasting
framework. These three examples were modelled after scrapie in
sheep, Chlamydia in humans, and squirrelpox in squirrels. Scrapie
in the US has been subject to an intense control effort since around
2002. Between 2003 and 2009, the estimated prevalence decreased
from 0.2% to 0.05%, a reduction of 75%,equivalent to a 12.5% reduc-
tion per year over 6 years (United States Department of Agriculture,
2010, p7). In terms of the Lotka-Volterra dynamics discussed ear-
lier, scrapie would correspond to a slow-growing pathogen with
a longterm chronic infection, the third of the three generic disease
types. The development of scrapie in the US was thus modelled us-
ing a starting incidence of 0.2%, a 12.5% reduction per year over 6
years, using disease type 3 acting on a timescale where peak pathogen
burden is reached after 3 years, the typical time of onset of clinical
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signs for scrapie (United States Department of Agriculture (2010), p9
).
Chlamydia incidence in Sweden decreased between 1990 and 1995,
after which the trend reversed and increased until 2007. In 2006,
a mutated strain of Chlamydia trachomatis that was not detected by
the standard tests started spreading in some Swedish counties (Her-
rmann et al., 2008). By the time this strain had been discovered and
tests adjusted, a number of cases that would otherwise have been
detected continued to carry the infection and infect others. By 2007,
the number of cases reported yearly had increased from ~32500 in
2004 to 47500, a 50% increase. Based on these events, a scenario
was modelled by assuming a 0.02% incidence (the approximate in-
cidence among 20-24 year olds, the highest-risk group). Chlamydia
was considered a type 1 disease where the disease dynamic plays
out over approximately 2 years (to model both the potential for per-
sistent infections and the duration of antibodies), and a trend of 50%
increase over these two years.
Squirrelpox is a viral disease that plays a major role in the decline
of European red squirrel (Sciurus vulgaris) populations in the UK.
The eastern grey squirrel (Sciurus carolinensis), which are asymp-
tomatic carriers of squirrelpox, was imported to the UK in the late
1800s (Stritch et al., 2015). Grey squirrels have since spread the dis-
ease to red squirrels, for which squirrelpox is a deadly infection.
Squirrelpox infections have recently been reported in Ireland, and
a study there indicated a 34% seroprevalence; though it is unknown
how long the virus has been circulating. This setting was modelled
by assuming a 30% incidence at the time of sampling, a fast-acting
type 2 disease where the dynamic process lasts over three years (the
life expectancy of red squirrels). Since the trend of squirrelpox is un-
known, a range of different slopes were examined.
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The scrapie scenario is used to investigate the number of cases re-
quired to use the hindcasting framework for evaluating the effect of
control measures in a low-incidence, livestock context. The Chlamy-
dia scenario is used to investigate the number of cases required to
recover increasing trends in a medium-incidence human context.
The squirrelpox scenario investigates the precision with which one
can estimate differing trends in a high-incidence, wildlife context
where the number of available samples are limited. For these three
case studies, ten different datasets was generated for each set sam-
ple size, and the hindcasting framework was applied to each data
set.
3.5.3 Sampling from the posterior using JAGS
For conducting inference of the endemic trend, the posterior distri-
bution of parameters described in the previous section is evaluated,
conditional on observed test data and knowledge of expected test
kinetics.
A high level language for hierarchical Bayesian models known as
JAGS (Plummer, 2003) was used to implement the statistical frame-
work and evaluate the posterior distribution using the Metropolis-
Hastings algorithm combined with Gibbs sampling (see section 1.5.2
for a more detailed discussion). The code was called from within R
using the rjags package (Plummer, 2014). Initial starting values for
the parameters in the MCMC were chosen at random from the prior
distributions, independently sampled for each chain. Samples were
then taken from the joint posterior distribution of times since infec-
tion across all individuals, and parameters of the trend of incidence.
As noted in the introduction (section 1.5.4) a key question with the
implementation of MCMC algorithms is that of convergence and
mixing. The reliability of our sampling tools were assessed using
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Gelman-Rubin (GR) statistics for the posteriors as well as visual
inspection of trace plots. Figure 3.6 shows typical trace plots from
three scenarios (decreasing, constant and increasing trend) the last
1000 draws for each chain (thinned so that every 10th draw is shown)
of the population level trend parameter β, the intercept parameter α,
and the mean incidence λˆ , from five different chains after all chains
have been run for a 1500 iteration burn-in.
For the full range of scenarios, it was not feasible to inspect trace
plots. Instead, a Gelman-Rubin statistic above 1.15 was used to filter
out those runs that had not converged (~5% of the total runs). The
results from these runs were excluded from subsequent analysis.
3.6 results
3.6.1 Scenarios with increasing, constant, and decreasing trends
For the first set of scenarios, the posterior distribution was evaluated
using the JAGS implementation of the framework as described ear-
lier, and the results studied in-depth. Figure 3.7 shows the posterior
distributions for the incidence parameter α, the slope parameter β,
and the mean incidence λˆ using data from the three scenarios.
Figure 3.7 clearly indicates that the posterior distributions of the
trend parameter differ significantly between the increasing, the con-
stant and the increasing trend scenarios, and correctly identifies the
direction of change, with the 95 % credible intervals excluding the
zero for the increasing and decreasing scenario. In each scenario the
posteriors associated with the five realisations (denoted by the five
colours) overlap, indicating that the MCMC chain has converged. It
is however interesting to note that the estimates are all biased com-
pared to the true value, although the true value lies within the 95 %
credible interval.
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Figure 3.6: Traceplots of the the MCMC samples of the α(incidence at the time of
sampling) and β(trend) parameters for three different scenarios, with
five chains each. Colours indicate the respective chains.
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Figure 3.7: Density plots for the MCMC samples of α and β from the posterior,
fitted to data generated assuming populations with decreasing(top
row),constant (middle row), and increasing (bottom row), and of inci-
dence. Each colour for a density distribution indicates the results from
one of the five chains that was generated from each MCMC run. The
vertical line indicate the true parameter values.
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Figure 3.8: Histogram of estimated times since infection, together with the trend
line based on estimated parameter values of ftsi(t) (red) and the trend
line based on true parameter values for ftsi(t)(black). Bars indicate
the proportion of mean posterior estimates of infection times for indi-
viduals falling into that time point. Grey shading indicates the 95%
posterior credible interval for the trend.
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The distribution of estimated infection times across the population
of samples is plotted in Figure 3.8. This figure displays the histogram
of the mean posterior estimates of the infection times, overlaid with
a red line indicating the probability distribution of times-since-infection
(TSI) defined by the mean posterior estimates of the trend and inter-
cept parameters and the definition of ftsi from section 3.3. The black
line indicates the TSI distribution defined by the true parameters
and that was used to generate the data. The true trend curve and
the estimated trend curves follow each other reasonably well, and
the histogram of estimated times since infections also seem to follow
the true trend. However, there seem to be small bias in very recent
infections - the final bar of the histogram is lower than preceding
ones, and the trend (in particular the decreasing trend) seem to be
dragged down by this. This seems to indicate that the source of the
bias is a minor tendency for the hindcasting framework to estimate
very recent infections as having been infected for a longer time pe-
riod.
As mentioned in section 3.3.3, because of the way reinfections hide
preceding infections, the trend lines are roughly exponentially in-
creasing for all three scenarios. The good fit of the estimated trend
can be better seen by viewing them in a traditional manner as indi-
cating the incidence of cases over time (see figure 3.9). This graph
shows the linear trend lines defined by the estimated parameters,
together with histograms of the number of cases that were infected
in each time period. Note that the uncertainty of the estimated inci-
dence increase as you go back in time.
3.6.2 Scenarios with different test kinetics and trends of different magnitude
Following evaluation of the individual runs, performance was fur-
ther evaluated by generating data with different slopes of the inci-
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Figure 3.9: Histograms of actual times of infection generated under the different
scenarios, (counting multiple infections per individual separately) to-
gether with estimated trend line. Grey shading indicate 95% posterior
credible intervals of the linear trend
3.6 results 101
Figure 3.10: Estimated trend lines (thin lines) for different disease types (indi-
cated by colour), using different combinations of number of sampled
positive individuals and strength of slope. The thick black lines indi-
cate the true trend line
102 chapter 3 : hindcasting trends of infection from multiple test data
dence trend, with different numbers of collected positive samples,
and different disease type. Figure 3.10 shows the mean posterior es-
timated trends obtained by applying the hindcasting framework to
generated data sets for each combination of slope, sample size and
disease types. These plots indicate that the mean of the posterior dis-
tribution of the trend parameter usually correspond well with the
true trend lines (indicated in black), if the sample size was 500 posi-
tive individuals or more. For trends of +/-25% change over the time
period and samples sizes of 250 or less, the estimated trend was no
longer reliable, and could even have the wrong direction of slope.
There was no obvious relationship between disease type and perfor-
mance.
It is also of interest to quantify the level of uncertainty in the esti-
mated trend. Figure 3.11 show posterior credible intervals of the
trend parameter in the various scenarios. Here it can be clearly seen
that with a sample size of 2000 positive individuals, all posterior
credible intervals exclude zero for the scenarios with 50% increase,
25% decrease, and 50% decrease over the time period of interest.
With 1000 samples, the posterior credible intervals exclude zero
for the +/-50% change scenarios. With 500 samples, the maximum
posterior estimates are still close to the true values for most scenar-
ios, but the credible intervals start overlapping zero. At 250 samples
or less, the posterior estimates of all scenarios become unreliable.
Again, no obvious pattern between different disease types can be
seen.
Figure 3.12 shows the reliability of the posterior estimates, sum-
marised in terms of the average proportion of the mass of the pos-
terior distribution that lies on the correct side of zero. This quantity
can be interpreted as the posterior probability for the correct sign
of the slope. . Note that these proportions are somewhat unreliable,
as we only have 11 replicates for each point. Nevertheless, some in-
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Figure 3.11: Posterior Credible intervals for the slope parameter of the trend from
scenarios with different sample size and slope relative to an incidence
at the time of sample of 0.1 per time unit and individual. Thick grey
line indicates zero slope, dashed black line indicate true slope. Dots
indicate mean posterior estimate of the slope; lines indicate 95% pos-
terior credible interval. Color indicate different disease type
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Figure 3.12: Average posterior probability for the true sign of the trend parame-
ter . The posterior probability is defined as the proportion of the 95%
posterior credible interval that indicate correct sign for the trend pa-
rameter. The dots indicate the posterior probability averaged over the
11 replicates for each combination. Colour indicate different disease
types.
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teresting patterns can be seen. A proportion of 75% of runs exclud-
ing zero seems to be reached at 1000 samples for the 50% increase,
25% and 50% decrease scenarios; for the +/-50% change scenarios,
500 samples seem to have been enough to clearly distinguish the
trend from a constant one. Also, as long as the number of samples
are 250 or above, the hindcasting procedure can distinguish between
an increasing and a decreasing trend, as indicated by the upper row,
though it seems more difficult to correctly identify an increasing
trend than a decreasing one. As in the earlier graphs, no clear pat-
terns between different disease types could be identified.
3.6.3 Scenarios comparing different test kinetics and number of tests
The effect of combining diagnostic tests for hindcasting, compared
to using only single tests, was evaluated in scenarios assuming a
50% increasing trend (see figure 3.13). Whereas the combination
of tests performed well for sample sizes above 250, the single-test
scenarios showed some peculiarities. Scenarios with a single anti-
body test and disease type 3 produced exceptionally bad estimates
of the trend no matter the sample size. On the other hand, scenarios
with either disease type 1 or 2 fell down when using only a nucleic-
acid based test. Equally surprising is that for disease type 1 and 2,
the performance was almost identical with a single antibody test,
as with a combined test; similarly with disease type 1 and nucleic
acid test. This indicates that the interaction of types of tests used,
the trend of disease in the population, and the type of pathogen
considered is not completely straight-forward and warrant further
research.
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Figure 3.13: Posterior Credible intervals for the slope parameter of the trend from
scenarios with different sample size and number of tests used. Thick
grey line indicates zero slope, dashed black line indicate true slope.
Dots indicate mean posterior estimate of the slope; lines indicate 95%
posterior credible interval. Colour indicate type of disease. Column
indicate whether only antibody tests was used, only nucleic acid
based tests, or both types of tests combined
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3.6.4 Scenarios modelled after real-world settings
The resulting estimates of the three different cases-studies using
real-world plausible parameters can be seen in figure 3.14.
The scrapie-based scenario indicates that for these parameters, it
would be possible to prove a disease reduction with as few as 100
samples, seeing as all but one of the posterior credible intervals ex-
clude zero. With 1000 samples, the posterior credible interval indi-
cates the correct slope to within a factor of 2.
For the chlamydia-based scenario, 500 cross-sectional samples would
be needed to prove that the trend is increasing; with 2000 cross-
sectional samples, the correct slope could be estimated to within a
factor of 2.
Finally, with the squirrelpox scenario, it was assumed that only a
limited number of animals would be able to be caught. Assuming
that 250 animals were caught, the true trend would have to be +/-
50% change in incidence over the three years, in order to conclu-
sively demonstrate an increasing or decreasing trend.
3.7 discussion
This chapter has introduced and tested a novel technique for hind-
casting the history of exposure to disease in a population using only
cross-sectional data combined with information on pathogen test
kinetics. The results demonstrate that this procedure enables esti-
mation of changes in disease incidence over time. The results also
demonstrated how this approach is able to distinguish between an
increasing trend and a stable, or decreasing trend, as well as pro-
duce posterior estimates quantifying this disease trend. This goes
beyond previous sero-incidence studies which estimated the average
incidence in a population, without attempting to estimate tempo-
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Figure 3.14: Posterior Credible intervals for the slope parameter of the trend from
three different scenarios with real-world plausible parameters. For the
scrapie and Chlamydia scenarios, the trend was fixed and the sample
size varied. For the Squirrelpox scenario, sample size was fixed at
250 animals, and the trend varied. Dots indicate mean posterior esti-
mate of the slope; lines indicate 95% posterior credible interval. Black
dashed lines indicate true trend, and light-grey line indicate zero.
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ral trends in prevalence (Baguelin et al., 2011; Nielsen et al., 2011;
Simonsen et al., 2008).
The use of Lotka-Volterra (LV) equations to describe the pathogen-
host dynamic, and thus the joint development over time of an anti-
body and an antigen-based test, made it possible to consider several
different archetypes for the pathogen-host dynamic. Hindcasting
was found to be possible for all of the different archetypes exam-
ined. Further, different archetypes proved to result in very similar
overall hindcasting performance, with the exception of robustness to
changes in number of tests used. The results on number of tests ver-
sus performance in section 3.6.3 seem to indicate that using a combi-
nation of diagnostic tests is more robust across the board than using
a single diagnostic test; and that it may be possible to use a single
diagnostic test for hindcasting, but it may also fail completely. This
warrants further research into the specific requirements of disease
kinetics for hindcasting.
The results obtained from evaluating scenarios with parameters
close to observed epidemiological patterns in scrapie, Chlamydia,
and Squirrelpox, indicate that useful precision levels can be reached
with realistic sample sizes. The scrapie scenario indicated that on
the order of 100-1000 samples could provide useful information.
Given the size of the sheep industry, and that schemes for the surveil-
lance of Scrapie already exists, such studies could feasibly be con-
ducted (under the assumption that suitable test diagnostics could
be found). The chlamydia scenario indicated that at least 500, and
preferably more than 2000, crossectional samples would need to be
taken. This would be a large study, but in settings where chlamydia
surveillance is otherwise lacking, could potentially still be motivated
by the overall public health costs of Chlamydia. Finally, in the case
of squirrelpox, it was indicated that at least 250 animals would need
to be caught and tested. Thisis a very large study in wildlife settings;
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further, the trend would only rarely be as large as 50%. Hindcasting
would thus only be usable for squirrelpox in certain special cases,
such as a setting where it had only recently been introduced to a
naive population, and it was needed to demonstrate that the intro-
duction had happened.
The results described in this chapter indicate that the hindcasting
procedure can provide reliable estimates of epidemic trends under
a range of conditions. However, as indicated in section 3.6.1 and by
figure 3.7, there seem to be a consistent, small bias when estimating
the incidence and slope parameters. The source of this bias has yet
to be fully explained. The prior distributions used in the hindcast-
ing framework are weak, and in the case of the slope and incidence
parameters, unbiased. Further, the density surface shown in figure
3.3, indicate that conditional on knowing the true time of infection,
the maximum likelihood estimates for slope and incidence are unbi-
ased. Together, this means that the source of the bias lie in the imple-
mentation of the MCMC algorithm and/or in the estimation of the
times since infection. Indeed, figure 3.8 indicate that the proportion
of very early infection tends to be underestimated (which would
lead to the estimated trend lines being pulled toward zero, causing
the described bias in the trend parameters). Further research would
be required to understand why this is the case. Early infections are
close to the edge of the support for the distribution of times of in-
fection, and the lognormal distribution used for these has a discon-
tinuity at t = 0 - both discontinuities and sampling at the edge of
support could be creating problems for the MCMC sampler. A solu-
tion might be to choose a prior density that does not asymptotically
vanish at t = 0, but it is not obvious what distribution(s) would be
suitable. It could also be the case that the optimal step size is differ-
ent for very early infections and for later infections. Since the lognor-
mal distribution is implemented with tail switching, this could then
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mean that samples from early times are disproportionally likely to
be rejected, biasing the resulting posterior samples. Drawing sam-
ples from a transformed variable might in that case be helpful but
again, it is not obvious which transformations would be suitable.
In real world applications, the kinetics used to inform the hindcast-
ing technique would likely be derived from other published data,
such as experimental infection studies. In such cases, the LV cal-
culations could be replaced with a simple lookup table for the ex-
pected mean response of the test at a given point in time, combined
with information on the variability of the test. Alternatively models,
such as the LV equations, fitted to available test kinetic data could
be used.
The natural pairing of tests to be modelled with the LV approach
is a nucleic acid test for genetic material from the pathogen (e.g. a
realtime PCR test) or an antigen ELISA, combined with a test mea-
suring the antibody test response, such as a quantitative ELISA test.
However, any combination of two or more tests commonly used for
pathogen diagnostics could be used, though a LV approach would
no longer be suitable. Other examples are a pairing of a culture-
based test combined with IGG antibodies, or even the severity of
symptoms measured on an ordinal scale combined with viral load
measurements. Thus, a wide range of diagnostic measures could po-
tentially be used within the hindcasting framework presented here.
The results from this and the next chapter provide strong arguments
in favour of recording raw test results together with the resulting
diagnosis, and for utilising more than one diagnostic test whenever
feasible. Thus, when setting up surveillance systems, it should be
emphasised that the results of all diagnostic tests used should be
recorded in the database. Such a database should also detail the
quantitative level of evidence (i.e. the test level) in addition to the
regular binary ”infected/non-infected” result. The cost of conduct-
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ing and recording the result of two or more diagnostic tests should
be considered in relation to the benefits. For example in terms of
feedback to farmers and policymakers on the impact of control mea-
sures and for detecting any potential costly changes in the preva-
lence. It should also be noted that the methods introduced here en-
able such benefits to be derived from cross-sectional data and there-
fore the additional costs described above should be compared with
the costs of running longitudinal studies.
An important extension to the work presented here is to consider
more complex changes in pathogen incidence than simple linear
trends. In principle, since the hindcasting procedure provides ap-
proximate times of exposure any model that describes the pattern of
times of exposure could be considered. The linear trends described
here are primarily suitable for endemic diseases. Therefore, in the
following chapter, development of the hindcasting technique is con-
tinued by considering outbreaks of epidemic diseases.


4C H A P T E R 4 : T H E A P P L I C AT I O N O F H I N D C A S T I N G
I N E P I D E M I C S C E N A R I O S
The following chapter has been submitted as a paper to PloS Com-
putational Biology on the 18th of June 2015, and is reproduced here
in the format of that journal. The original title of the paper was
Using combined diagnostic test results to hindcast trends of infection from
cross-sectional data
The paper describes an expansion of the hindcasting framework
described in chapter 3 to the hindcasting of disease outbreaks. In
such settings the timescale of interest is shorter than for endemic
diseases, and so the issue of reinfections can be ignored. Since the
disease incidence change more rapidly, the assumption of a linear
trend is exchanged for that of a lognormal trend. The hindcasting
framework assuming lognormal trends is then applied to two case
studies, based on one outbreak of bluetongue and one outbreak of
whooping cough, to estimate the incidence trend in both increas-
ing epidemics, as well as epidemics past their peak. In this way, it
is shown that hindcasting can be used to determine the stage of an
outbreak at the time of sampling, thus informing potential outbreak
responses.
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4.2 abstract
Infectious disease surveillance is key to limiting the consequences
from infectious pathogens and maintaining animal and public health.
Following the detection of a disease outbreak a response in propor-
tion to the severity of the outbreak is required. In order to assess
this severity, it is critical to obtain accurate information concerning
the origin of the outbreak and its forward trajectory. However, there
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is often considerable uncertainty about the outbreak’s history prior
to first detection, which may lead to over- or under-reaction.
Data on the infectious status of individuals is accessible from a widen-
ing range of diagnostic tests that typically have different tempo-
ral characteristic, e.g. in terms of when peak test response occurs
relative to time of exposure. We have developed a statistical frame-
work that combines data from multiple diagnostic tests and is able
to hindcast (infer historical trend of) an infectious disease epidemic
prior to the time of detection.
Assuming diagnostic test data from a cross-sectional sample of in-
dividuals infected with a pathogen during an outbreak, we use a
Bayesian Markov Chain Monte Carlo (MCMC) approach to estimate
time of exposure and the overall epidemic trend in the population
prior to the time of sampling. We evaluate the performance of this
statistical framework on simulated data based on two historical out-
breaks: a bluetongue outbreak in cattle, and a whooping cough out-
break in humans. The results show that hindcasting the outbreaks
can provide accurate estimates of epidemic trends, whether an out-
break is increasing or past its peak. We conclude that it is possible to
recover epidemic trends of both human and animal pathogens from
cross-sectional data collected at a single point in time.
4.3 introduction
Infectious disease surveillance is the first line of detection and de-
fence against infectious pathogens and therefore crucial to main-
taining animal and public health. However, the current state of dis-
ease surveillance has been characterised as deficient in terms of
both coverage and reporting speed for both humans (Butler, 2006)
and animals (Mörner et al., 2002; The Royal Society, 2002). The chal-
lenge is to use the data generated by this often sparse and biased
118 chapter 4 : the application of hindcasting in epidemic scenarios
surveillance, to decide on an appropriate response to disease out-
breaks. Any response needs to balance the social and economic con-
sequences of the adopted control strategy with the social and eco-
nomic risks posed by the outbreak (WHO, 2012b). In the case of the
pandemic H1N1 flu in 2009, early analyses mistakenly assumed the
epidemic had been only recently introduced, causing substantial
overestimates of the basic reproduction ratio (Mercer et al., 2011)
and case fatality rates (Echevarría-Zuno et al., 2009) that suggested
a far greater risk to human life than was actually the case, leading
to a more robust response than was necessary (Leung and Nicoll,
2010). The more complex settings typical of livestock and particu-
larly wildlife systems tend to result in the available surveillance data
being sparser still for animal diseases (Perez et al., 2011). In the UK,
the absence of routine surveillance for Salmonella in poultry in the
mid 1980s meant that the emergence of Salmonella Enteritidis PT4
was not recognised until it had become a major public health and
political problem by 1988 (Rodrigue et al., 1990). Early identification
of this epidemic caused by the new strain would have enabled faster
intervention..
Using the data available when an epidemic is first detected to esti-
mate its development at earlier times would help inform early deci-
sions of the potential risks posed by an outbreak, leading to a more
proportionate response than would be the case from waiting for the
epidemic trends to be revealed by subsequent real time monitoring.
In the current study, we introduce a novel statistical approach to re-
cover population-level trends of exposure from only cross-sectional
data by combining knowledge of the dynamic characteristics of mul-
tiple diagnostic tests to infer the timing of exposure events for indi-
viduals. Here we refer to the process of recovering such trends as
“hindcasting”, following terminology established in other papers
(Banakar et al., 2011; Kleczkowski and Gilligan, 2007; Wethey and
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Woodin, 2008) for reconstructing historical trends from currently
available data.
Several papers have recovered limited historical characteristics of
epidemics from cross-sectional data using a single diagnostic test,
e.g. an antibody test. For example, Giorgi et al. estimated the time
of the start of an HIV outbreak under assumptions of exponential
growth of viral load (Giorgi et al., 2010). Others have exploited in-
formation on diagnostic test kinetics, i.e., the pattern of diagnostic
test values during the course of infection, to estimate average inci-
dence rates. Examples include the use of antibody test kinetics to
estimate sero-incidence rates for influenza (Baguelin et al., 2011),
Salmonella in cattle (Nielsen et al., 2011) and Salmonella in humans
(Simonsen et al., 2008). One challenge in these kind of studies is that
the relationship between the magnitude of signals from diagnostic
tests and time since exposure is usually not monotonic; they tend
to increase and then decrease. This means that the inverse problem
of estimating time since exposure given a test value is non-unique
and although this can be framed as a statistical problem the result-
ing inference is highly uncertain (Giorgi et al., 2010; Simonsen et
al., 2009), limiting what can be estimated from test data. However,
there are often several diagnostic tests available that target differ-
ent aspects of the multi-faceted dynamic interaction between host
and pathogen, and thus exhibit different test kinetics (Casadevall
and Pirofski, 2000). That is, the profile of test responses, as a func-
tion of time since exposure, will differ depending on the underlying
diagnostic used and the immunopathogenesis of the disease. Thus,
in principle we can generate a unique signal for a given time since
exposure by combining results of diagnostic tests that respond on
different time scales. Here, we exploit this fact to develop a more ro-
bust statistical approach for analysing cross-sectional field data from
multiple diagnostic tests. To do so we make use of empirical infec-
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tion models that characterise test kinetics to infer the time since ex-
posure for each individual. While there is a considerable uncertainty
in the estimated exposure time for each individual, the combined es-
timates from multiple individuals can be used to describe the over-
all population-level distribution of infection times and estimate the
shape of the overall epidemic trend with a high level of confidence.
A detailed description of the hindcasting framework and case stud-
ies can be found in the methods section. We demonstrate the hind-
casting of epidemic trends by applying the developed framework to
case studies of real outbreaks of two contrasting diseases, whoop-
ing cough in humans and bluetongue in cattle (see Fig 4.1). For each
disease, we investigate two scenarios representing detection during
either the increasing or the decreasing phase of the epidemic. We
conclude that when combined with two (or more) appropriate di-
agnostic tests (i.e. that differ in their temporal response following
exposure, see Fig. 4.2) our methods allow historical epidemic trends
to be recovered from cross sectional sample data. Moreover for the
example diseases considered, suitable diagnostic tests already exist.
4.4 results
We applied the hindcasting framework (described in the methods
section, below) to case studies based on a recorded outbreak of whoop-
ing cough in humans, and a bluetongue outbreak in cattle (see Fig
4.1). For each outbreak we assumed two scenarios, firstly where a
cross-sectional sample was taken midway through the outbreak (in-
creasing epidemic trend/early detection), and in a second scenario
towards the end of the outbreak (decreasing epidemic trend/late
detection). Based on published temporal characteristics of real di-
agnostics, test results were then simulated for these samples (see
methods). For each disease (whooping cough and bluetongue) and
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each scenario (increasing and decreasing outbreaks) the hindcast-
ing technique was applied to the corresponding test results to assess
performance in recovering early increasing phases and late decreas-
ing phases of outbreaks.
Figure 4.1: Outbreak scenarios together with estimated epidemic curves. Top left:
Testing 100 whooping cough cases at week 35 of the Wisconsin out-
break. Top Right: Testing 100 bluetongue cases at week 7 of the 2007
UK outbreak. Bottom left: Testing 25 cases at week 25 of the Wiscon-
sin outbreak. Bottom right: Testing 30 cases at week 3 of the 2007 UK
outbreak. In all scenarios, cases were sampled from the full population
of cases shown in the outbreak data of Fig. 4.1 that had been exposed
before the time of testing. Vertical dashed lines indicate time of cross-
sectional sample. Red bars indicate cases included in the sampling
frame for testing, grey bars indicate cases not included. Red lines indi-
cate the mean posterior hindcast trend based on the cross-sectional test
data. The grey transparent regions around the trends indicate the 95%
posterior credible interval.
We evaluated the robustness of the hindcasting framework by re-
stricting the number of individuals sampled (i.e. in the outbreak
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data of Fig. 1 selecting only a subset of individuals infected at the
sampling time), and by using only a single diagnostic test.
The results show this technique was able to estimate epidemic trends
for both increasing and decreasing scenarios, in both whooping
cough and bluetongue outbreaks (Fig 4.2). For the increasing whoop-
ing cough epidemic, when assuming a sample of all 122 cases that
had occurred between the start of the epidemic up to week 25, the
coefficient of determination (R2) between underlying case counts
(smoothed by a 7-day moving average) and the estimated epidemic
trends was 0.74, with a 95% confidence interval of [0.69-0.78]. When
sampling 230 cases from the full whooping cough epidemic up un-
til week 36, after it had declined, the curve fit was somewhat better,
with R2 of 0.82[0.68-0.94].
We also looked at the bluetongue epidemic, which had substantially
fewer cases. When assuming a sample of the 26 animals that had oc-
curred during the increasing phase, during the first two weeks, the
fitted curve was nearly perfect, with an R2 of 0.9[0.86-0.92]). How-
ever, for the corresponding decreasing scenario, assuming a sam-
ple of the 61 animal cases that had occurred up to week seven, the
hindcast trend could not fully capture the erratic nature of the un-
derlying case count data, as indicated by R2 values of 0.21[0.15-0.27].
Nonetheless, the trend did indicate an elevated incidence over the
stretch of time when the majority of cases occurred, thus capturing
the approximate time that had elapsed between the start of the epi-
demic and the time of sampling.
When reducing the sample size, the hindcasting technique was still
able to recover both increasing and decreasing phases. The good fit
was maintained with sample sizes as low as 20 individuals, with R2
values for the whooping cough scenarios, of 0.77[0.27-0.83], for the
increasing and 0.67[0.09-0.86] for the decreasing scenario. Similarly,
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Figure 4.2: Graphs of the kinetics of diagnostic tests used in the paper. Top: Diag-
nostic test kinetics for Whooping cough, with an antibody test(solid
line) and a test measuring bacterial load (dashed line). Bottom: Diag-
nostic test kinetics for bluetongue, with an antibody test (solid line),
and a test measuring viral load (dashed line). The graph is showing
idealised test kinetics, based on published data on Pertussis (Bidet et
al., 2008; Teunis et al., 2002) and Bluetongue tests (López-Olvera et
al., 2010) (see methods for details).
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for the increasing bluetongue scenario, also assuming 20 samples,
the R2 was maintained at 0.91[0.87-0.93]).
The performance of the hindcasting technique was significantly
hampered when using a single diagnostic test instead of two con-
trasting ones. For the increasing phase of the bluetongue and whoop-
ing cough outbreaks, the average performance was still acceptable
when hindcasting trends based on a single antibody test from 20 in-
dividuals, but with substantially higher variability. The average R2
was 0.83[0.04-0.86] for the increasing whooping cough, and 0.85[0.74-
0.89] for the increasing bluetongue scenario. Hindcasting performed
substantially worse when using only one test in the decreasing whoop-
ing cough scenario, with R2 of 0.59[0.28-0.89] even when using the
full set of cases, and failed completely when using just 20 cases (R2
0.04[0-0.28]).
To get a better understanding of the effect of different tests on the
performance of the hindcasting technique, we investigated how di-
agnostic test data and the combination of different tests affected the
prediction of the time since infection. The images in Fig 4.3 show
how the likelihood of estimated times of infection given observed
test data varies as a function of actual time since exposure. Each
pixel is coloured by generating 10 observations from the distribution
of test measurements at a time since exposure given by the X axis,
and calculating the likelihood for a time of exposure given by the Y
axis, conditional on these observations. Areas in dark red indicate
regions of higher likelihood. From the point of view of accurately re-
covering historic trends in the epidemic the ideal result would have
the maximum likelihood values along the diagonal which would
mean the likelihood of time since exposure was very firmly focussed
on the true exposure time given observed data.
It was interesting to compare the kinetics of the whooping cough an-
tibody test as seen in Fig 4.2, with the corresponding image (4.3a) of
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Figure 4.3: The graphs show the log likelihood of inferred times of exposure as a
function of true time since exposure, given test data generated assum-
ing that the individual was exposed to whooping cough (top row) or
bluetongue (bottom row) at the true time. Both the X and Y axes are
on a log scale. Each pixel represents the value of the likelihood at a
time of exposure given by the Y axis, given 10 test results, generated
assuming a time since exposure given by the X axis.. The colour of
the pixel indicate the likelihood for an estimated time, given the sam-
ple data, with dark red being most likely, and pale yellow being least
likely. A clear, dark red diagonal indicates that the time since infection
is easily recoverable, while a more diffuse diagonal indicates higher lev-
els of uncertainty (see the results section for details). The first column
shows results based only on data from the antibody test relevant to the
disease in question, the middle column results based on an appropriate
nucleic acid test, and the right hand column shows the results based
on both tests (see text for details).
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the likelihood of exposure time, based on observing test data from
this single diagnostic test. The times shown in both Figures 4.2 and
4.3 are times since exposure; short times since exposure represent
more recent infections. The times of 20 days or less since exposure
correspond to the phase of infection where the test response is in-
creasing rapidly. Here, the probable infection times (red coloured
pixels), given the data, are centred on the diagonal (i.e. the true ex-
posure times) with a narrow band of high-probability red pixels. We
can see that for times since exposure of greater than 20 days, when
the kinetics of the antibody test are developing at a slower pace, the
diagonal of red pixels becomes wider and more diffuse, indicating
a greater variation around the true times since exposure. Further-
more, we can see that there are two different diagonals crossing at
25 days. This corresponds to the peak of the diagnostic response
curve, with the two diagonals indicating the possibility that a given
test result could have been the result of testing an individual dur-
ing either the increasing or the decreasing phase of the response
curve. In general, estimation of the time since exposure is more pre-
cise when the true time since exposure corresponds to phases where
the response is changing rapidly, and is more difficult to infer when
the test response levels out (4.3b and d). For diagnostic tests with a
peaking response, estimating the time of infection can be precise but
not unique, with two different regions of probable infection times
for a given test response (4.3e). By combining early responding tests
with later responders, it becomes possible to create a test signature
that combines the best feature of both tests. The best combination of
tests is the combination that provides unique and precise signature
along the timeline of infection for an individual (4.3 c and f).
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4.5 discussion
In this paper, we have shown that it is possible to recover epidemic
trends of both human and animal pathogens from cross-sectional
data collected at a single point in time. We were able to recover this
temporal information using a novel statistical framework which
combines paired diagnostic test measurements made on collected
samples with the temporal kinetics of diagnostics test measurements
over the course of infection.
The inferential framework introduced here enables utilisation of
all the case data available up until identification of an outbreak.
Here we focussed on purely cross-sectional samples but the meth-
ods are applicable to longitudinal data and data sets combing both
longitudinal and cross sectional samples. We were able to estimate
the trends of both increasing epidemics and decreasing epidemics,
as well as estimate the approximate pace of increase or decrease.
Such information would be valuable for tailoring appropriate man-
agement decisions immediately when an outbreak has been de-
tected, without the need to observe subsequent spread to estimate
the trend.
The implementation of the framework used in this paper combines
surveillance data with information on the test kinetics using a sim-
plified model. For example, individual variation in the test response
is modelled as variation around a common mean test curve, rather
than as variation in the shape of the curve itself. Variations in the
two tests are considered independent, and the error distribution is
assumed to be log normal. This limits the pattern and range of vari-
ation our model can capture, but facilitates model specification and
estimation. More detailed modelling of the individual and popula-
tion level processes in order to tailor the model to a particular dis-
ease is entirely consistent with the statistical framework introduced
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and would increase the real-world validity and predictive power be-
yond that shown in the applications presented here.
Likewise, we make use of the lognormal distribution as a parsimo-
nious parametrization of the epidemic trend. This is suitable for epi-
demics where only a single peak is expected, allowing fast model
fitting whilst capturing the time span and general direction of the
trend. The trade off is that more complex aspects of trends in the
epidemic cannot be captured. Moreover, the lognormal distribution
requires the trend to decline to zero after any peak. Should either of
these limitations pose a problem, more suitable models can be used,
though such models are likely to come at higher computational cost.
The hindcasting framework introduced here estimate epidemic trends
by combining observed data with information on how tests responses
develop after exposure. Matthews and Woolhouse (2005) give an ex-
tensive overview of studies that incorporate different data sources
to recover the underlying dynamics of disease spread (Haydon et
al., 2003; Presanis et al., 2011), and argue that the future of disease
analysis lies in models taking account of a wider range of inputs,
such as diagnostic test performance, disease pathogenesis, or trans-
mission mechanics, in addition to regular surveillance data. Our
methodology improves on earlier studies incorporating test kinet-
ics (Baguelin et al., 2011; Nielsen et al., 2011; Simonsen et al., 2008)
in three ways: by incorporating information from more than one di-
agnostic test; by considering their joint kinetic pattern; and by mod-
elling non-constant incidence.
Similar approaches could be used to model other aspects of the dis-
ease system such as population demography, contact networks, or
spatial location, to estimate more complex aspects of disease dy-
namics e.g. not only temporal patterns of spread, but also, spatial
spread, and the pattern of spread through the demographic struc-
ture of the population.
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Hindcasting exploits knowledge of the host-pathogen interaction,
and thus relies on previously conducted longitudinal studies of
such interactions, and in particular on the test response after initial
pathogen exposure. Our results demonstrate one of the many ways
in which experimental infection studies can provide substantial ad-
ditional benefits to disease control and research. Currently, only a
fraction of pathogen tests have published information on how time
since exposure affects test response; the method introduced here
gives another reason why such studies on test kinetics are useful.
We have described a new framework for hindcasting the temporal
patterns of epidemics, using two example host-pathogen systems
and the pairing of antibody tests with pathogen load. The frame-
work demonstrates the potential to utilise the information inherent
in the increasing variety of diagnostic tests. We were able to esti-
mate both increasing and declining epidemic trends under the as-
sumption that all individuals were being tested at a single point in
time, implying its usefulness for cross-sectional surveillance data
as well as in less restrictive settings. Recovering temporal incidence
trends using multiple tests on cross-sectional field data has the po-
tential to be of considerable value in the early phase of an outbreak
and as a key determinant of introducing proportionate responses to
newly detected disease threats.
4.6 methods
4.6.1 Statistical framework
Our method assumes test data yik from multiple disease diagnostics
indexed by k = 1, . . . , K on individuals i = 1, . . . , N. We assume
that each individual is tested at some time ti, after having been ex-
posed to the pathogen at some earlier time ei. We further assume
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that these individuals are chosen in an unbiased, random manner
from a larger population. Each diagnostic test is assumed to return
a value in the form of a continuous ‘level’, which might, for example
be the highest dilution at which antibodies are detected in a serolog-
ical test. Without loss of generality we assume that these levels are
scaled to the unit interval [0,1].
Initial exposure to a pathogen is the start of a complex dynami-
cal process within the host. We conceptualize such internal host-
pathogen interactions as a multivariate process that depends on the
time since initial exposure. Each diagnostic test is assumed to tar-
get the state of a different component of this process so that each
test k carried out at time ti on individual i can be modelled as a
latent variable lik (ti, ei) = lik (di), with each test having differing
but correlated response patterns over the time since initial exposure
di = ti − ei. We model these latent variables using results from exper-
imental infection studies for a given host-pathogen system, where
the length of time since initial exposure di is known.
The known data, across all individuals in the sample, comprises a
set of test results denoted by Y = {yik} with sampling times T =
{ti}. Our aim is to infer the unknown set of exposure times E = {ei}
, using information on the behaviour of the latent processes L =
L (T, E) = {lik(ti, ei)} generating the test results. Note that when
describing these sets the limits of each index k = 1, . . . , K and i =
1, . . . , N are implicit.
Under our statistical model we assume that the sampling times T
are precisely known whereas the quantities Y, L and E are assumed
to be subject to uncertainty and variation. There are thus three com-
ponents to the statistical model: a latent process model P(L|T, E, θL)
describing uncertainty and variation in the host-pathogen interac-
tion process within the host in terms of the time since initial expo-
sure; a testing or observation model P(Y|L,θY) describing the distri-
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bution of results from tests carried out on the hosts conditional on
the internal latent process; and an epidemic trend model P(E|T, θe),
describing the historical development of the epidemic in terms of
the distribution of exposure times in the sampled host population,
at the time of sampling. We discuss specific implementations of each
of these components in the examples described below.
Combining the three parts of the model, we write the full data likeli-
hood given an observed data set {Y, T} as
P (Y, E, L|T,θ) = P (Y|L, θY) P(L|T, E,θL)P(E|T, θE) ,
where θ = {θY, θL, θE}. Thus the likelihood combines models for test-
ing with those for within and between host pathogen interactions.
According to Bayes’ theorem, the so-called posterior distribution for
the unknown parameters is proportional to the data likelihood and
prior P(θ). We can express this relationship for the parameters of
interest, the latent process L, the exposure times E and the parame-
ters θ, given the observed test data Y and sampling times T , by the
equation
P (L, E, θ|Y, T) = P (Y, E, L|T,θ) P(θ)
P(Y, T)
Within the Bayesian framework all inference is based on the poste-
rior. The prior P(θ) can result from previous measurements or ex-
pert opinion, and represents knowledge about the values of parame-
ters before we see the data used in the likelihood.
In what follows, we will make the simplifying assumption that the
latent process L is modelled by a known deterministic function of T
and E, and represents the expected value of the test results given the
times since exposure. This means that the term P (L|T, E,θL) drops
out of the likelihood which then simplifies to P (Y, E|T,θ) =
P (Y|L (T, E) , θY) P (E|θE), and the posterior becomes
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P (E, θ|Y, T) = P (Y, E|T,θ) P (θ)
P(Y, T)
Note that under this notation any parameters defining the determin-
istic latent process L (T, E) = {lnk(tn, en)} are suppressed since they
are not inferred i.e. θ = {θY, θE}.
In both cases above the normalisation factor P(Y, T) is typically un-
known and computationally expensive to calculate. However, stan-
dard Markov Chain Monte Carlo (MCMC) methods circumvent this
problem and are able to generate samples from the posterior even
though the normalisation is unknown. The results presented in this
paper are generated from an MCMC sampler implemented with
a Metropolis-Hastings algorithm in JAGS (Plummer, 2003) using
Gibbs sampling (Casella and George, 1992).
4.6.2 Case studies
Whooping cough is a human disease caused by the bacteria Bor-
detella pertussis, causing prolonged spasmodic coughing. Despite
widespread vaccination coverage there has been a resurgence of
cases in several countries; in the Netherlands there has been a steady
increase in the incidence since 1996, and in California, USA in 2011,
there was a widespread outbreak with 9000 cases and ten deaths
(Winter et al., 2012). Possible reasons for such resurgence include
decreasing vaccine coverage and/or antigenic drift (Greeff et al.,
2010). Here we make use of data describing a countywide outbreak
of Pertussis primarily among adolescents and adults in Fond du Lac
County, Wisconsin, USA in 2003-2004, (Sotir et al., 2008). After an
early cluster of cases in a high school in early May 2003, there was
a large outbreak of Whooping Cough throughout the county start-
ing from October. After some time, this outbreak was contained, and
the final cases occurred in February 2004. The upper part of Fig 4.1
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shows interpolated case counts per 48-hour period over the duration
of the outbreak.
Bluetongue virus (BTV) is a midge-borne virus that can infect rumi-
nants such as sheep, cattle, deer and camelids, causing bluetongue
disease with symptoms such as internal haemorrhages, swelling of
the tongue, lesions in the mouth, and in some species death (most
notably in naïve sheep and white tailed deer). Bluetongue infections
can have severe economic consequences for livestock farming, both
due to loss of productivity, and because of the severe control mea-
sures needed to prevent spread (Alban et al., 2010). In 2006, BTV
emerged throughout northern Europe, with recorded outbreaks
in the Netherlands, Belgium, Germany, and Luxembourg. In 2007,
the UK had its first recorded outbreak (DEFRA, 2008). The first in-
fections occurred sometime in early August 2007 (DEFRA, 2008)
when midges introduced the pathogen to the British Isles, but the
first case was not detected until September. The lower part of Fig 1
shows the case count per day, with numbers interpolated from the
published weekly data (DEFRA, 2008).
In order to assess our methodology we consider two scenarios for
each pathogen outbreak. In the “increasing” scenarios we assume
the epidemic is recognised early and explore test results from sam-
ples taken at a time early on in the outbreak (when the outbreak is
increasing, see e.g. Fig 4.1). In contrast in the “decreasing” scenar-
ios we use test results assumed to be obtained from individuals ex-
posed during the entire outbreaks, with samples collected at a rela-
tively late stage in the outbreak (i.e. when it is in decline). The goal
was to see how well hindcasting could distinguish between such in-
creasing scenarios, and scenarios where the epidemic had declined.
We were also interested to see if it was possible to estimate the ap-
proximate time span of the epidemics, measured as the longest esti-
mated exposure time among tested cases.
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4.6.3 Implementation of the Whooping Cough scenarios
Outbreak data and detection scenarios
We based our whooping cough data set on the case count curve of
the 2003 Wisconsin whooping cough outbreak. We used published
bi-weekly case counts, and interpolated these using a LOESS (Cleve-
land and Devlin, 1988) approach to generate estimated 48 hour case
counts.
We investigated two hypothetical scenarios for when the outbreak
could have been first detected and cases tested. We simulated one
scenario where we assumed that cases were sampled and the sam-
ples tested 25 weeks after the first observed case. At this time point,
the first wave had passed, and the second sharp increase in inci-
dence had been going on for about a month. 126 cases had been
reported by this time in the actual outbreak. The second scenario
assumed that testing of cases occurred at week 36, taking samples
from the 230 cases from the full whooping cough epidemic up until
that time. This time point marks the end of the epidemic, with no
later cases reported.
Diagnostic test characteristics
The results of diagnostic testing are characterised in terms of an
underlying mean trend and a model which accounts for variation
around this reflected measurement error, and within and between
individual variability in test response.
The sampled cases produced from the scenarios as described above
were assigned simulated test results, based on the elapsed time
between the time of exposure in the actual outbreak and the as-
sumed time of sampling, using published kinetics of real-time PCR
analysis and quantitative ELISA for Pertussis (Bidet et al., 2008; Te-
unis et al., 2002), to inform a latent process P(L|T, E, θL). Specifi-
cally these were the kinetics of ELISA IgG pertussis antitoxin (Te-
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unis et al., 2002) for antibody test response ab (d) as a function of
time since exposure d, and real-time PCR measurement of persis-
tence over time of Bordetella pertussis DNA in nasopharyngeal secre-
tions (Bidet et al., 2008) (see Fig 4.2) for the pathogen load DNA (d)
. As noted earlier formally, we defined the deterministic function
L(di) = (DNA (di) , ab (di)) by fitting interpolated curves to the pub-
lished data on DNA and antibody levels using LOESS (Cleveland
and Devlin, 1988).
The distribution P (Yi|L (di)) of test measurements was modelled
as a lognormal distribution conditional on the state of the latent
process: let yi = (yNA, yab)i represent a bivariate measurement
of nucleic acid and antibody levels on individual i, and define the
distribution P (Yi|L (di)) = lN (L (di) ,Σ2)) , where Σ2 is a diago-
nal covariance matrix, reflecting the assumption of no correlation
between test results when conditioned on the time since exposure.
The variance for each test (i.e. the diagonal elements of ) was as-
sumed known. Antibodies as well as level of pathogens in a host
often follow log-normal distributions, as has been rigorously argued
(Koch, 1966); the suitability of using the lognormal distribution for
modelling a wide range of biological phenomena has also been de-
scribed more recently (Limpert et al., 2001).
Epidemic trend
A lognormal distribution was also used to parameterize the un-
known distribution P(E|T, θe) of times of exposure given the time
of testing, P (E|T, θe = {µ, σ}) = lN (µ, σ). (See section 4.7 for tech-
nical details). In this case, we exploit the ability of the lognormal to
model extreme skewness to capture both increasing and decreasing
epidemics using only two parameters.
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4.6.4 Implementation of the Bluetongue scenarios
Outbreak data and detection scenarios
As with Whooping Cough, we assumed two different hypothetical
scenarios for when the outbreak was noticed and animals tested:
one assuming that animals tested are sampled from the 26 exposed
cases at week two, and the other assuming that animals tested were
sampled from the 61 animals exposed by the end of week seven (Fig
2).
Diagnostic test characteristics
We modelled test behaviour based on published data (López-Olvera
et al., 2010), and assumed lognormal distributions for the epidemic
trend, as well as for the variance of the diagnostic tests (Fig 3). Specif-
ically we based the behaviour of the latent process P(L|T, E, θL) on
a study of experimental infection of European red deer with BTV
serotype 1 and 8 that described the dynamics of BTV serotype 1 vi-
ral load (vl) as measured with RT-PCR, and antibody levels (ab) as
measured with ELISA (López-Olvera et al., 2010). As above we de-
fine the latent process describing antibody concentration and viral
load as a deterministic bivariate function of the duration d elapsed
since exposure as L = {l (di)} ≡ {vl (di) , ab (di)} which does not
vary between individuals. We estimate L by fitting smooth and in-
terpolated curves to the experimental study data on viral load and
antibody levels independently and take the values of these curves at
each exposure time d to define the values of the deterministic func-
tions, vl (d) , ab (d) . LOESS (Cleveland and Devlin, 1988) was used
as a nonparametric fitting method.
Conditional on the time since exposure, the observed test values
yi = (yvl, yab)i were modelled as a bivariate log-normal distribu-
tion with mean equal to the deterministic latent process = {l (di)} =
(vl (di) , ab (di)) . For individual i, this can be formally written as
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P (yi|l (di)) =lN (l (di) ,Σ2), where lN indicates a bivariate lognor-
mal probability function, and Σ2 is the covariance matrix. We as-
sumed that the variation in observed antibody levels and viral loads
to be independent so that the covariance matrix Σ2 is diagonal, with
variance components σ21 , σ
2
2 . The variance for each test (i.e. the diago-
nal elements of ) was assumed known.
4.6.5 Epidemic trend
The third and final part of the model, the distribution of times since
exposure (E|T, θe) , was modelled as a lognormal distribution
P (E|T, θe = {µ, σ}) = lN (µ, σ)
(see section 4.7 for further details).
4.6.6 Choice of priors
We followed the recommendations of Gelman (2006) and used a
combination of informative and weakly informative priors for the
parameters. The means for the lognormal distribution describing
the epidemic trends were themselves given lognormal priors. It was
assumed that any prior information about the start of the epidemic
would be correct to within an order of magnitude. This translated to
prior means for the increasing whooping cough of 100 days, and
prior means for the decreasing whooping cough scenario of 200
days. The corresponding values for BTV were 10 days and 100 days,
respectively. The standard deviations for the prior distributions were
chosen as log
(√
3/2
)
, corresponding to 95% confidence intervals of
(mean ∗ 1/3, mean ∗ 3). This standard deviation was chosen to model
a confidence that the “best guess” was within a factor 10 from the
true values.
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The standard deviation of the lognormal distributions for the epi-
demic trend was assumed to follow a vague folded t-distribution,
with five degrees of freedom and standard deviation of log(100).
The high standard deviation was chosen so as to allow even an epi-
demic trend that is currently increasing to have cases occurring sev-
eral hundred days ago.
We also attempted to use uninformative priors, but these were found
to lead to slow and /or failing convergence of the MCMC algorithm.
Changing the specific values of the priors did not influence the pos-
terior estimates noticeably.
4.7 supplementary information
4.7.1 Evaluation of convergence
When evaluating convergence of the MCMC runs used to estimate
the parameters of the epidemic trends of outbreaks (see the results
section in main body of the paper), the Gelman-Rubin (GR) statistic
(Gelman and Rubin, 1992) was used as a first indicator. This widely
used statistic (Kathryn et al., 1996) measures the ratio of the within-
chain variability to the between-chain variability e.g. for multiple
chains started from different initial conditions.
The convergence behaviour (Fig 4.4) was quantified for the MCMC
algorithm for each of the 100 different data sets generated for each
combination of scenario, type of disease diagnostic, and the number
of individuals tested (see main text). For each of these datasets the
MCMC samples were generated using a 10 000 iteration burn in,
and subsequent capturing of the following 10 000 iterations. In each
case 5 chains were run in parallel to ensure sufficient information on
between-chain variability.
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As indicated in Fig 4.4, for the whooping cough scenarios, the GR
statistic was nearly always below the threshold of 1.1 recommended
by Gelman et al. (2004). The convergence was less fast for bluetongue
scenarios using paired disease diagnostics with only approximately
50% of the runs having converged by 20 000 iterations as measured
by the threshold standard.
Fig 4.5 show examples of traceplots from scenarios with diagnostic
test results from 100 individuals. The patterns of the bluetongue tra-
ceplots indicate that that chains are mixing slowly, which explains
the low values of the GR statistic obtained. Fig 4.6 shows the esti-
mated epidemic trends using mean parameter values from the final
5000 iterations of the MCMC algorithm, with separate trends for
each of the 5 chains. These plots indicate that despite the slow mix-
ing, the practical difference between chains was miniscule.
4.7.2 Generating simulated data
The bluetongue and whooping cough data sets we applied the hind-
casting inference framework to were simulated in R using the fol-
lowing procedure:
• Choose an observation time T after the first recorded case of
the epidemic we base our simulated data on.
• Record the observed exposure times E = {ei} for all cases that
had occurred in the real epidemic up until the time of obser-
vation T and evaluate the duration of infection/exposure for
each individual {di = T − ei} at time T.
• Use the deterministic function l(di) based on the interpolated
test trajectory to assign mean test values for each case given
the durations of infection
• Set the variance Σ2 of the log-normal distribution to corre-
spond to published test variability.
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Figure 4.4: Distribution of the GR statistic across the different scenarios. Each
box represents the distribution of GR calculated on different sets
MCMC samples, the samples generated by fitting the hindcasting
model 100 times to different data sets. The runs represented by each
box was all generated assuming the same combination of scenario, di-
agnostic tests used, and number of individuals sampled. The middle
line of the boxes indicate the median, the top and bottom of the boxes
indicate 25 and 75% quantile, respectively, and the thin black lines
indicate the range of results. The horizontal red lines indicates a GR
value of 1.1, which is considered to be an indicator that the chains
have reached full convergence
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Figure 4.5: Examples of MCMC traceplots, generated by fitting the hindcast-
ing model to scenarios assuming that disease diagnostics were
collected from 100 individuals. Each colour indicates a different
chain (i.e. started with different initial conditions). “Peak.time”
and”duration" are the parameters for the mean and variance
of the lognormal distribution describing the epidemic trends.
“Peak.time.dev” is the variance of the prior of peak.time.
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Figure 4.6: Estimated epidemic trends by chain. The parameters of the lognormal
distribution describing the epidemic trend was calculated from the
mean of the last 5000 samples of “peak.time” and “duration” in the
traceplots in Fig 4.5, above.
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• Generate test results from the log normal distribution with Σ2
variance and mean test values generated in steps 3 and 4.
Test scores corresponding to viral load and antibody response are
then simulated using the deterministic function L = {l (di)} ≡
{vl (di) , ab (di)} described in the methods section. Note that the
infection times are not subsequently used in the inference proce-
dure, but they do provide an opportunity to assess the inferences
obtained.
The lognormal variation around this curve was set to be 57% follow-
ing data on B. Pertussis antibody variability published by Versteegh
et al. (2005). DNA measurements and antibody measurements were
assumed to have the same level of noise.
Based on published data (Chatzinasiou et al., 2010) on variability of
RT-PCR we set the log-normal variability to 27%. For simplicity, we
assume equal variability for antibody measurements.
4.7.3 An alternative formulation of the lognormal distribution to allow the
MCMC sampler to efficiently sample multimodal likelihood surfaces
As shown in figure 4.3 in the main text, the likelihood for times
since exposure is often multimodal. Combining multiple tests can
reduce this problem, but if the MCMC sampler is initiated in the
wrong region, convergence can be an issue where the chain becomes
‘stuck’ around one mode with an extremely small probability of
jumping to an alternative mode. By allowing the MCMC sampler
to jump between disjoint regions of exposure times in one step, the
different modes are no longer isolated from each other. The follow-
ing describes how to implement such a solution in the case of the
lognormal distribution used in the paper.
Assume that times of exposure ei are lognormally distributed, ei ∼
logN(µ, σ) For the standard lognormal parametrization, the density
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for a particular time of exposure e given mean µ and variance σ is
given by
p (e|µ, σ) = lN (e|µ, σ) = N (log (e)|µ, σ) = φ( log (e)− µ
σ
)
, where φ (x) = N (x| µ = 0, σ = 1).
Tautologically, we can rewrite e as
e = elog(e) = eµ+log(e)−µ = eµ+[(log(e)−µ)/σ]∗σ = eµ+∆∗S∗σ
where S ∈ {−1, 1}, and ∆ =
∣∣∣ log(e)−µσ ∣∣∣ ≥ 0.
Now, instead of assuming that e is coming from a lognormal distri-
bution, we can
assume that S has a discrete probability function,
a) p (S = 1) = p (S = −1 ) = 0.5
, and that ∆ has a folded standard normal distribution with a proba-
bility density function given by
b) p (∆, ∆ > 0 ) = φ (∆) + φ (−∆) = 2φ (∆)
In this way, ∆ can be interpreted as how far e is away from the mean
of the lognormal distribution, measured in the number of standard
deviations, and S indicates whether it is in the upper or lower quan-
tile. Note that for fixed µand σ, each exposure time e can be written
uniquely as a combination of ∆ and S.
p (e|µ, σ) = p (∆, S|µ, σ) = p (∆) ∗ p (S)
From a) and b), we get that
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p (∆) ∗ p (S) = 2 ∗ φ (∆) ∗ 0.5 = φ(∆) = φ(| log (e)− µ
σ
|)
Thus, (since the normal distribution is symmetric) this new formula-
tion results in the same probability distribution for T as the lognor-
mal distribution, and thus an equal contribution to the data likeli-
hood. For the bluetongue and whooping cough examples, the full
posterior likelihood is written as
L (E, θ|Y, T)∼
(
∏
∀i
( lN (Y|L (T− ei) ,Σ2))lN (ei |µ, σ)
)
Prior (µ) Prior(σ)
Using the new formulation, this becomes
p (E, θ|Y, T)∼
(
∏
∀i
(
lN
(
L
(
T − eµ+∆i∗Si∗σ
)
,Σ2
))
φ (∆i) ∗ 2 ∗ p(Si)
)
Prior (µ) Prior(σ) =
(
∏
∀i
(
lN
(
L
(
T − eµ+∆i∗Si∗σ
)
,Σ2
))
φ (∆i)
)
Prior (µ) Prior(σ)
In an MCMC setting, this formulation allows for generating a new
proposal T′ by jumping from (∆, S+) → (∆, S−), thus reducing the
risk of getting stuck in local maximums of the likelihood. In effect,
by decomposing e into two separate variables, we are adding an ex-
tra dimension that the MCMC sampler can jump through, bringing
the separate modes closer together.

5C H A P T E R 5 : T H E C H A L L E N G E S O F E S T I M AT I N G
T E S T K I N E T I C S
5.1 introduction
In previous chapters, we have shown how to use hindcasting to un-
derstand the past spread of infectious diseases from cross-sectional
studies, and thereby better inform current actions. This estimation
of historic trends from recent samples is done by treating diagnos-
tic test measurements as “clocks” that can indicate the time since
pathogen exposure. The development of test measures as a func-
tion of time since exposure is often referred to as “test kinetics”, and
knowledge of these kinetics is crucial in order to be able to calibrate
the clocks used for hindcasting. Understanding test kinetics is also
important in other contexts such as producing accurate diagnoses
(Pawlotsky, 2002); estimating the duration of host immunity (Hallan-
der et al., 2005); and understanding the pathogenesis and dynamics
of the within-host infectious processes (Kirschner and Linderman,
2009).
During development of the hindcasting framework, it was neces-
sary to consider how and where to find information on test kinet-
ics. However, a major bottleneck for current kinetic studies is the
reliance on experimental or longitudinal follow-up data, which are
difficult to collect. Consequently, published information on kinet-
ics is scarce. This chapter represents a preliminary investigation of
whether it is possible to estimate test kinetics from observational
data in a way that makes them usable for modern statistical pro-
147
148 chapter 5 : the challenges of estimating test kinetics
cedures such as hindcasting, or sero-incidence studies that rely on
kinetics to inform inference.
Commonly used sources for data on test kinetics are experimen-
tal infection studies, longitudinal follow-up studies, and observa-
tional studies. Each study design bring with it a particular tradeoff
between factors such as ease of implementation, study size, study
cost, number of observations per time unit, and bias in the resulting
estimates. In an experimental infection study, such as that by López-
Olvera et al. (2010) used in Chapter 4 to model BTV kinetics, indi-
viduals are infected in a controlled manner with a particular dose
of pathogens, and then tested using available diagnostics at regular
intervals until the end of the experiment. Such studies require strict
ethical consideration, and can require access to facilities with high
biosafety level ratings. In some cases, such as with biosecurity level
4 (BSL4) pathogens, (US Department of Health and Human Services,
1999) only a handful of institutions world-wide have the suitable
containment facilities to carry out experimental infections . Because
of the costs of containment, experimental studies tend to only infect
a small number of individuals. This means that estimated test kinet-
ics can fail to be fully representative for the population as a whole.
The question of how representative such studies are of the entire
population is intensified by the fact that study criteria usually ex-
clude individuals that suffer from sickness, malnutrition, and other
conditions that are common in field situations (OIE (2013), p. 10). In
addition, modes of primary and secondary disease contact in exper-
imental conditions can be far removed from those encountered in
field conditions.
Alternatively, naturally occurring infections can be tracked in lon-
gitudinal follow up studies, such as the study by Versteegh et al.
(2005) that was used to model Pertussis antibody kinetics in Chapter
4. Infected cases are detected via routine or enhanced surveillance,
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and are then tested repeatedly for some length of time thereafter.
On the one hand, such studies do not come with the same limita-
tions as experimental studies: kinetics estimated based on naturally
occurring cases are more likely to be representative of other cases
occurring in the field; there are fewer ethical considerations; and a
larger number of individuals can be included in the study for the
same cost. On the other hand, identifying cases poses a challenge,
especially for rare or emerging pathogens, as can identification of
the initial infection time. Furthermore, repeated testing of cases can
be difficult or impossible, in particular for wildlife pathogens in free-
ranging animals.
The term “observational study” is here used for studies conducted
on samples from infected individuals that has been discovered (ob-
served) in the course of regular surveillance, and not necessarily
comprising of a random sample from the entire population. This
implies that samples are collected from naturally infected individ-
uals, with no follow-up sampling. This is even more limiting than
follow-up studies, since there is no information on how the test mea-
surements of the individual develop over time. However, it is a lo-
gistically much easier design than a follow-up study and often, es-
pecially in the case of rare, less studied, or emerging pathogens, the
only available source of kinetics data.
An ideal inference method would therefore be able to estimate test
kinetics even from regular observational studies. Given the above
considerations, it would need to be usable even when only a single
observation per individual is available, and account for uncertainty
in the time of infection. In situations with limited observations per
individual, it becomes important to leverage as much as possible
from previously obtained knowledge of the host-pathogen dynam-
ics. Describing within-host disease processes with mathematical
models can make it possible to fit the kinetic curve parsimoniously
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using a few key parameters. Given that such processes are driven,
at a minimum, by two components, namely immune response and
pathogen growth, this implies that incorporating multiple tests that
correspond to each of these components into mathematical and/or
statistical models would improve the estimate of the test kinetics.
The work of Simonsen et al. (2009) is one of the more detailed pub-
lished papers that estimates test kinetics from population data. They
used a mathematical model of antibody kinetics that also implic-
itly describes antigen levels, and longitudinal follow-up data on
Salmonella immune response to estimate the parameters of the model.
However, the study was limited by not having access to antigen
data, and the assumed model for antigen response was therefore
quite simplistic.
In section 5.2, the model of Simonsen et al. is described and used
as a stepping stone for considering the benefit of including multi-
ple measurements of different aspects of the host-pathogen system,
by explicitly incorporating antigen measurements. Section 5.3 then
discusses the challenges for developing methods for estimating test
kinetics from observational data to inform the growing number of
studies and models that use test kinetics as clocks, such as hindcast-
ing and sero-incidence studies (e.g. Teunis et al. (2012), Simonsen
et al. (2009), Simonsen et al. (2011), Baguelin et al. (2011) and many
more).
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5.2 a suggested approach for improving the joint estima-
tion of multiple test kinetics
5.2.1 Reimplementing Simonsen etal (2009) with added nucleic acid measure-
ments
Simonsen et al. (2009) describe a study in two parts: part 1 consisted
of a longitudinal study of Salmonella antibody kinetics where 302 pa-
tients with a culture-confirmed diagnosis of Salmonella enteritidis or
Salmonella typhimurium infection were tested up to four times over
an 18 month period following the detection of infection. Samples
thus generated were tested for three different types of antibodies:
IgG, IgA, and IgM. The test results were then used to estimate the
kinetics of these antibodies after infection, assuming the reported
dates of onset of symptoms were the actual times of infection. Part
2 of the study involved a cross-sectional sample of the population,
where 1780 individuals were tested for antibodies against Salmonella.
Using the kinetics of antibody levels following exposure estimated
in part 1, the average time since exposure to Salmonella could be
calculated and used to estimate the incidence of exposure, or sero-
incidence, of Salmonella in the population.
In the Simonsen et al. study, only antibody measurements were col-
lected, and therefore antigen levels were only included implicitly in
the model as a driving force for the antibody response. However, the
formulation they used allows us to include antigen measurements
in the observation process with only a slight adjustment, and thus
explore the potential benefits of including antigen measurements.
The model they used was reimplemented using the RStan (Stan De-
velopment Team, 2014) MCMC engine (see section 1.5.3). A model
with only antibody measurements was compared with a model that
assumed paired antibody and antigen measurements. For simplicity,
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it was assumed that only a single type of antibody was measured
instead of the three types of antibodies considered in the original
paper.
The modelling approach is based on describing the interaction of
a particular antibody level (denoted by IG(t)) and pathogen load
(denoted by Z(t)) by the following pair of equations:
dIG(t)
dt
= S× Z(t)− a× (IG(t)− X?)
and 
Z(t) = (1− t/D) for t < D
Z(t) = 0 for t ≥ D
These equations represent a system where pathogen load is at its
maximum value at the time of infection, and then decreases lin-
early with time until the pathogen is cleared. The antibody levels
increases with S units for each unit increase of pathogen load per
time unit, and a proportion a of the difference between current an-
tibody level and the steady state antibody level X? is removed per
time unit. Thus X? represents the background antibody level that is
present even in the absence of infection. These are first-order linear
differential equations which allows them to be solved as a function
of time since infection t. Doing so leads to the following explicit ex-
pressions for IG(t), under the condition that IG(0) = X?:
IG(t) = X? +
S + aS(D− t))
Da2
− S + aSD
Da2
e−at
if t < D, and
IG(t) = X? +
SeaD − S− aSD
Da2
e−at
otherwise.
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The statistical model for observed test values is then constructed in
the following manner: Assume that a set of test results X = {xij}
has been obtained by taking samples from individuals i = 1, . . . , N
, with each sample j having been taken at certain times since expo-
sure eij. The model is hierarchical; the test response for each individ-
ual i is assumed to be governed by individual parameters θi, which
in turn are sampled from a population-level lognormal distribution,
θi ∼ log N(Θ2,Σθ), where Θ2 denotes the population means for the
parameters, and Σθ denotes the covariance matrix between the pa-
rameters. To facilitate legibility, let Θ1 = {θ1, ...θN} denote the set of
individual parameters i.e. across all individuals in the population.
Given the parameters and an infection time for individual i, the
test values X = {xij} taken at times j = 1, 2, . . . , N are then as-
sumed to come from a separate log-normal distribution. In the case
of antibody-only tests, this can be written as
xij|eij, θi ∼ log N(IG(eij|θi),ΣIG)
where ΣIG denotes the variability of the IG levels around the value
of the mean test kinetics at time eij, assuming parameters θi for the
test trajectory.
Given these elements, the posterior for the model given observed
test values X can be written as a product of the likelihood for the
population-distribution parameters Θ2, the likelihood of the individ-
ual parameters Θ1 given the population distribution, and the like-
lihood for the observed test values X given individual parameters,
and the priors for the parameters. The posterior probability thus be-
comes
P(Θ1,Θ2,Σθ |X) ∝∏
∀i
[
P(θi|Θ2,Σ)∏
∀j
(
P(xij|θi, eij)
)]
Prior(Θ2)Prior(ΣΘ)Prior(ΣIG) =
∏
∀i
[
log N(θi|µ = Θ2,ΣΘ)∏
∀j
(
log N(xij|µ = IG(eij|θi),ΣIG)
)]×
Prior(Θ2)Prior(Σθ)Prior(ΣIG)
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When including antigen measurements, IG(t) is replaced with F(t) =
{IG(t), Z(t)}, and xij = (xab, xna)ij ∈ X are then defined as vectors
of antibody and antigen test levels, with values coming from a bi-
variate lognormal distribution:
xij = (xab, xna)ij ∼ log N(µ = {IG(t), Z(t)},ΣF)
where ΣF is a 2x2 covariance matrix; it will be assumed that the
off-diagonal elements are zero, i.e. that the two components of the
lognormal distribution are conditionally independent. The individ-
ual variance of the two components may differ, however. Note that
when modelling antibody and antigen measurements jointly, X be-
comes a two-column matrix.
All parameters were given vaguely informative priors (as discussed
in section 1.5), that regularise the posterior distribution without re-
quiring precise information about the parameters. The log of the
population-level parameter means Θ2 were given Cauchy(0, 2) pri-
ors. The between-parameter covariance Σθ was defined as the prod-
uct of a LKJ(1.5)-prior on the between-parameter correlation and
a Cauchy(0, 2) priors on the variance around each parameter mean.
The notation LKJ refers a distribution on correlation matrices that
was introduced in Lewandowski et al. (2009) (“LKJ” stands for the
first letters of the surnames of the authors). The measurement vari-
ances ΣF were given exponential priors with parameter 1/ log(1.05).
In order to compare the inferences when collecting either a single
or a double test measurement, RStan was used to implement both
the model with only antibody levels, and the model with both anti-
body and antigen levels. These models were then applied to simu-
lated data sets with known parameter values. For both models, indi-
viduals were assumed to be sampled at three different time points
over the course of infection,with the sampling times being randomly
sampled from a uniform U(0, 300) distribution. After confirming
that the sampler had converged using MCMC trace plots and the
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Gelman-Rubin statistic, the resulting posterior estimates could then
be compared to the true underlying parameter values. Fig 5.1 shows
resulting estimates of the antibody and antigen kinetic curves, com-
pared with the underlying true population-level kinetics, and the
observed individual-level measurement trajectories. As can be seen,
the estimated mean kinetics were nearly identical for the two-test
and the one-test models, both for antibody kinetics and for antigen
kinetics, and close to the population-level mean trajectories. How-
ever, in the one-test model, the variation of individual-level anti-
gen kinetics is non-existent, while the estimated spread is closer to
the actual spread in the two test model. Since the one-test model
lacks any data on antigen levels, any estimated variance would be
strongly influenced by the Cauchy prior on the log parameter scale,
which places a large proportion of the prior density at low values
and therefore has a shrinking effect. The fact that the two test model
underestimates the actual variability can be explained by the fact
that very few individuals have more than one measurement before
the antigen has declined fully, making it difficult to estimate the ex-
act slope of this decline.
Despite the these difficulties in estimating variability, these results
seem to indicate that one could estimate antigen kinetics without
measuring mean antigen kinetics. However, this is likely a conse-
quence of the assumption that the antigen levels follow a simple lin-
ear decay with fixed initial value 1. For some situations, such as for
pathogens with a very rapid initial growth, or where the timescale
of interest is long relative to the increasing phase, this may well be
an adequate description. In general, however, a more flexible de-
scription of the development of pathogen load is clearly desirable.
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Figure 5.1: Estimated antibody and antigen kinetics using the Simonsen et al.
(2009) model on a generated data set. Results are from either a model
including only antibody test(“One test”) or antibody and antigen test
measurements (“Two tests”). Thin red lines indicate estimated test
kinetics for the individual, and the black dots measured test values
observed at these times; thin black lines connect the three samples
taken from each individual. The thick red line indicates the estimated
population-mean kinetics, while the thick black line (mostly hidden by
the estimated red line) indicates the true population-mean kinetics.
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5.2.2 Using piecewise linear curves to describe pathogen load kinetics
Assuming a linear trend is a very simplified and unrealistic model
for the antigen kinetics. This was not an issue for the Simonsen et al.
paper as it was primarily focused on antibodies, and was interested
in using the test kinetics on a time scale where antigen presence was
low. However, it is a clear obstacle when the antigen levels are of
interest as well. A major reason for assuming a linear trend is that
this leads to mathematically tractable explicit solutions for the an-
tibody curves, a requirement when implementing inference with
the current generation of MCMC engines (see section 1.5.3). A more
flexible approach would be to include differential equations, such as
the Lotka-Volterra equations used in Chapter 3, directly in the sta-
tistical model, and use ODE-solvers to generate numerical solutions.
This would remove the need for analytical solutions, and allow for
a wide range of dynamics to be modelled. An ODE solver with lim-
ited capacity has recently been made available in RStan (with the
v2.5.0 release on 20 October 2014). An attempt was made to use the
RStan implementation, but unfortunately, it was not found to be suf-
ficiently robust for modelling noisy and partially observed data.
An alternative approach to including more realistic pathogen load
kinetics in observational studies would be to allow the kinetics to
follow a piecewise linear curve. Here we show that such an approach
is compatible with currently available statistical tools such as Rstan
as it remains mathematically tractable, while allowing for greater
flexibility in the kinds of patterns that could be captured (see Figure
5.2). Using the framework described in the previous section, this can
be implemented by replacing the expression for Z(t) with a piece-
wise linear curve, and solving the systems of equations in this more
general case.
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Recall that the explicit expressions for IG(t) in the simplified Lotka
Volterra model, under the condition that IG(0) = X?:
IG(t) = X? +
S + aS(D− t))
Da2
− S + aSD
Da2
e−at
if t < D, and
IG(t) = X? +
Sead − S− aSd
Da2
e−at
otherwise.
If the above is generalised by assuming that Z(t) can be any linear
trend, i.e. Z(t) = αt + β, the expression for IG(t) instead becomes:
Ig(t) = X? +
αaSt− αS + βaS
a2
+ ke−at
where k is a constant chosen so as to match any boundary condi-
tions.
Recall that the original formulation assumes that the pathogen load
follows a simple linear decrease until it is cleared. If the pathogen
load is instead allowed to have a piecewise linear trajectory, then the
resulting differential equations are still solvable, but a wider range
of kinetics can be captured. Specifically, assume that the pathogen
load passes through four stages instead of two: an increasing phase,
a steady phase, a declining phase, and a cleared phase. This can be
parametrised by
Z(t) =

t/R, for t < R
1 for R ≤ t < tD + R
1+ (tD + R− t)/D for tD + R ≤ t < R + tD + R
0 for t ≥ R + tD + D
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R is then the initial rate of increase, tD is the length of time that the
pathogen load is constant, tD + R is the time it starts declining, and
D is the rate of the decline.
Using these expressions for Z(t), the explicit form for IG(t) becomes
IG(t) =

X? + S(at−1)Ra2 + k1e
−at for t < R
X? + Sa + k2e
−at for R ≤ t < tD + R
X? + aS(D+tD+R−t)+SDa2 + k3e
−at for tD + R ≤ t < R + tD + D
X? + k4e−at for t ≥ R + tD + D
In order to find the constant k1, we note that IG(t) must be continu-
ous at (and thus equal at either side of) all change points, and that
IG(0) = X?.
For k1, this implies that
IG(0) = X? +
S(a ∗ 0− 1)
Ra2
+ k1e−a∗0 = X? ⇒ k1 = SRa2
Given k1 and the change point at R, we can then calculate k2 by the
following:
IG(R) = X? +
S(aR− 1)
Ra2
+
S
Ra2
e−aR = X? +
Sa
a2
+ k2e−aR ⇒
k2e−aR =
S(aR− 1)
Ra2
+
S
Ra2
e−aR− Sa
a2
⇒ k2 = S(aR− 1)e
aR
Ra2
+
S
Ra2
− Sae
aR
a2
=
=
aRSeaR − SeaR + S− aRSeaR
Ra2
⇒
k2 = S× 1− e
aR
Ra2
Again, given k2, and the change point at t = tD + R, we get k3 from
the following:
IG(tD + R) = X? +
Sa
a2
+ S× 1− e
aR
Ra2
e−a(tD+R) =
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= X? +
aS(D + tD + R− (tD + R)) + S
Da2
+ k3e−a(tD+R) ⇒
k3 =
(
Sa
a2
+ S× 1− e
aR
Ra2
e−a(tD+R) − S(Da + 1)
Da2
)
ea(tD+R) =
= S×
(
RDaea(tD+R) + D(1− eaR)− R(Da + 1)ea(tD+R)
RDa2
)
=
= S×
(
D(1− eaR)− R(Da− Da + 1)ea(tD+R)
RDa2
)
⇒
k3 = S×
(
1− eaR
Ra2
− e
a(tD+R)
Da2
)
Finally, using the value for k3, k4 is calculated by looking at the value
for IG(t) at tD + D + R:
IG(tD + D + R) = X? +
aS(D + tD + R− (tD + D + R)) + S
Da2
+
S×
(
1− eaR
Ra2
− e
a(tD+R)
Da2
)
e−a(tD+D+R) = X? + k4e−a(tD+D+R) ⇒
k4 = S×
(
ea(tD+D+R) − ea(tD+R)
Da2
+
1− eaR
Ra2
)
The expressions defined above combine to define joint antibody/anti-
gen test kinetics, allowing for a piecewise linear development of the
antigen kinetics, and consequently a more nuanced model for the
antibody kinetics as well. Figure 5.2 shows an example of the trajec-
tory of kinetic curves using this new parametrisation.
These expressions could directly replace simpler models for test ki-
netics used when fitting curves to directly or indirectly observed
multiple test data. In the model described in 5.1.1, it is simply a mat-
ter of redefining F(t) = {IG(t), Z(t)}. However, when using MCMC-
type algorithms for fitting piecewise-defined curves, care needs to
be taken with the sampling algorithm and priors to ensure conver-
gence.
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Figure 5.2: Example trajectories for test kinetics using piecewise linear trends for
the pathogen load kinetics
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Unfortunately, preliminary naive implementations of the piecewise
linear model in RStan struggled with the discontinuous derivatives
inherent in the piece wise linear formulation. In general, models
in which the parameterisation of a curve changes at known or un-
known “knots” are known as change point models, and there is an ex-
tensive literature for fitting these in an MCMC context (the introduc-
tion of Fearnhead (2006) provides an overview). There is no reason
to believe that the piecewise linear curves described here could not
be fitted via such approaches, but it requires additional work on the
sampling implementation, which is beyond the scope of this thesis.
5.3 discussion
This chapter has described two extensions to existing methods for
the estimation of test kinetics; first a description and a worked ex-
ample of how to infer antibody- and antigen-based tests jointly;
and second, a suggestion for how the kinetics of antigen based tests
could be modelled more realistically using piece-wise linear curves.
The study by Simonsen et al. (2009) that was used here as a starting
point is part of a group of studies (Graaf et al., 2014; Simonsen et al.,
2009; Teunis et al., 2012; Versteegh et al., 2005) that estimate test ki-
netics using a statistical approach for fitting mathematical equations
(derived as the solutions to simple differential equations) to longi-
tudinal measurements. All of these are restricted to only measuring
antibodies, and including the antigen development in their model
as an unobserved variable. Based on the results shown here, these
studies would likely benefit from expanding the scope of inference
to including antigen measurements (note that for many pathogens,
this would require that cases are sampled at an early stage before
the infection has cleared). In order for resulting estimates of antigen
kinetics to be usable as clocks indicating time since infection, such
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expansions should use a flexible parametrisation for the antigen ki-
netics. A piecewise linear curve would be one option for doing so,
while still allowing for the joint antibody and antigen kinetics be
solved analytically. Such tractability is extremely useful in the imple-
mentation of inference using the current generation of MCMC en-
gines. However, such practical requirements are likely to be relaxed
for the next generation of such tools.
In that case another option would be to model the dynamic sys-
tems without the constraint of having to provide analytical solutions.
There exists a substantial literature on the simulation of viral within-
host kinetics (Canini and Perelson, 2014), that makes use of complex
systems of differential equations. These equations typically use a
large number of parameters; Heffernan and Keeling (2008) model
the dynamics of Measles infection using a complex system of differ-
ential equations with 19 parameters to capture the interplay of CD8
T-cells, peripheral blood mononuclear cells (PBMCs) and measles
virus, while Ciupe et al. (2007) use a system of differential equations
with 14 parameters to model Hepatitis B infection. Indivdual pa-
rameters estimates are taken from the literature - fitting all model
parameters simultaneously would require that a wide range of mea-
surements be taken on a large number of subjects for the parameters
to be identifiable. As a consequence, this approach is limited to very
intensely studied systems of pathogen and hosts.
Systems of ordinary differential equations (ODE), such as the Lotka-
Volterra equations used for simulation test kinetics in chapter 3, that
are not analytically tractable but less complex than those used in
the within-host kinetic models mentioned above, would be a natural
intermediate step between these two extremes. As an added bene-
fit, such relatively parsimonious models would be able to be fitted
not only to well-studied disease systems, but also to rare, neglected,
or emerging diseases. However, this approach would require imple-
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menting a custom MCMC sampler, since the ODE solvers in off-the-
shelf software such as RStan are not yet stable enough to be used in
fitting models to noisy data.
The approach by Simonsen et al. (2009) and others replicated and
improved upon in this chapter rely on longitudinal follow-up mea-
surements of infected individuals, and furthermore treat times of
infection as known without uncertainty. For pathogens where re-
peated (longitudinal) testing of cases is difficult, the only available
data may be single cross-sectional samples taken from infected indi-
viduals. In this situation, the only known information available for
an individual would be the value of a test measurement at a particu-
lar time, and no information on how those values behaved earlier or
later. Consequently, it would not be possible to estimate how trajec-
tories differ between individuals, or indeed identify individuals that
deviate in a systematic manner from the average. However, if the in-
dividuals from whom samples are taken cover the whole range of
the infection process (i.e. different individuals in the sample were
infected very recently, a very long time ago and at all points in be-
tween), population-average test kinetics may still be estimable. For
the purpose of inference approaches such as hindcasting, which fo-
cus on population-level patterns, this may still be sufficient. An ini-
tial attempt was made to fit such a model, and initial results were
promising, but had difficulty converging, and time did not permit
further exploration or development.
The assumption of infection times being known without uncertainty
could also be problematic, in particular for non-livestock animals
which are not continuously monitored for disease, or for diseases
with a substantial delay between the time of exposure and onset
of symptoms. In such situations, the times of exposure E = {eij}
could be replaced with the times of observation O = {oij}. These
could then be related to exposure times by assuming that the time
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elapsed from exposure until observation {eij} follow some random
distribution modelling the incubation period of the disease (and pos-
sibly other factors, such as the probability of an individual being ob-
served), such as a gamma distribution (Nishiura, 2007). In this way,
it would be possible to replace the times of exposure in the frame-
work described in 5.2 via the relation {ei j} = {oij − eij}. This would
require modelling the time delay until observation together with the
other parameters and would increase the uncertainty of estimated
test kinetics, but would likely still be possible. Attempts were made
to fit such models including incubation terms, and initial attempts
were promising.
A major obstacle to the use of hindcasting and similar methods is
the difficulty of finding usable data describing the kinetics of di-
agnostic tests as a function of time since infection. Most published
experimental infection studies (Cray and Moon, 1995; Hoffman et
al., 2006; Komar et al., 2003; López-Olvera et al., 2010; Major et al.,
2004) only present their results in the form of graphs and summary
statistics, which poses an obstacle to incorporating the results in sta-
tistical procedures. Similarly, while the longitudinal studies and the
mathematical modelling studies mentioned above sometimes (but
not always) present parameter estimates, producing kinetic curves
from these estimates can be very difficult. The lack of easily acces-
sible data may be because statistical methods exploiting such kinet-
ics in epidemiological studies are not yet in wide use. It would be
highly beneficial if kinetics data were more widely available in eas-
ily usable formats. Each study may be expensive, but making the
results available would allow the study to have a long-lasting im-
pact, which is clearly beneficial to the individual scientists, as well
as to society as a whole. Most importantly, having the kinetics from
diagnostic tests available would make approaches such as the hind-
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casting described in previous chapters, usable on a wide scale and
in a wide range of settings.
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In the field of infectious disease surveillance, there is often a paucity
of data, nationally (Parliamentary Office Of Science & Technology,
2014) and globally (World Health Organization, 2000), which con-
stitute a substantial challenge for monitoring endemic trends, and
detecting epidemics, and the emergence of novel pathogens. Lack
of information further complicates the already challenging task of
managing disease risks and deciding on appropriate actions. It is
therefore imperative to make full use of the data that has been col-
lected.
With the the rapid scientific development of computer-based meth-
ods for Bayesian inference (Lunn et al., 2009), it is increasingly feasi-
ble to integrate multiple sources of data into coherent models. Wool-
house and Matthews (Matthews and Woolhouse, 2005) give an ex-
tensive overview of studies that incorporate different data sources
to recover the underlying dynamics of disease spread (Haydon et al.,
2003; Presanis et al., 2011), and argue that the future of disease anal-
ysis lies in models taking into account a wider range of inputs, such
as quantitative diagnostic test measurements, disease pathogenesis,
or transmission mechanics, in addition to standard case count data.
The work presented in the thesis is in line with such arguments,
combining information on quantitative test measurements with
knowledge of the within-host dynamics in the form of test kinetics,
and developing methods that can be used to inform policy response
in situations where only cross-sectional data are available. The the-
sis was carried out as part of the WildTech Framework 7 project.
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WildTech was a project to develop advanced multiplex diagnostics
for detecting wildlife diseases, using both nucleic acid and immune
response based tests. The inspiration for hindcasting came from this
setting of multiple tests and combined nucleic acid and immune re-
sponse data. The simple case of two paired diagnostic test measure-
ments was used as natural starting point for developing methods
that exploit the synergy from multiple tests. However, as noted ear-
lier the Bayesian and computational tools used here lend themselves
to the integration of data from multiple sources. Therefore, as the
use of multiplex testing develops further the framework for infer-
ence developed in this thesis could be applied to the results from
multiple (i.e. >2) diagnostic tests.
6.1 summary of the results
The simplest case of multiple testing is that of using two tests with
binary outcomes. Compared to a single test, two tests used in two
populations with different incidences enable estimation of test sen-
sitivity and specificity as well as the incidence levels. This is com-
monly done using a latent class model approach, first introduced in
Hui and Walter (1980). This approach has become very popular; a
recent review by Smeden et al. (2013) identified 111 published pa-
pers that used latent class models to evaluate diagnostic tests in hu-
mans and animals, the large majority published after 2000. In chap-
ter two of this thesis, a Hui-Walter type latent class analysis was de-
veloped for a situation involving vaccinated animals. A simulation
study was used to analyse the relationship between the properties
of the newly developed Distinguishing between Infected and Vacci-
nated Animals (DIVA) tests for bovine tuberculosis, and the study
size used to estimate these properties.
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The extension of the classical Hui Walter approach used in chapter
2 made it possible to estimate the efficacy of the vaccine used in the
study as opposed to assuming it was known, in addition to estimat-
ing unknown properties of the two DIVA tests. It was demonstrated
that in such a situation, vaccine efficacy can be estimated with good
precision, as well as estimating the sensitivity and specificity of two
diagnostic tests with unknown sensitivity and specificity. This has
important practical implications for the feasibility of simultaneously
introducing novel tests and implementing control strategies using
vaccines for which the efficacy is not fully known. As far as we are
aware, this is the first study demonstrating the joint estimation of
vaccine efficacy, incidence, and the sensitivity and specificity of diag-
nostic test. Of the 111 papers covered in the review mentioned ear-
lier (Smeden et al., 2013), only one considered the use of latent class
models in the context of vaccinated animals (Engel et al., 2008), and
this study never included vaccine efficacy as a model parameter.
Of particular interest was the relationship between study size, as-
sumptions of true DIVA test properties, and the resulting estimates
of the specificity of the tests, when the specificity reached values
of 99.9% and higher. An important objective of the study was to
demonstrate that the DIVA tests have a sufficiently high specificity,
with a threshold level of 99.85%, as this is critical for a large-scale
bTB vaccination program to be cost effective (Conlan et al., 2015).
The results of the simulation study indicated that demonstrating
that the tests superseded the performance threshold would require
either a very large study, (above 100 000 animals), or that true speci-
ficity was near perfect, with less than 1 in 100 000 truly negative an-
imals testing positive. As an alternative, the results indicated that
strengthening the main study with a pilot study that made use of
reference animals that are verified positive or negative to bTB a pri-
ori would reduce the required sample size. In light of these results,
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a joint field trial of a bTB vaccine together with DIVA tests as rec-
ommended in AHAW (2013) may allow for a good evaluation of
the vaccine efficacy. However, it is unlikely to provide sufficient ev-
idence of DIVA test performance to satisfy the 99.85% specificity
threshold, and therefore other types of evidence will need to be con-
sidered to demonstrate that the test satisfies this criteria. The full
results of the simulation study have been included in a report sub-
mitted to DEFRA and the Welsh Government, to be used in discus-
sions as to whether to conduct a large-scale vaccine/DIVA trial in
the UK.
In the third chapter, the use of multiple tests with non-binary re-
sults was considered, using a model that assumes that the tests have
quantitative results depending on the state of infection, and that
they follow a particular known trajectory after exposure to a pathogen.
By considering the diagnostic tests measurement in combination
with the kinetics of the tests, a ”clock” was incorporated that could
be used to estimate time since infection. Earlier studies have com-
bined test values and kinetics (Baguelin et al., 2011; Nielsen et al.,
2011; Simonsen et al., 2008) using a single test, and estimated the
mean incidence of infection over some period of time. This chapter
demonstrated that by incorporating information from more than
one diagnostic test, and by considering their joint kinetic pattern,
it becomes possible to relax the assumption of a constant level of
incidence and estimate not only the historic mean incidence, but lin-
early increasing or decreasing epidemic trends. In this thesis, the
the terminology of ”hindcasting” was introduced for this type of
analysis. In particular, the results used syntethic data generated un-
der a wide range of conditions to demonstrate that a cross-sectional
sample using two diagnostic tests could reliably be used to esti-
mate whether the incidence trend has been increasing or decreas-
ing. Counterintuitively, it was also discovered that the estimation of
6.1 summary of the results 173
an increasing trend was more difficult than estimating a decreasing
trend, implying that different levels of effort are required for moni-
toring the effect of policy interventions depending on their expected
success.
The approach used in chapter 3 models the distribution of times
since infection in a cross-sectional sample, in effect modelling the
cumulative incidence. This approach is closely related to “force of
infection” studies (Hens et al., 2010) which considers age-stratified
prevalence data to estimate how the so-called “force of infection”
varies with age. As an example of the similarity, the chapter redis-
covered an equation first described by Griffiths (1974) that models
the distribution of times since infection in a cross-sectional sample,
assuming a previous linear trend β, an instantaneous incidence at
the time of sampling α, and including possible censoring of times
since infection larger than some value C:
p(t = T) =
(α+ βT)e−(α+βT/2)T
1− e−(α+βC/2)C
The context is different however. Griffiths modelled the exposed
fraction of a population in a situation where the incidence is sta-
ble over time, but differs by age, and where the force of infection
follows a linear trend as a function of age. In contrast, our equation
assumes a homogenous population, but a changing incidence over
time, and is implemented in a framework where the times since
infections (equivalent to age in Griffiths’ implementation) are in-
ferred rather than known. Moreover if ages of individuals or other
covariates can be estimated for the individuals tested in our cross-
sectional data then the methods introduced here could be extended
to account for them.
In chapter four, the application of hindcasting was expanded to that
of epidemic diseases where reinfections can be ignored, but where
the trend of incidence develops in a more dynamic fashion, e.g. ris-
ing and then falling. By considering epidemics, the study can be
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compared with recent papers that focus on recovering transmis-
sion networks with a combination of epidemiological and phylo-
genetic data. The recent study by Jombart et al. (2014) combined
genetic data with case counts to estimate unobserved epidemic pa-
rameters of the 2003 SARS outbreak. In a similar fashion, Biek et al.
(2012) used the number of genetic mutations between cases to re-
construct the network of spread between cattle herds and badger
groups. These studies also recover epidemic patterns from cross-
sectional data, but rely on genetic mutation rates as “clocks”. Since
genetic mutation rates are measured in transmission events, such
phylogenetic models can describe epidemics on a time scale of in-
fected generations, but have difficulty with estimating the absolute
time between events unless the mutation rates are very high. By us-
ing a test kinetic based approach in the hindcasting model we mea-
sure the absolute time since infection, which is more suited to de-
scribing the overall population-level development of the epidemic.
Since test kinetics can be measured on a time scale of days or weeks,
it should also be better suited to estimate rapidly developing early
phase of an epidemic than phylogenetic models where the genetic
mutation rates are measured on the order of weeks or months for
viruses (Duffy et al., 2008) and much slower for bacteria.
The content of chapter 4 is a reproduction of the paper ”Recovering
epidemic trends from cross-sectional data using multiple diagnostic
tests” (submitted to PloS Computational Biology on the 18th of June
2015). The paper is based on two case studies; a 2007 Bluetongue
outbreak in Cattle in the UK, and a B. Pertussis outbreak in humans
in Wisconsin, USA. In the chapter it is demonstrated that epidemic
trends can be fitted by using a single log-normal parametrization
of the trend for both epidemic trends in an exponentially increas-
ing phase as well as epidemic trends past their peak. It also demon-
strated that in addition to the trend, the approximate length of time
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since the start of the outbreak can be estimated, information that
would be of benefit to outbreak investigations. The statistical frame-
work described in the paper can be applied to estimate both com-
plex trends and time since introduction from cross-sectional data
provided that two or more sufficiently different diagnostic tests are
used to measure the state of disease in the host. The paper also con-
tains an indepth analysis of how different diagnostic tests combine
to add information on individual-level time since infection, high-
lighting in particular the problem of non-identifiability. The anal-
ysis indicate that when combining multiple tests, the tests should
be chosen so as to measure aspects of the host-pathogen interaction
that develop over different time scales, as opposed to measuring the
same process.
The implementation of the epidemic hindcasting model in Chap-
ter 4 utilizes a novel parametrization of the lognormal distribution
describing the trend, which is described in the included supplemen-
tary information. This was motivated by the fact that in the frame-
work utilized in the chapter, the overall likelihood of times since in-
fection given observed test data often have multiple modes. Even if
one mode had the dominant mass, the multi modality can lead to
the MCMC algorithm getting stuck around the local maximum. In
the case of the hindcasting model, for many types of kinetic curves,
the time since infection that would maximise the likelihood for an
observed data point can be either before or after a peak in the test
kinetics, with a range of time since infection in between (where the
test kinetic peaks) that would result in low likelihood values. If the
time of infection is parametrized with a single parameter, it can then
be difficult for the sampler to go from a sample of the posterior with
recent time-of-infection parameter value for an individual to sample
with the pre-peak, or distant time of infection for the same individ-
ual. In order to make the overall posterior computationally tractable,
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the log-normal distribution was parametrized in terms of a binary
variable signifying upper or lower tail and a positive variable mea-
suring distance in number of standard deviations away from the
mean, and the mean and standard deviation of the distribution:
Lognorm(µ,∆) =
eµ+∆Sσ,
S ∈ {−1, 1}
∆ ∼ Nstandard(∆)I[∆ ≥ 0]
Using this parameterization, the MCMC sampler can jump between
either tail of the lognormal distribution by switching the value of S,
leading to better mixing than the standard formulation, and avoid-
ing either tail being isolated from the other in the sampling space.
So-called mode-hopping MCMC algorithms that can jump between
different modes of the posterior are well described in the literature
(Behrens, 2008; Sminchisescu et al., 2003; Tjelmeland and Hegstad,
2001), but tend to focus on general solutions that are implemented
in the jumping kernel. The solution describe above is simple and
straightforward to implement in any MCMC-engine and can be eas-
ily generalised to any situation where modes of the posterior are
likely to lie in either tail of a symmetric distribution.
Together, chapters three and four demonstrated the importance of
detailed quantitative diagnostic test kinetics for extracting maxi-
mum information from infectious disease studies. Since these meth-
ods require us to have knowledge of the test kinetics, access to stud-
ies generating such information are crucial. Some of the studies on
test kinetics found in the literature use highly sophisticated models
of within host dynamics (Baccam et al., 2006; Hancioglu et al., 2007;
Heffernan and Keeling, 2008; Mallet et al., 2013). These typically re-
quire a large number of parameters (Heffernan and Keeling use 19
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parameters), which are fitted by assigning values or priors from the
literature and expert opinion. This type of approach generates de-
tailed predictions of the entire dynamic of the host pathogen system,
but is only feasible for systems such as Measles-humans which have
been very intensely studied. On the other end of the spectra, the ex-
perimental infection studies found tend to only report measured val-
ues without the use of any statistical inference framework (Cray and
Moon, 1995; Hoffman et al., 2006; Komar et al., 2003; López-Olvera
et al., 2010). There is thus a need for approaches that can be used to
generate parametric descriptions of test kinetics in non-experimental
settings or for emerging diseases. A group of studies focusing on
the use of seroincidence models (Graaf et al., 2014; Simonsen et al.,
2009; Teunis et al., 2012; Versteegh et al., 2005) strike an appealing
balance between statistical sophistication and use of observed longi-
tudinal data. Chapter five explores how the approach used in these
studies could be taken further by replicating the study by (Simon-
sen et al., 2009), detailing the potential benefit of using two or more
diagnostic tests, and showing how it would be possible to increase
the realism of the model used by assuming a piecewise linear anti-
gen curve. The chapter also discusses additional research that needs
to be done in this field to strengthen diagnostic test usage, and as a
result thereof strengthen disease surveillance.
6.2 future directions
The results in this thesis have highlighted the importance of consid-
ering the diagnostic tests used for disease surveillance and epidemi-
ological studies, and in particular the use of multiple diagnostic
tests. They have also shown the kind of unexpected and useful con-
clusions that can be drawn from data collected with more than one
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test. However, there are a number of different research questions
that have yet to be pursued owing to lack of time and resources.
In the Hui-Walter work conducted in chapter 2, it was assumed that
the results of the two DIVA tests were mutually independent. This
is a strong assumption that can be questioned. An extension of the
described work could thus be to consider the issue of dependence.
Since introducing covariance structures in a two-test Hui Walter
framework lead to a non-identifiable system (Georgiadis et al., 2003),
this would imply either considering the situation with three tests
with different properties, or to consider tests that produce a quanti-
tative rather than binary results. Quantitative type tests could also
be used to consider the issue of disease progression. The presented
analysis intentionally ignored this issue, but it is well known that
the progression of bTB in the host has a strong impact on the ability
to identify the pathogen (Whelan et al., 2010) , whether by immune
response or by pathology. Assuming either a latent quantitative indi-
cator variable, or an explicitly quantitative test would make it possi-
ble to model this dependency.
The hindcasting framework introduced and developed in this the-
sis shows a lot of promise in endemic settings for tracking trends
in populations where ongoing surveillance is lacking. Chapter 3
demonstrated the example of linear trends, but there is a need to
evaluate both the robustness of this modelling approach when as-
sumptions of linearly changing incidences are not met. Non-linear
trends could be considered as well, such as exponential trends, or
even fitting smoothly varying trends with the use of splines or lasso.
However, there are a number of complications that need to be con-
sidered when generalising hindcasting in endemic settings. If the
incidence is high enough, the issue of reinfections of individuals
needs to be considered. The assumption used in the chapter was
that the test kinetics of a reinfected individual followed the same
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pattern as a naive individual infected for the first time. This is a
simplification, and a more nuanced approach would be needed for
pathogens where infection confer a substantial level of immunity.
For many diseases, reinfections are an important aspect of the epi-
demiology; in particular for diseases where behaviour is an impor-
tant risk factor, such as Chlamydia (Edgardh et al., 2009). When gen-
eralising the type of trend considered, a statistical complication is
that the approach used for hindcasting in this thesis requires that
the distribution of ”times since infection” at the time of sampling is
modelled. The “times since infection” distribution is the integral of
the continuous-time trend expression, and thus have a substantially
more complicated parametrisation than is commonly used in regu-
lar curve fittings. Parameterising the models used for hindcasting
in a different way may circumvent this issue, but it is unclear what
other approach could be used. A related issue is that the current
approach requires that there is a limit to the time span for which
hindcasting is applied, or that the incidence goes down to zero at
some point in the past. This is not a fully satisfactory approach, and
finding a different way of considering this issue would be beneficial.
The use of hindcasting in epidemic settings, as described in chap-
ter 4, could prove important for outbreak response, in particular for
outbreaks where detecting is delayed. The work described in the
chapter used a lognormal parametrisation which seems to be capa-
ble of capturing the essence of even quite irregular epidemics. How-
ever, here as for endemic settings, more complex parametrisations
could be considered. One interesting approach would be to model
the disease dynamics explicitly, by the use of SIR type models, as
this might allow for estimating pathogen characteristics such as R0
in addition to estimating the epidemic trend. As SIR models are
analytically intractable this would require the solving of a system
of ODEs. Unfortunately at present none of the generalist Bayesian
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MCMC packages have ODE solvers that are sufficiently capable, and
so it would require coding the sampler in a general programming
language.
The hindcasting approach could be extended even further by incor-
porating additional aspects of the disease system such as popula-
tion demography (e.g. age- and sex-structure), contact networks,
or spatial location. This might enable the estimation of disease dy-
namics not only in time but also in spatial spread, or of the pattern
of spread through the demographic structure of the population. In
Birrell et al. (2011), a number of data sources is combined to esti-
mate the dynamics of the H1N1 influenza pandemic in London
during 2009, including age-structured patterns of disease spread.
This is done using observed binary data, and thus cannot estimate
time since infection for observed cases. Similar types of evidence
synthesis using quantitative diagnostic measures combined with a
hindcasting type approach would have the potential for even more
in-depth understanding of the disease dynamics.
The approach used in both chapter 4 and 5 for describing test ki-
netics is intentionally simplistic. By only using one parameter to
describe the combined effect of measurement error and individual
variation in the trajectory, inference in the MCMC framework is sim-
plified, allowing the chapters to focus on highlighting the potential
of hindcasting. It might well be that using a one-parameter descrip-
tion of error is enough to recover trends even in more realistic set-
tings, as the hindcasting procedure has been surprisingly robust to
even high levels of noise, at least in an epidemic setting where the
overall shape of the curve is more important than producing esti-
mates of e.g trend or location parameters. However, it is likely that
when this approach is used on field data, it would benefit from mod-
eling the various influences on test measurements separately: from
individual-level variation in the underlying process being measured,
6.2 future directions 181
via contamination and preservation issues, to noise introduced in
the laboratory process of sample preparation and measurement. In
order to model the individual-level variation, the lookup-table ap-
proach used in chapters 3 and 4 would have to be replaced with
parametric hierarchical descriptions of the kinetics, where the pa-
rameters for each individual come from population-level probability
distributions.
Modelling the test kinetics in a more complex manner requires that
there are data available on the kinetics of the test, of sufficient qual-
ity to support such models. The proposal in chapter 5 to recover the
test kinetics from observational data would be one way to make it
more feasible to collect such data. The work described in the chap-
ter is just a very first step, and there are a number of improvements
that could be implemented. Instead of assuming that the time of
infection reported is correct, one could incorporate the incubation
time into the model as an unobserved variable. Another improve-
ment concerns the parametrisation of the kinetic curve: in Simon-
sen et al. (2009) it is assumed that the pathogen level declines lin-
early from a high starting point, which is clearly a strong simplifica-
tion. As an alternative chapter 5 suggested using a piecewise linear
pathogen curve. Another option would be to model the interaction
of immune response and pathogen levels directly as a pair of differ-
ential equations instead of attempting to find explicit expressions for
the curves. Making use of this would allow for much more realistic
descriptions of the test kinetics.
The hindcasting models developed in this thesis incorporate a ”clock”,
that translates observed data to a time since infection via knowl-
edge of diagnostic test levels as a function of time since infection.
This clock could be constructed in other ways as well. As mentioned
above, in phylogenetic analyses, the rate of mutation of a pathogen
is known, and this rate of mutation combined with genetic distance
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translates into a time since the last common ”ancestor pathogen”.
Hindcasting could be generalized by combining phylogenetic data,
quantitative diagnostic test data, and test kinetics. Potential other
”clocks” exist that could also be used for the purpose of hindcasting.
On the farm level, the diffusion pattern of pathogens into the envi-
ronment means that the distance from e.g. a farm that a pathogen
was detected, possibly combined with knowledge of past weather
and rain volume, could be used to determine how long the pathogen
had been diffusing from the farm, and thus the time since the farm
was first infected. A common practice in animal disease surveillance
is the use of pooled samples, such as sampling from the bulk milk
tank at a dairy cattle farm rather than from individual animals, or
combining blood samples from multiple individuals. In such pooled
samples, the direct relationship between time and indicators be-
comes diffuse; however, the relative prevalence of different disease
indicators would still reflect aspects of the disease dynamic of the
sampled population, providing information that could be utilized
in a hindcasting type framework. Looking at the individual level,
clinical descriptions of stages of disease could be used as ordinal
measurements of time since infection. Such measurements might not
be precise enough in themselves, but when combined with one or
more of the other clocks mentioned here, could help decrease uncer-
tainty and consequently increase the accuracy of estimated popula-
tion level trends.
6.3 policy implications
Current systems of disease surveillance are often limited in terms of
timeliness and completeness. The quality and existence of disease
surveillance is particularly limited in developing countries (Butler,
2006; US General Accounting Office, 2001), in wildlife (Mörner et al.,
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2002), and for pathogens that are not currently considered high risk
(US General Accounting Office, 2001). The risk posed by infectious
diseases is increasing (Jones et al., 2008), due to climate change (Fox
et al., 2011; McMichael et al., 2006), increasing air traffic volume
which increases the risk that a local epidemic becomes a global prob-
lem (Lipkin, 2013), and a number of other factors. As a consequence
of this, the capacity and flexibility of disease surveillance needs to
improve. Because of the costs involved in establishing surveillance
systems, improvements in the use of existing systems and the data
they produce are likely to be most cost effective.
DEFRA (2013), provides a series of suggested objectives for improve-
ment in the animal disease surveillance sector. The policy objectives
include: timeliness/ early identification; risk assessment; trend anal-
ysis and detection of change in endemic diseases; effective surveil-
lance data gathering and analysis; and development of improved
surveillance methodology.
This thesis has presented a number of results that can be used to
reach objectives such as these by making better use of existing surveil-
lance systems, extracting more information from cross-sectional data
than was previously thought possible, and supporting the decision
making of epidemiologists and policy makers. The extent of the
time delay between an infection event, via its detection, to it being
registered by the overall disease surveillance system, plays an espe-
cially important role during outbreaks of disease or when a novel
pathogen has been introduced. While multiple testing in itself will
not improve the time from infection to registration, hindcasting the
times of infection before the point of detection could help mitigate
the effects of delayed detection by allowing one to act as if the dis-
ease had been tracked all along. In this way, it can also help improve
the risk assessment of emerging diseases once the disease has been
identified, by providing information of its previous trajectory and
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rate of spread, thus informing predictions about future trajectories
and rates of spread. This in turn would help to inform a more pro-
portionate response in terms of disease control effort.
In situations where a novel pathogen has been discovered, two of
the most pressing questions are how long the pathogen has been
present, and if it is on the increase. A current example is the recent
discovery of a leprosy-like disease in Scotland among squirrels (Mered-
ith et al., 2014). Being able to sample across the squirrel popula-
tion and establish whether it has been spreading over the last few
years, or if it has already reached an endemic steady state, would be
highly relevant for helping decision-makers decide on what actions
to take.
In the context of endemic diseases, one of the most important objec-
tives for assessing the burden of disease and evaluating the impact
of policy measures, is to estimate and track trends of incidence. As
suggested by the results in chapter 3, cross-sectional studies could
be used to estimate trends and detect changes in incidence over
multi-year periods. In settings where ongoing surveillance systems
exists, the results could be used to validate data and trends as esti-
mated by routine surveillance. In addition, it would enable the track-
ing of trends in populations for pathogens where routine surveil-
lance is not conducted and only occasional cross-sectional studies
are implemented.
Because of the high cost of surveillance systems, it is important to
utilise available effort and collected data as efficiently as possible.
In DEFRA (2013), it is stated that ”Development and use of new or
improved methodologies for collating, interpreting and analysing
such diverse data is likely to be needed to aid in the implementation
of improved surveillance methodologies”. With the rapid develop-
ment of novel diagnostic methods, it becomes possible to conduct
statistical analyses that exploit the additional information inherent
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in these new diagnostic tests. As the results in this thesis demon-
strate, by taking the quantitative nature of diagnostic tests test into
account, and by combining multiple tests, there is a substantial gain
in statistical power that can be used to estimate critical aspects of
the epidemiology of disease.
Thus, increasing the collection and usage of quantitative information
at all levels of the surveillance system should be a priority. Often,
what is registered in databases as case/non-case is the result of ap-
plying a cutoff to a quantitative result of a diagnostic test. Collecting
the underlying quantitative test data as well as the cut-off classifi-
cation would be a good first step that could likely be taken without
a great increase in expenditures. Switching from binary tests in sit-
uations and for diseases where such are used, to tests with quanti-
tative information, and ideally with known test kinetics, would be
a benefit, both at the point-of-care or point-of-diagnosis in terms
of modern tests with better performance and faster turn-around,
as well as to epidemiologists and statisticians working with the col-
lected data to understand population level patterns. With quantita-
tive data enabling richer analysis of the dynamics and state of dis-
ease in a population, this would in turn provide a stronger evidence
base from which to conduct research, manage the effects of disease,
and decide on policy measures to reduce the burden of disease.
6.4 conclusion
The research put forward in this thesis highlights the importance of
considering the choice of diagnostic tests not only from a cost per-
spective but from the perspective of gaining as much information
as possible from collected data. Despite the additional cost, using
two or more diagnostic tests is from this perspective a tremendous
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gain in terms of the kinds of analyses it enables, and the informa-
tion these can provide.
This thesis has shown the rich possibilities for analyses that open
up with the advent of quantitative diagnostic test data. At all lev-
els, there needs to be an understanding of the additional informa-
tion that can be derived from such analyses; those conducting tests
and filling out forms; those designing databases for the collection of
surveillance data; those analyzing the data; those implementing the
surveillance systems; and those responsible for using these data to
inform their decisions on management of infectious diseases.
In summary, multiple quantitative tests can measure the progression
from a naive to an infected individual, and recover disease trends in
a population. Embracing their use will allow us to shed light on the
past to inform our actions in the future!
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